LEGISLATION AND REGULATION COMMITTEE REPORT

Summary of the Meeting Held June 25, 2012

ATTACHMENT 1

PART I REGULATIONS

a. Board Approved

ATTACHMENT 2

a. Add Title 16 Section 1727.2 – Requirements for Pharmacist Interns
b. Amend Title 16 Section 1728 – Requirements for Pharmacist Examination
   Requirement for Applicants to Submit a Self-Query Report from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB)

In 2011, the board initiated a rulemaking to add Title 16 CCR § 1727.2 and to amend Title 16 CCR § 1728 to require a Pharmacist Intern applicant and an applicant for the pharmacist examination to submit with his or her application a Self-Query Report from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB). The board determined that the requirement(s) to submit a Self-Query Report, as specified in the proposal, was necessary and pertinent to the board’s investigation of an applicant and will allow the board to determine if an applicant has been the subject of discipline in another state prior to making a decision on an application. This is the same type of Self-Query Report that was approved in 2011 for Pharmacy Technician applicants.

With regard to the regulation adopted at Section 1727.2 (requirements for a pharmacist intern), the OAL reviewing attorney contacted staff to remind the board that pursuant to Business and Professions Code Section 4207(d), the board may request any information it deems necessary to complete an application investigation – and that for the purposes specified in § 4207 the board is not required to adopt such a requirement by regulation, subject to OAL review.
b. Discussion and Possible Action – Board Approved Regulations Noticed

ATTACHMENT 3

1. Proposed Amendments to Title 16, California Code of Regulations Section 1735.1, 1735.2, 1735.3, and 1751.2 Related to Compounding Drug Products

On March 9, 2012, the board noticed for a 45-day public comment period, proposed amendments to Title 16 California Code of Regulations beginning at Section 1735.1 relating to compounding drug products. The 45-day comment period concluded on April 23, 2012, and the Board conducted a Regulation Hearing on May 1, 2012.

At the Board Meeting held May 1-2, 2012, the board considered comments received during the 45-day public comment period and at the Regulation Hearing and voted to modify the text of Section 1735.3(a)(6) to incorporate by reference USP 797 related to “Redispensed CSPs”; and to amend Section 1751.2(d) modifying the text of the special label used for cytotoxic agents. The board directed that the modified language be made available for a 15-day public comment period.

A Notice of a 15-Day public comment period was issued on July 5, 2012; this public comment period will conclude on July 20, 2012. A copy of the Modified Text is provided in Attachment 3.

2. Proposed Amendments to Title 16, Section 1746 – Emergency Contraception Protocol

Background
Business and Professions Code Section 4052.3 authorizes a pharmacist to initiate emergency contraception therapy in accordance with either (1) standardized procedures or protocols developed by the pharmacist and an authorized prescriber, as specified; and (2) standardized procedures or protocols developed and approved by both the Medical Board of California and the Board of Pharmacy, as specified.

The current state protocol was developed by the Medical Board in 2004 and was adopted by the Board of Pharmacy that same year. Title 16 CCR § 1746 became operative on December 2, 2004. Since that time, there have been changes in the availability of emergency contraception medicine, the manufacturers who produce the medication. The protocol also has a typographical error that requires correction (mcg instead of mg).

In October 2011, the board voted to initiate a proposed rulemaking to update the board’s Emergency Contraception Protocol at Title 16 Section 1746, to reflect the language and protocol approved by the Medical Board of California in July 2011.
The board noticed the proposed regulation on January 6, 2012, and the 45-day public comment period concluded on February 20, 2012. The board received one comment during that period.

Following the adoption of a new emergency contraception protocol, the board will then need to update its patient information fact sheet. This fact sheet is required by Section 4052.3(e) of the Business and Professions Code and is provided to the patient by the pharmacist using the protocol to dispense emergency contraception. The update of a fact sheet would be vetted through the board’s Communication and Public Education Committee.

At the May 1, 2012 Board Meeting Dr. Kathleen Hill-Besinque, the women’s health specialist designated by the California Pharmacists Association appeared before the board to answer questions related to the proposed protocol. Thereafter, the board voted to reject the comments received during the 45-day public comment period. The next step is for the Medical Board of California to consider the 45-day comments. Given the Medical Board’s approval, the board directed staff to finalize the rulemaking and authorize the Executive Officer to make any nonsubstantive changes before adopting the regulation.

Recent Update:
Following the May 2012 Board Meeting, Dr. Besinque provided the board with suggested modifications to the Table of Dedicated Emergency Contraception (at Section 1746 (b)(11)) to provide clarity on the administration of the two-tablet regimes. Attachment 3 contains a copy of the EC Protocol, showing these modifications in the Table of Dedicated Emergency Contraception. This version is being considered by the Medical Board at its next meeting, to be held in Sacramento on July 19-20, 2012.

Staff Recommendation: Upon the concurrence and approval of the modified text by the Medical Board of California, direct staff to take all steps necessary to complete the rulemaking process, including issuing the modified text for a 15-day comment period. If after the 15-day public comment period, no adverse comments are received, authorize the Executive Officer to make any non-substantive changes to the proposed regulations before completing the rulemaking process, and adopt Section 1746 of the proposed regulations as noticed in the modified text notice.

c. Board Approved Regulations Awaiting Formal Public Notice

1. Proposed Addition of Section 1762 – Additional Grounds for Unprofessional Conduct

In October 2010, the board began discussions to add 16 CCR § 1762 to implement components of the DCA’s Consumer Protection Enforcement Initiative relative to unprofessional conduct. In February 2011 the board addressed draft language and moved to initiate the rulemaking process to amend Section 1762 to specify that certain acts would constitute unprofessional conduct including: gag clauses in a civil suit settlement; failure to provide information as requested by the board; failure to
comply with a court order or subpoena for records; and authorize the board to revoke a license or deny an application for an act requiring an individual to register as a sex offender.

Staff is working to prepare a rulemaking package for a 45-day public comment period, together with proposed amendments to Sections 1745 and 1769. Attachment 4 includes a copy of the proposed text approved by the board.

2. Proposed Addition of Section 1769 – Addition of Application Review to Criteria for Rehabilitation

Protection Enforcement Initiative with regarding to 16 CCR § 1769 – a proposal that would authorize the board to request that an applicant for licensure undergo an examination, as specified, to determine if the applicant is safe to practice. The board directed that staff initiate the rulemaking process to amend 16 CCR § 1769, specifying that once it has been determined that an applicant is to be evaluated, the evaluation shall be completed within 60 days, and that within 60 days of the evaluation, the report be received by the board.

Staff is working to prepare a rulemaking package for a 45-day public comment period, together with proposed amendments to Sections 1745 and 1762. Attachment 4 includes a copy of the proposed text approved by the board.

3. Proposed Amendments to Section 1745 – Partial Filling of Schedule II Controlled Substance Prescriptions

At the October 2010 Board Meeting the board voted to initiate a rulemaking to amend Section 1745(c)(2) to allow pharmacies to maintain electronic records or document on the original prescription when partially filling a Schedule II controlled substance. The language approved by the board is below. Staff is working to prepare a rulemaking package for a 45-day public comment period, together with proposed amendments to Sections 1762 and 1769.

1745(c)(2) The pharmacist records the date and amount of each partial filling in a readily retrievable form and or on the original prescription, also recording the initials of the pharmacist dispensing the prescription;

4. Proposed Addition of Section 1751.9 – Standards for Agencies that Accredit Sterile Injectable Compounding Pharmacies

At the May 2012 Board Meeting the board considered a recommendation from the Licensing Committee to adopt requirements to specify standards for agencies that accredit licensed sterile injectable compounding pharmacies. At that meeting the board voted to initiate a formal rulemaking to add Section 1751.9 to Division 17 of Title 16 of the California Code of Regulations. The proposed text approved by the board but not yet noticed for public comment is provided in Attachment 4.
5. Proposed Amendments to Section 1732.2 – Board Accredited Continuing Education

At the Board Meeting held January 31, 2012, the board considered amendments to the board’s continuing education regulation. At that time, a rulemaking to amend Section 1732.2 related to continuing education was pending final review at the Office of Administrative Law. The board voted to withdraw from OAL its rulemaking to amend Title 16 of the California Code of Regulations Section 1732.2 and refer the matter to the Licensing Committee.

At the May 2012 Board Meeting, the board considered proposed language to modify Section 1732.2, and the board voted to initiate a rulemaking. The language approved by the board for public notice is provided in Attachment 4. Staff is in the process of preparing a notice package for this rulemaking.

6. Proposed Amendments to Section 1732.5 – Specification of Continuing Education Credit in Specific Content Areas

The board has considered requirements related to requiring continuing education in certain areas. At the February 2012 Board Meeting, the board determined to proceed with a rulemaking to require six of the 30 units required for a pharmacist license renewal every two years to be in specified content areas. The matter was referred back to the Licensing Committee, and at the May 2012 Board Meeting, the board voted to initiate a rulemaking to amend Section 1732.5 of Title 16 of the California Code of Regulations as noted below. Staff is in the process of preparing a notice package for this rulemaking.

1732.5. Renewal Requirements for Pharmacists.
(a) Except as provided in section 4234 of the Business and Professions Code and section 1732.6 of this Division, each applicant for renewal of a pharmacist license shall submit proof satisfactory to the board, that the applicant has completed 30 hours of continuing education in the prior 24 months.
(b) At least six of the 30 units required for pharmacist license renewal shall be completed in one or more of the following subject areas:
   (1) Emergency/Disaster Response,
   (2) Patient Consultation,
   (3) Maintaining Control of a Pharmacy’s Drug Inventory,
   (4) Ethics,
   (5) Substance Abuse.
Pharmacists renewing their licenses which expire on or after July 1, 2015, shall be subject to the requirements of this subdivision.
(b) (c) All pharmacists shall retain their certificates of completion for four years following completion of a continuing education course.
7. Proposed Amendment of Section 1732.05 to Update Accreditation Agencies for Continuing Education

At the May 2012 Board Meeting, the board considered a request from the California Pharmacists Association requesting a modification to Section 1732.05 of Title 16 of the California Code of Regulations to reflect the restructuring of the Pharmacy Foundation of California and its transference of duties related to the provision of continuing education to the California Pharmacists Association. At that meeting the board voted to amend Section 1732.05 and to initiate a formal rulemaking. The language approved by the board is provided in Attachment 4. Staff is in the process of preparing a notice package for this rulemaking.

d. Under Development

1. Proposed Amendments to Section 1780 – Update the USP Standards Reference Manual (Minimum Standards for Drug Wholesalers) [referred to subcommittee]

Background
Section 1780 of the California Code of Regulations sets minimum standards for drug wholesalers. This regulation currently references the 1990 edition of the United States Pharmacopeia Standards (USP Standards) for temperature and humidity. USP Standards are updated and published annually. Section 1780(b) requires amendment to reflect the 2005 version of the USP Standards and to hold wholesalers accountable to the latest standards, if determined appropriate.

Because of stated concerns about whether referencing the 2005 USP Standards would be an unreasonable burden on wholesalers, at the October 2008 Board Meeting, the board voted to address the issue of updating the USP Standards reference materials within this section.

The board established a subcommittee for this purpose but, as a result of board vacancies, the subcommittee has not held any meetings and no action has been taken with respect to this regulation change. At the May 2012 Board Meeting, Board President Weisser encouraged the board to begin work in this area soon.

2. Proposed Amendments to Section 1785 – Self-Assessment of a Veterinary Food-Animal Drug Retailer [referred to Licensing Committee]

Background
The requirements of § 1785 establish a self-assessment form for veterinary food-animal drug retailers and requires a designated representative-in-charge to complete this form to ensure compliance with pharmacy law. Self-assessment forms also aid licensees in complying with legal requirements of their operations and, therefore, increase public safety as a result of this compliance.

In 2007 the Enforcement Committee and the Board approved draft amendments to the regulation and related self-assessment form; subsequently, the licensing
committee was advised of potential problems with the licensing requirements for designated representatives working at these facilities.

The Licensing Committee has not yet initiated a program review of the Veterinary Food-Animal Drug Retailer program. At such time that the committee completes a review, draft language will be brought back to the board for reconsideration.

e. Discussion and Possible Action to Initiate a Rulemaking to Amend California Code of Regulations, Title 16, Section 1760 – Disciplinary Guidelines, and to Add a New Section Regarding Implementation of Uniform Standards for Substance Abusing Licensees

ATTACHMENT 5

Relevant Sections
California Code of Regulations Section 1760 requires the board to consider disciplinary guidelines when reaching a decision on a disciplinary action.

Business and Professions Code Section 315 established the Substance Abuse Coordination Committee (SACC) within the Department of Consumer Affairs. The committee was charged with formulating uniform and specific standards in several areas for dealing with substance-abusing licensees.

Chapter 9, Division 2, Chapter 19 (business and professions code sections 4300-4315) defines disciplinary proceeding for the board as well as the grounds for taking such discipline.

Background
Last year the board directed staff to a restructuring and updating of its Disciplinary Guidelines last year. Subsequent to this, in April 2011, the SACC finalized the uniform standards required in B&PC section 315. At that time it was understood that the standards needed to be incorporated into the board’s disciplinary guidelines to facilitate implementation.

During the July 2011 Board meeting, staff was directed to incorporate the uniform standards into the disciplinary guidelines for consideration by the board at a future meeting. During the September 2011 Board Meeting, the board voted to pursue a regulation change to disciplinary guidelines which were noticed in October 2011 and later modified during the January 2012 board meeting.
More recently, during the May 2012 Board Meeting, the board was advised of a recent advice provided to the department from the Government Law Section of the Attorney General’s Office as well as a legal opinion from the Legislative Counsel Bureau. Based on these opinions, the department sent memorandum clarifying that the board has no discretion on how to implement the standards. The board was advised of two options – proceeding as is or rescinding the current regulation. Two areas where the board has discretion were identified including: (1) whether the Uniform Standards should be placed in a regulation separate from the Disciplinary Guidelines; and (2) if the regulation should include a definition of (or criteria by which to determine) what constitutes a “substance-abusing licensee.” Based on this information the board voted to rescind the current rulemaking file and requested that counsel craft language to facilitate implementation of the standards as well as language to define “substance-abusing licensee.”

The scope of the proposed changes to the Disciplinary Guidelines included more than just the uniform standards. As such, a regulation change is necessary to implement those additional changes. Attachment 5 contains the proposed changes that have been identified and drafted for board consideration for incorporation into the board’s Disciplinary Guidelines.

Provided below is a list of each of the proposed changes to the guidelines.

**Changes resulting from reorganization of the guidelines**

- Consolidation of all of the individual license types.
- Removal of all legal citations under each separate category of violations
- Improved definitions and inclusion of sample violations within each category of violation.

**Individual Licensees**

New terms of probation
- Suspension

Changes to existing terms of probation
- Cooperate with Board Staff
- Restrictions on Supervision and Oversight of Licensed Facilities
- Reimbursement of Board Costs
- Certification Prior to Resuming Work (Pharmacy Technician Only)
- Notification of Departure
- License Practice Requirements – Tolling
- Restricted Practice
- Pharmacist Exam (Pharmacists Only)
- Psychotherapy
- Medical Evaluation
- Pharmacists Recovery Program (Pharmacists and Pharmacist Interns Only)
- Abstain from Drugs and Alcohol
- Prescription Coordination and Monitoring of Prescription Use
- Community Service Program
• Supervised Practice
• Surrender of DEA Permit (Pharmacists and Pharmacist Interns Only)
• Ethics Course

Changes to incorporate SB 1441 Uniform Standards
• Reporting of Employment and Notice to Employers (Uniform Standard 3)
• Clinical Diagnostic Evaluation (Uniform Standard 1 and 2)
• Drug and Alcohol Testing (Uniform Standard 4)
• Facilitated Group Recovery and/or Support Meetings (Uniform Standard 5)
• Work Site Monitor (Uniform Standard 7)

Premises Licensees

New terms of probation
• Definition: Respondent
• Sale or Discontinuance of Business
• Premises Open for Business
• Suspension

Changes to existing terms of probation
• Cooperate with Board Staff
• Reimbursement of Board Costs
• Status of License
• Posted Notice of Probation
• Report of Controlled Substances
• Posted Notice of Suspension

Counsel is preparing the language requested by the board regarding the definition of substance abusing licensee as well as language to incorporate SB 1441 standards and will discuss this with the members during the meeting. Language will be provided in advance of the meeting when available.
Attachment 1
Minutes
California State Board of Pharmacy
LEGISLATION AND REGULATION COMMITTEE

Meeting Date:
June 25, 2012

Location:
Department of Consumer Affairs
1625 N. Market Blvd.
El Dorado Conference Room – 2nd Floor
Sacramento, CA 95834

Committee Members Present:
Shirley Wheat, Chair
Debbie Veale, RPh
Ramon Castellblanch, Ph.D.

Committee Members Not Present:
Tappan Zee

Staff Present:
Virginia Herold, Executive Officer
Anne Sodergren Assistant Executive Officer
Carolyn Klein
Kristy Shellans, DCA Sr. Staff Counsel

Ms. Wheat called the meeting to order at 10:09 a.m.

Agenda Item A. Legislation Report

The committee members discussed the following legislative measures:

Board Sponsored Legislation
1. **SB 1575** (Price) – Omnibus. Ms. Wheat summarized the current status of the board’s sponsored legislation. No change in position was recommended.

Legislation Impacting the Practice of Pharmacy or the Board’s Jurisdiction
2. **AB 389** (Mitchell) – Bleeding Disorders: Blood Clotting Products. Ms. Wheat provided an overview of the status of the measure and reminded the committee of the board’s current position (Oppose), as well as a basis for the position. No change in position was recommended.
3. **AB 1442** (Weickowski) – Pharmaceutical Waste. Ms. Sodergren summarized the status of the bill, stating that the author has taken some of the board’s amendments, but staff is continuing to work with the author’s office to negotiate additional amendments. Because the author has addressed the board’s concerns, staff recommended that the board’s position be changed from Oppose Unless Amended to Neutral. There was no public comment.

   **M/S: Veale/Castellblanch** – Recommend that the board change its position from Oppose Unless Amended to Neutral

   Vote: 3-0-0
4. **AB 2348** (Mitchell) – Registered Nurses: Dispensation of Drugs. Ms. Wheat summarized the current status of the bill, noting that staff continues to watch this measure. There was no committee recommendation on this measure.

5. **SB 419** (Simitian) – Solid Waste: Home-Generated Sharps. Ms. Wheat noted that the board does not have a position on this measure, and that the bill remains on the Assembly Inactive File. There have been no changes to this bill since 2011. The committee made no recommendation on this measure.

6. **SB 1301** (Hernandez) 0 Prescription Drugs: 90-Day Supply. Ms. Wheat provided an overview of the bill and reminded the committee of the board’s position: SUPPORT. The committee made no recommendation on this measure.

7. **SB 1329** (Simitian) – Prescription Drugs: Collection and Redistribution Program. Ms. Wheat noted the board’s position of SUPPORT IF AMENDED, and that the author’s office has addressed some of the board’s concerns. Ms. Herold noted that staff continues to work with the author’s staff to negotiate amendments. She added that a few areas that remain to be addressed include the transferring of drugs between county program, the frequency of reporting and some of the facilities that would be able to donate medications. No change in position was recommended. There was no public comment.

Sunset Review and Legislative Oversight

8. **SB 1237** (Price) – Pharmacy Sunset. Ms. Wheat noted the board’s current position of SUPPORT. There was no committee or public discussion of this bill.

Licensing and Pharmacy Operations

9. **AB 377** (Solorio) – Pharmacy (Hospital Central Fill). Ms. Wheat noted the board’s current position of Support if Amended (April 2011). Philip Swanger representing the California Society of Health-System Pharmacists (the sponsors) stated that they are looking to amend the bill in the coming week or so. He said stakeholders are reaching consensus. Ms. Herold advised the committee of the anticipated scope of the expected amendments, and the committee discussed the benefits of the bill’s provisions. Mr. Swanger told the committee that the board could likely see amendments by the July Board Meeting.

10. **AB 1588** (Atkins) – Reservist Licensees: Fees and Continuing Education. Ms. Wheat summarized the status of this bill, noting that the committee has never discussed this measure before, and that the board does not have a position. Ms. Wheat noted that this bill would require the board to waive a licensee’s renewal fee and continuing education requirements, if applicable, for any licensee who is a reservist called to active duty. Sr. Staff Counsel Kristy Shellans noted that this bill would not require that the status of the license to be “inactive,” nor does the bill define the term “good standing.” Ms. Shellans recommended that staff seek clarification of the meaning “in good standing.” Public comment included that if someone is only licensed in California and is serving as a pharmacist, placing them on an Inactive status would cause a concern. In addition, the public comment indicated that the military provides training that is not ACPE or CAPE approved and, as such, that training would not count towards CE under current law. Staff will clarify the intent of the law as well as other concerns.
11. **AB 1896** (Chesbro) – Tribal Health Programs: Health Care Practitioners. Ms. Wheat summarized the status of this bill, and reminded the committee that the board has not taken a position on this measure. Staff share concerns and counsel advised the committee of her concerns including that it is unclear what legal standing the board would have. Staff will clarify the intent of the language.

   *M/S (Veale/Castellblanch) Recommend that the board establish a position of Oppose Unless Amended and offer amendments to require licensure if the tribal health program will be providing services to Californians outside of the tribal lands.*

   Vote 3-0-0

12. **AB 1904** (Block) Military Spouses: Expedited Licensure. Ms. Wheat noted that the board established a position of SUPPORT at the May Board Meeting. Ms. Shellans stated her concern with the bill language “shall expedite the licensure process,” indicating the language sounds like the board would have to give the applicant a license. The committee discussed Ms. Shellans concerns and directed staff to alter the language so as to clarify the term “current license.”

13. **AB 2570** (Hill) – Licensees: Settlement Agreements. Ms. Wheat provided an overview of the measure and reminded the committee that the board has a position of OPPOSE UNLESS AMENDED. Ms. Shellans expressed concern with the restitution provision and explained why this provision of the measure is problematic. The committee did not make a recommendation to change the board’s position.

14. **SB 1095** (Rubio) – Pharmacy: Clinics. Ms. Wheat summarized the current status of the bill, reminding the committee that the board currently has a position of OPPOSE UNLESS AMENDED. The committee was advised by the sponsor that amendments should be in print by tomorrow and they have asked that the committee hearing (ASM Health) be postponed to July 3 so that the amendments would be in print. Ms. Herold noted that the expected amendments address the board’s concerns. Ms. Wheat indicated the board will continue discussion of the measure at the July Board Meeting.

15. **SB 1481** (Negrete McLeod) Clinical Laboratories: Community Pharmacies. Ms. Wheat noted the current status of the bill, and the board’s current position of SUPPORT. No change in position was recommended.

*Other*

16. **AB 2369** (Valadao) – Prisoners: Pharmacy Services. There was no committee or public discussion of this measure.

17. **SB 1185** (Price) – Centralized Intelligence Partnership Act. There was no committee or public discussion of this measure.
Agenda Item B. REGULATION REPORT

Board Approved – Undergoing Review by the Administration

a. Ms. Wheat advised the committee that the Office of Administrative Law recently approved the board’s rulemaking and that the regulation will be effective on July 18, 2012:

Add Title 16 Section 1727.2 – Requirements for Pharmacist Interns and
Amend Title 16 Section 1728 – Requirements for Pharmacist Examination

To Require Specified Applicants to Submit a Self-Query from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB)

Board Approved – Regulations Currently Noticed

a. Proposed Amendments to Title 16 Section 1746 – Emergency Contraception Protocol

Ms. Wheat advised the committee on the status of the regulation, as well as the action that will be required by the Medical Board of California. Ms. Herold advised the committee that one amendment is necessary, noting the scope of the amendment related to two screening items that will be added to the protocol.

b. Proposed Amendments to Title 16 Starting at Section 1735.1 Related to Compounding Drug Products

Ms. Wheat provided the committee with an update on the status of the regulation. Public comment from the California Society of Health-System Pharmacists expressed gratitude for the board’s efforts and commented that the Frequently Asked Questions (FAQs) document may be a bit out of sync. Ms. Herold encouraged CSHP to submit comments to the board on the FAQs.

Board Approved – Awaiting Notice (Information Only)

a. Proposed Addition of Section 1762 – Additional Grounds for Unprofessional Conduct
b. Proposed Addition of Section 1769 – Addition of Application Review to Criteria for Rehabilitation
c. Proposed Amendment of Title 16 Section 1745 – Partial Fill of Schedule II Controlled Substance

Ms. Wheat advised the committee that the three regulations noted above are currently being developed for release of the notice.

Proposed Regulations Being Discussed By Committees (Not for Action - Update Only)

Ms. Wheat highlighted the regulations that are currently being reviewed for possible action by other committees.

a. Licensing Committee
   • Updates to the USP Standards Reference Manual
   • Standards for Agencies that Accredit Licensed Sterile Injectable Compounding Pharmacies
   • Continuing Education
   • Accreditation Agencies for Continuing Education
   • Self-Assessment of a Veterinary Food-Animal Drug Retailer
b. Enforcement Committee
   • Requirements for Unique ID Numbers for Rx / E-Pedigree
   • Development of “Grandfathering” Provisions for Non-Pedigree Dangerous Drugs

c. Communication and Public Education Committee
   • Notice to Consumers Posters / Video Display Format Option / Interpreter Availability

There was no additional public comment.

Ms. Wheat adjourned the meeting at 11:25 a.m.

Adjournment  (Note: Adjournment time is approximate)
Attachment 2
Add Section 1727.2. to Article 3 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1727.2. Requirements for Pharmacist Intern.

Every applicant for a pharmacist intern license shall submit as part of the application process, a sealed, original Self Query Report from the National Practitioner Data Bank—Healthcare Integrity and Protection Data Bank (NPDB-HIPDB), dated no earlier than 60 days before the date an application is submitted to the board.


Amend Section 1728. in Article 3 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1728. Requirements for Examination.

(a) Prior to receiving authorization from the board to take the pharmacist licensure examinations required by section 4200 of the Business and Professions Code, applicants shall submit to the board the following:

(1) Proof of 1500 hours of pharmacy practice experience that meets the following requirements:

(A) A minimum of 900 hours of pharmacy practice experience obtained in a pharmacy.
(B) A maximum of 600 hours of pharmacy practice experience may be granted at the discretion of the board for other experience substantially related to the practice of pharmacy.

(C) Experience in both community pharmacy and institutional pharmacy practice settings.

(D) Pharmacy practice experience that satisfies the requirements for both introductory and advanced pharmacy practice experiences established by the Accreditation Council for Pharmacy Education.

(2) Satisfactory proof that the applicant graduated from a recognized school of pharmacy.

(3) Fingerprints to obtain criminal history information from both the Department of Justice and the United States Federal Bureau of Investigation pursuant to Business and Professions Code section 144.

(4) A signed copy of the examination security acknowledgment.

(5) A sealed, original Self Query Report from the National Practitioner Data Bank–Healthcare Integrity and Protection Data Bank (NPDB-HIPDB), dated no earlier than 60 days before the date an application for examination as a pharmacist is submitted to the board.

(b) Applicants who hold or held a pharmacist license in another state shall provide a current license verification from each state in which the applicant holds or held a pharmacist license prior to being authorized by the board to take the examinations.
(c) Applicants who graduated from a foreign school of pharmacy shall provide the board with satisfactory proof of certification by the Foreign Pharmacy Graduate Examination Committee prior to being authorized by the board to take the examinations.

Note: Authority cited: Sections 851 and 4005, Business and Professions Code.

Reference: Sections 144, 851 and 4200, Business and Professions Code.

Virginia Heald
Executive Officer
Board of Pharmacy
To Amend Section 1735.1 of Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.1. Compounding Definitions.

(a) “Equipment” means items that must be calibrated, maintained or periodically certified.

(b) “Integrity” means retention of potency until the expiration date noted on the label.

(c) “Potency” means active ingredient strength within +/- 10% of the labeled amount.

(d) “Quality” means the absence of harmful levels of contaminants, including filth, putrid, or decomposed substances, and absence of active ingredients other than those noted on the label.

(e) “Strength” means amount of active ingredient per unit of a compounded drug product.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

To Amend Section 1735.2 of Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.2. Compounding Limitations and Requirements; Self-Assessment.

(a) Except as specified in (b) and (c), no drug product shall be compounded prior to receipt by a pharmacy of a valid prescription for an individual patient where the prescriber has approved use of a compounded drug product either orally or in writing. Where approval is given orally, that approval shall be noted on the prescription prior to compounding.

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.

New or added text is shown by double underline, thus: added language.
(b) A pharmacy may prepare and store a limited quantity of a compounded drug product in advance of receipt of a patient-specific prescription where and solely in such quantity as is necessary to ensure continuity of care for an identified population of patients of the pharmacy based on a documented history of prescriptions for that patient population.

(c) A “reasonable quantity” as used in Business and Professions Code section 4052(a)(1) means that amount of compounded drug product that:

(1) is sufficient for administration or application to patients in the prescriber’s office, or for distribution of not more than a 72-hour supply to the prescriber’s patients, as estimated by the prescriber; and

(2) is reasonable considering the intended use of the compounded medication and the nature of the prescriber’s practice; and

(3) for any individual prescriber and for all prescribers taken as a whole, is an amount which the pharmacy is capable of compounding in compliance with pharmaceutical standards for integrity, potency, quality and strength of the compounded drug product.

(d) A drug product shall not be compounded until the pharmacy has first prepared a written master formula record that includes at least the following elements:

(1) Active ingredients to be used.

(2) Equipment to be used.

(3) Expiration dating requirements.

(4) Inactive ingredients to be used.

(5) Process and/or procedure used to prepare the drug.

(6) Quality reviews required at each step in preparation of the drug.

(7) Post-compounding process or procedures required, if any.

(8) Expiration dating requirements.

Changes to the originally proposed language are shown as follows:
Deleted text is shown by double strike-through, thus: deleted language.
New or added text is shown by double underline, thus: added language.
(e) Where a pharmacy does not routinely compound a particular drug product, the master formula record for that product may be recorded on the prescription document itself.

(f) The pharmacist performing or supervising compounding is responsible for the integrity, potency, quality, and labeled strength of a compounded drug product until it is dispensed.

(g) All chemicals, bulk drug substances, drug products, and other components used for drug compounding shall be stored and used according to compendial and other applicable requirements to maintain their integrity, potency, quality, and labeled strength.

(h) Every compounded drug product shall be given an expiration date representing the date beyond which, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used. This “beyond use date” of the compounded drug product shall not exceed 180 days from preparation or the shortest expiration date of any component in the compounded drug product, unless a longer date is supported by stability studies of finished drugs or compounded drug products using the same components and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

(i) The pharmacist performing or supervising compounding is responsible for the proper preparation, labeling, storage, and delivery of the compounded drug product.

(j) Prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment for compounding pharmacies developed by the board. (Incorporated by reference is “Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment” Form 17M-39 Rev. 01/11 02/12.) That form contains a first section applicable to all compounding, and a second section applicable to sterile injectable compounding. The first section must be completed by the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must be completed by the pharmacist-in-charge before any sterile injectable compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of each odd-numbered year, within 30 days of the start of a new pharmacist-in-charge, and within 30 days of the issuance of a new pharmacy license. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.
New or added text is shown by double underline, thus: added language.
To Amend Section 1735.3 of Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.3. Records of Compounded Drug Products.

(a) For each compounded drug product, the pharmacy records shall include:

(1) The master formula record.

(2) The date the drug product was compounded.

(3) The identity of the pharmacy personnel who compounded the drug product.

(4) The identity of the pharmacist reviewing the final drug product.

(5) The quantity of each component used in compounding the drug product.

(6) The manufacturer, expiration date and lot number of each component. If the manufacturer name is demonstrably unavailable, the name of the supplier may be substituted. Exempt from the requirements in this paragraph are sterile products compounded on a one-time basis for administration within twenty-four seventy-two (72) hours and stored in accordance with United States Pharmacopeia Standards for “REDISPENSED CSPs” in Chapter 797 (35th Revision, Effective May 1, 2012), which is hereby incorporated by reference, to an inpatient in a health care facility licensed under section 1250 of the Health and Safety Code.

(7) The equipment used in compounding the drug product.

(8) A pharmacy assigned reference or lot number for the compounded drug product.

(9) The expiration date of the final compounded drug product.

(10) The quantity or amount of drug product compounded.

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.

New or added text is shown by double underline, thus: added language.
(b) Pharmacies shall maintain records of the proper acquisition, storage, and destruction of chemicals, bulk drug substances, drug products, and components used in compounding.

(c) Chemicals, bulk drug substances, drug products, and components used to compound drug products shall be obtained from reliable suppliers. The pharmacy shall acquire and retain any available certificates of purity or analysis for chemicals, bulk drug substances, drug products, and components used in compounding. Certificates of purity or analysis are not required for drug products that are approved by the Food and Drug Administration.

(d) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created.

Note: Authority cited: Sections 4005, 4127 and 4169, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

To Amend Section 1751.2 of Article 7 of Division 17 of Title 16 to read as follows:

§ 1751.2. Sterile Injectable Labeling Requirements.

In addition to the labeling information required under Business and Professions Code section 4076 and section 1735.4, a pharmacy which compounds sterile injectable products shall include the following information on the labels for those products:

(a) Telephone number of the pharmacy, except for sterile injectable products dispensed for inpatients of a hospital pharmacy.

(b) Name and concentrations of ingredients contained in the sterile injectable product.

(c) Instructions for storage and handling.

(d) All cytotoxic agents shall bear a special label which states “Chemotherapy - Dispose of Properly,” or “Cytotoxic Product – Dispose of Properly.”

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, 4076 and 4127, Business and Professions Code.

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.
New or added text is shown by double underline, thus: added language.
Attachment 3
Board of Pharmacy
Modified Language

To Amend § 1746 in Article 5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1746. Emergency Contraception

(a) A pharmacist furnishing emergency contraception pursuant to Section 4052(a)(8) 4052.3.(a)(2) of the Business and Professions Code shall follow the protocol specified in subdivision (b) of this section.

(b) Protocol for Pharmacists Furnishing Emergency Contraception (EC).

(1) Authority: Section 4052 of the California Business and Professions Code authorizes a pharmacist to furnish emergency contraception pursuant to the protocols specified in Business and Professions Code section 4052.3. Use of the following protocol satisfies that requirement.

(1) Authority: Section 4052.3(a)(2) of the California Business and Professions Code authorizes a pharmacist to furnish emergency contraception pursuant to a protocol approved by the California State Board of Pharmacy and the Medical Board of California. Use of the protocol specified in this section satisfies that requirement.

(2) Purpose: To provide timely access to emergency contraceptive medication within required limits and ensure that the patient receives adequate information to successfully complete therapy.

(3) Procedure: When a patient requests emergency contraception, the pharmacist will ask and state communicate the following:

Are you allergic to any medications?

Timing is an essential element of the product's effectiveness. EC should be taken as soon as possible after unprotected intercourse. Treatment may be initiated up to five days (120 hours) of after unprotected intercourse. EC effectiveness declines gradually over five days and EC use will not interfere with an established pregnancy.

EC use will not interfere with an established or implanted pregnancy.

If more than 72 hours have elapsed since unprotected intercourse, the use of ella™ (ulipristal) may be more effective than levonorgestrel. Other options for EC include consultation with your physician regarding insertion of an IUD.

MODIFIED TEXT FOR CONSIDERATION
Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language

New or added text is shown by double underline, thus: added language
(4) The pharmacist shall provide the fact sheet and review any questions the patient may have regarding EC. In addition, the pharmacist shall collect the information required for a patient medication record required by Section 1707.1 of Title 16 of the California Code of Regulations.

Fact Sheet: The pharmacist will provide the patient with a copy of the current EC fact sheet approved by the Board of Pharmacy as required by Business and Professions Code Section 4052(b)(3) 4052.3(e).

(5) Referrals and Supplies: If emergency contraception services are not immediately available at the pharmacy or the pharmacist declines to furnish pursuant to conscience clause, the pharmacist will refer the patient to another emergency contraception provider. The pharmacist shall comply with all state mandatory reporting laws, including sexual abuse laws.

(6) The pharmacist may provide up to 12 non-spermicidal condoms to each Medi-Cal and Family PACT client who obtains emergency contraception.

(7) Advanced provision: The pharmacist may dispense emergency contraception medication for a patient in advance of the need for emergency contraception.

(8) EC Product Selection: The pharmacist will provide emergency contraception medication compatible with product information from the list of products specified in this protocol. This list must be kept current and maintained in the pharmacy. Along with emergency contraception products, the list will include adjunctive medications indicated for nausea and vomiting associated with taking EC containing estrogen. Patients will be provided information concerning dosing and potential adverse effects.

(9) Documentation: Each prescription authorized by a pharmacist will be documented in a patient medication record as required by law.

(10) Training: Prior to furnishing emergency contraception, pharmacists who participate in this protocol must have completed a minimum of one hour of continuing education specific to emergency contraception.

(11) Brands and Doses of Oral Contraceptive Tablets Used for Emergency Contraception.

MODIFIED TEXT FOR CONSIDERATION
Changes to the originally proposed language are shown as follows:
- Deleted text is shown by double strike-through, thus: deleted language
- New or added text is shown by double underline, thus: added language
(11) Brands and Doses of Oral Contraceptive Tablets Used for Emergency Contraception.

### Dedicated Emergency Contraception

<table>
<thead>
<tr>
<th>Brand</th>
<th>Manufacturer</th>
<th>Tablets per Dose</th>
<th>Ethinyl Estradiol per Dose (mg)</th>
<th>Levonorgestrel per Dose (mg)**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>One Dose Regimen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plan-B</td>
<td>Women's Capital Corporation</td>
<td>2-tablets</td>
<td>0</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Two Dose Regimens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plan-B</td>
<td>Women's Capital Corporation</td>
<td>1-tablet per dose</td>
<td>0</td>
<td>0.75</td>
</tr>
<tr>
<td>Preven</td>
<td>Gynécics</td>
<td>2-tablets per dose</td>
<td>100</td>
<td>0.50</td>
</tr>
</tbody>
</table>

### Oral Contraceptive Pills

<table>
<thead>
<tr>
<th>Brand</th>
<th>Manufacturer</th>
<th>Tablets per Dose (two doses 12 hours apart)*</th>
<th>Ethinyl Estradiol per Dose (mg)</th>
<th>Levonorgestrel per Dose (mg)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levora</td>
<td>Watson</td>
<td>4-white tablets</td>
<td>120</td>
<td>0.60</td>
</tr>
<tr>
<td>Ovral</td>
<td>Wyeth</td>
<td>2-white tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Ogestrel</td>
<td>Watson</td>
<td>2-white tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Nordette</td>
<td>Wyeth</td>
<td>4-light-orange tablets</td>
<td>120</td>
<td>0.60</td>
</tr>
<tr>
<td>Tri-Levlen</td>
<td>Berlex</td>
<td>4-yellow tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Alesse</td>
<td>Wyeth</td>
<td>5-pink tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Aviane</td>
<td>Duramed</td>
<td>5-orange tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Triphasil</td>
<td>Wyeth</td>
<td>4-yellow tablets</td>
<td>120</td>
<td>0.50</td>
</tr>
<tr>
<td>Levlen</td>
<td>Berlex</td>
<td>4-light-orange tablets</td>
<td>120</td>
<td>0.60</td>
</tr>
<tr>
<td>Trivora</td>
<td>Watson</td>
<td>4-pink tablets</td>
<td>120</td>
<td>0.50</td>
</tr>
<tr>
<td>Levilite</td>
<td>Berlex</td>
<td>5-pink tablets</td>
<td>100</td>
<td>0.50</td>
</tr>
<tr>
<td>Lo/Ovral</td>
<td>Wyeth</td>
<td>4-white tablets</td>
<td>120</td>
<td>0.60</td>
</tr>
<tr>
<td>Low-Ogestrel</td>
<td>Watson</td>
<td>4-white tablets</td>
<td>120</td>
<td>0.60</td>
</tr>
<tr>
<td>Ovrette</td>
<td>Wyeth</td>
<td>20-yellow tablets</td>
<td>0</td>
<td>0.75</td>
</tr>
</tbody>
</table>

*The progestin in Ovral, Lo/Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each dose is twice the amount of levonorgestrel.
## Medications Used for Emergency Contraception

### Dedicated Approved Products for Emergency Contraception

<table>
<thead>
<tr>
<th>Brand</th>
<th>Dose</th>
<th>Ethinyl Estradiol per dose (mcg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>One Dose Regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plan B™ One-Step</td>
<td>1 tablet</td>
<td>0</td>
</tr>
<tr>
<td>ella™</td>
<td>1 tablet</td>
<td>0</td>
</tr>
<tr>
<td><strong>Two Tablet Dose Regimens</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Next Choice™</td>
<td>2 tablets at once</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>(1.5mg total dose)</td>
<td>Each tablet is</td>
</tr>
<tr>
<td></td>
<td>1 tablet (0.75mg)</td>
<td>0.75 mg</td>
</tr>
<tr>
<td></td>
<td>12 hours later</td>
<td>levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>1 tablet per dose</td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>2 tablets at once</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>(1.5mg total dose)</td>
<td>Each tablet is</td>
</tr>
<tr>
<td></td>
<td>or 1 tablet (0.75mg)</td>
<td>0.75 mg</td>
</tr>
<tr>
<td></td>
<td>followed by</td>
<td>levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>1 tablet (0.75mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 hours later</td>
<td></td>
</tr>
<tr>
<td>Oral Contraceptive Pills</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brand</td>
<td>Tablets per Dose</td>
<td>Ethinyl Estradiol per dose (mcg)</td>
</tr>
<tr>
<td>Alesse</td>
<td>5 pink tablets</td>
<td>100</td>
</tr>
<tr>
<td>Aviane</td>
<td>5 orange tablets</td>
<td>100</td>
</tr>
<tr>
<td>Levlen</td>
<td>4 light-orange tablets</td>
<td>120</td>
</tr>
<tr>
<td>Levlite</td>
<td>5 pink tablets</td>
<td>100</td>
</tr>
<tr>
<td>Levora</td>
<td>4 white tablets</td>
<td>120</td>
</tr>
<tr>
<td>Lo/Ovral</td>
<td>4 white tablets</td>
<td>120</td>
</tr>
<tr>
<td>Low-Ogestrel</td>
<td>4 white tablets</td>
<td>120</td>
</tr>
<tr>
<td>Nordette</td>
<td>4 light-orange tablets</td>
<td>120</td>
</tr>
<tr>
<td>Ogestrel</td>
<td>2 white tablets</td>
<td>100</td>
</tr>
<tr>
<td>Ovral</td>
<td>2 white tablets</td>
<td>100</td>
</tr>
<tr>
<td>Tri-Levlen</td>
<td>4 yellow tablets</td>
<td>100</td>
</tr>
<tr>
<td>Triphasil</td>
<td>4 yellow tablets</td>
<td>120</td>
</tr>
<tr>
<td>Trivora</td>
<td>4 pink tablets</td>
<td>120</td>
</tr>
<tr>
<td>Ovrette</td>
<td>20 yellow tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

---

MODIFIED TEXT FOR CONSIDERATION

Changes to the originally proposed language are shown as follows:

- Deleted text is shown by double strike-through, thus: deleted language
- New or added text is shown by double underline, thus: added language
The progestin in Ovral, Lo/Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each dose is twice the amount of levonorgestrel.

In addition to the products specified in this paragraph, generic equivalent products may be furnished. Estrogen containing regimens are not preferred and should be used only when the other options are not available.

(12) Anti-nausea Treatment Options for use with Emergency Contraception

| Anti-Nausea Treatment Options For Use With Emergency Contraception |
|------------------------|------------------|---------------------------|
| Drug                   | Dose             | Timing of Administration  |
| Meclizine hydrochloride (Dramamine II, Bonine) | One or two 25 mg tablets | 1 hour before first EC dose; repeat if needed in 24 hours |
| Diphenhydramine hydrochloride (Benadryl) | One or two 25 mg tablets or capsules. | 1 hour before first EC dose; repeat as needed every 4-6 hours |
| Dimenhydrinate (Dramamine) | One or two 50 mg tablets or 4-8 teaspoons liquid | 30 minutes to 1 hour before first ECP EC dose; repeat as needed every 4-6 hours |
| Cyclizine hydrochloride (Marezine) | One 50 mg tablet | 30 minutes before first EC dose; repeat as needed every 4-6 hours |

Attachment 4
Title 16. Board of Pharmacy
Proposed Language

To Add Section 1762 to Article 8 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1762. Unprofessional Conduct Defined.

In addition to those acts detailed in Business and Professions Code Section 4301, the following shall also constitute unprofessional conduct:

(a) Including or permitting to be included any of the following provisions in an agreement to settle a civil dispute arising from the licensee’s practice, whether the agreement is made before or after the filing of an action:

(1) A provision that prohibits another party to the dispute from contacting, cooperating, or filing a complaint with the board; or,

(2) A provision that requires another party to the dispute to attempt to withdraw a complaint the party has filed with the board.

(b) Failure without lawful excuse to provide records requested by the board within 15 days of the date of receipt of the request or within the time specified in the request, whichever is later.

(c) Failure or refusal to comply with any court order issued in the enforcement of a subpoena, mandating the release of records to the board.

(d) Commission of any act resulting in the requirement that a licensee or applicant registers as a sex offender. The board may revoke the license of any licensee and deny the application of any applicant who is required to register as a sex offender pursuant to Section 290 of the Penal Code or any other equivalent federal, state or territory’s law that requires registration as a sex offender.


PROPOSED TEXT – NOT YET ISSUED FOR PUBLIC COMMENT
Title 16. Board of Pharmacy
Proposed Language

To Amend § 1769 in Article 8 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1769. Criteria for Rehabilitation.

(a) In addition to any other requirements for licensure, when considering the approval of an application, the board or its designee may require an applicant to be examined by one or more physicians and surgeons or psychologists designated by the board if it appears that the applicant may be unable to safely practice due to mental illness or physical illness affecting competency. An applicant’s failure to comply with the examination requirement shall render his or her application incomplete. The board shall pay the full cost of such examination. The board shall seek that the evaluation be conducted within 60 days of the date the applicant is advised that an examination is required. The board shall receive the examiner’s evaluation within 60 days of the date the examination is completed. The report of the examiner shall be made available to the applicant.

If after receiving the report of the evaluation, the board determines that the applicant is unable to safely practice, the board may deny the application.

(b) When considering the denial of a facility or personal license under Section 480 of the Business and Professions Code, the board, in evaluating the rehabilitation of the applicant and his present eligibility for licensing or registration, will consider the following criteria:

(1) The nature and severity of the act(s) or offense(s) under consideration as grounds for denial.

(2) Evidence of any act(s) committed subsequent to the act(s) or crime(s) under consideration as grounds for denial under Section 480 of the Business and Professions Code.

(3) The time that has elapsed since commission of the act(s) or crime(s) referred to in subdivision (1) or (2).

(4) Whether the applicant has complied with any terms of parole, probation, restitution or any other sanctions lawfully imposed against the applicant.

(5) Evidence, if any, of rehabilitation submitted by the applicant.

(c) When considering the suspension or revocation of a facility or a personal license on the ground that the licensee or the registrant has been convicted of a crime, the board, in evaluating the rehabilitation of such person and his present eligibility for a license will consider the following criteria:

Proposed Text – Not Yet Noticed for Public Comment
(1) Nature and severity of the act(s) or offense(s).

(2) Total criminal record.

(3) The time that has elapsed since commission of the act(s) or offense(s).

(4) Whether the licensee has complied with all terms of parole, probation, restitution or any other sanctions lawfully imposed against the licensee.

(5) Evidence, if any, of rehabilitation submitted by the licensee.

Title 16. Board of Pharmacy
Proposed Language

To Add § 1751.9 to Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1751.9. Accreditation Agencies for Pharmacies that Compound Injectable Sterile Drug Products

(a) An agency seeking to become an approved accrediting agency for pharmacies or nonresident pharmacies that compound sterile injectable drug products pursuant to Business and Professions Code sections 4127.1 or 4127.2 shall submit evidence satisfactory to the board as described in subdivision (b) that:

(1) The accrediting agency performs site inspections and re-accreditation reviews of each accredited pharmacy at least annually. Site inspections shall be conducted to ensure compliance with Article 4.5 (commencing with Section 1735) and Article 7 (commencing with Section 1751) of Division 17 of Title 16 of the California Code of Regulations governing the compounding of sterile injectable drug products.

(2) The standards for granting accreditation shall reflect the Pharmacy Law.

(3) The surveyors who perform site inspections possess qualifications necessary to evaluate the professional practices subject to accreditation. At least one member of the survey team must be a licensed pharmacist. All health care practitioner surveyors must maintain current, active and unrestricted licensure to practice their respective professions.

(4) The accrediting agency has sufficient personnel and resources to accredit California and non-resident pharmacies.

(5) The accrediting agency has been operating for a minimum of two years with a history of accrediting health care facilities.

(6) The accrediting agency shall provide the board access to an approved accrediting agency's report on individual pharmacies for a three-year period following issuance of the report. Upon request of the board, the agency shall provide the report within 10 business days.

(b) An agency seeking approval from the board must submit a formal written request to the board signed by an authorized representative that includes the applicant owner’s name, the company name, address of record, and contact information along with the following information:

(1) A side-by-side comparison showing the agency's sterile compounding standards and describing how each standard complies with each of the requirements of this Section.

(2) A list of employees performing survey inspections that also sets forth the name, title, license number, license type, state of licensure and licensure status for each employee.

(3) A list of payers or organizations that the agency is recognized by, if applicable.
(4) A list of health care facility sites currently accredited by the agency including the name, location, license type and license number of each site.

(5) A detailed description of the process used to evaluate health care facility sites seeking accreditation or reaccreditation.

(6) Documentation of compliance with the requirements listed in the self-assessment form referenced in section 1735.2(i) of Title 16 of the California of Code of Regulations in evaluating pharmacies and non-resident pharmacies.

(7) Documentary or other evidence of a process to address non-compliance that may include any or all of the following: (a) a requirement for correction of any identified deficiencies within a set timeframe; (b) a requirement that failure to comply shall result in the accrediting agency issuing a reprimand or suspending or revoking the accreditation; or, (c) a process for suspending or revoking the licensed sterile injectable drug compounding pharmacy’s accreditation.

(c) The Board of Pharmacy shall take action on a completed application at a scheduled board meeting, as follows:

(1) If granted, the approval shall be valid for three years from the date of action by the board.

(2) If the approval is denied, the agency will be notified of the basis for the denial, including a description of the standards that were not met. The agency may submit additional information to the board for reconsideration of the denial within 30 days of the date of the notice of denial. The reconsideration shall be considered at a scheduled board meeting and the accrediting agency may show compliance with the standards set forth in this Section by producing new documentary evidence, providing testimony or submitting other evidence demonstrating why the approval should be granted.

(d) After approval, an approved accreditation agency shall continue to meet the standards provided in this Section and meet any conditions under which it is approved by the board. Failure to comply with the standards set forth in this section or any conditions set by the board shall be grounds for rescission of the board’s approval.

(e) The accreditation agency shall, within 24 hours, report to the board any licensed sterile injectable drug compounding pharmacy issued a reprimand or any licensed sterile injectable drug compounding pharmacy whose accreditation has been suspended, revoked, or otherwise restricted by the accrediting agency.

(f) On an annual basis, no later than July 1 of each year, an approved accrediting agency shall submit a report to the board listing all board-licensed pharmacies or nonresident pharmacies that are currently accredited and have been accredited during the past 12 months with a notation of the outcome of each inspection conducted by the accrediting agency.

(g) The board may conduct unannounced inspections of accredited sites to determine if the licensed facility is in compliance with the Pharmacy Law. An accrediting agency shall cooperate with any board investigation or inspection conducted by the board.

(h) Three months before the end of an approval or re-approval period, an approved accrediting
agency must submit a formal, written request for re-approval to the board or its designee for continued recognition as an approved accrediting agency. The re-approval request shall provide the information set forth in subdivision (b). If the re-approval application fails to demonstrate compliance with this Section, or the board has evidence that the accrediting agency has failed to meet the requirements of this section, the Board or its designee may issue and serve a notice of denial of re-approval on the accrediting agency at its address of record with the board. The denial shall set forth the factual and legal basis for the denial. Within 30 days of the date of the notice, the accrediting agency may request an appeal of the decision to deny re-approval. If no appeal is requested, the denial shall become final. If the board receives a request for an appeal of the notice, the request for an appeal shall be considered a request for an informal hearing under the Administrative Procedure Act (commencing with Section 11445.10 of the Government Code).

(i) Recognition of an approval shall continue pending the outcome of any appeal from a notice of denial or rescission of any approval. However, if either a denial or rescission of an approval is upheld after appeal, the accrediting agency shall notify all affected pharmacies or nonresident pharmacies of the loss of the board’s approval.

(j) The board may evaluate the performance of an approved accreditation agency and may rescind its approval of the accreditation agency for failure to conform with the Pharmacy Law and standards relating to sterile injectable drug compounding or any of the provisions of this section. The Board or its designee may issue and serve a notice of rescission of approval on the accrediting agency at its address of record with the board. The rescission notice shall set forth the factual and legal basis for the rescission and set forth the process for appealing the notice. Within 30 days of the date of the notice, the accrediting agency may request an appeal of the decision to rescind approval. If no appeal is requested, the denial shall become final. If the board receives a request for an appeal of the notice, the request for an appeal shall be considered a request for an informal hearing under the Administrative Procedure Act (commencing with Section 11445.10 of the Government Code).
Title 16. Board of Pharmacy
Proposed Language

To Amend § 1732.2 in Division 17 of Title 16 of the California Code of Regulations to read as follows:

1732.2 Board Accredited Continuing Education Courses

(a) Individuals may petition the board to allow continuing education credit for specific coursework which is not offered by a provider but meets the standards of Section 1732.3.

(b) Notwithstanding subdivision (a) of this section, coursework which meets the standard of relevance to pharmacy practice and has been approved for continuing education by the Medical Board of California, the California Board of Podiatric Medicine, the California Board of Registered Nursing or the Dental Board of California shall, upon satisfactory completion, be considered approved continuing education for pharmacists.

(c) A pharmacist serving on a designated subcommittee of the board for the purpose of developing the California Practice Standards and Jurisprudence Examination for pharmacists pursuant to section 4200.2 of the Business and Professions Code may annually be awarded up to six hours of continuing education for conducting a review of exam test questions. A subcommittee member shall not receive continuing education hours pursuant to this subdivision if that subcommittee member requests reimbursement from the board for time spent conducting a review of exam test questions.

(d) A pharmacist or pharmacy technician who attends a full day board meeting may be awarded six hours of continuing education per renewal period. The board shall designate on its public agenda which day shall be eligible for continuing education credit. A pharmacist or pharmacy technician requesting continuing education pursuant to this subdivision must sign in and out on an attendance sheet at the board meeting that requires the individual to provide his or her first and last name, license number, time of arrival and time of departure from the meeting.

(e) A pharmacist or pharmacy technician who attends a full committee meeting of the board may be awarded two hours of continuing education per renewal period. A pharmacist or pharmacy technician requesting continuing education hours pursuant to this subdivision must sign in and out on an attendance sheet at the committee meeting that requires the individual to provide his or her first and last name, license number, time of arrival and time of departure from the meeting.

(f) An individual may be awarded three hours of continuing education for successfully passing the examination administered by the Commission for Certification in Geriatric Pharmacy.

Proposed Text – Not Yet Noticed for Public Comment
Title 16. Board of Pharmacy
Proposed Language

To Amend § 1732.05 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

1732.05. Accreditation Agencies for Continuing Education.

(a) The following organizations are approved as accreditation agencies:

(1) The Accreditation Council for Pharmacy Education.


(b) Accreditation agencies shall:

(1) Evaluate each continuing education provider seeking accreditation in accordance with the provider's ability to comply with the requirements of section 1732.1 of this Division.

(2) Maintain a list of the name and address of person responsible for the provider's continuing education program. The accreditation agency shall require that any change in the responsible person's identity shall be reported to the accreditation agency within 15 days of the effective date of the change.

(3) Provide the board with the names, addresses and responsible party of each provider, upon request.

(4) Respond to complaints from the board, providers or from pharmacists concerning activities of any of its accredited providers or their coursework.

(5) Review at least one course per year offered by each provider accredited by the agency for compliance with the agency's requirements and requirements of the board and, on request, report the findings of such reviews to the board.

(6) Take such action as is necessary to assure that the continuing education coursework offered by its providers meets the continuing education requirements of the board; and

(7) Verify the completion of a specific continuing education course by an individual pharmacist.

(c) Substantial failure of an approved accreditation agency to evaluate continuing education providers as set forth in subdivision (b) shall constitute cause for revocation of its approval as an accreditation agency by the board.
Attachment 5
DISCIPLINARY GUIDELINES

A Manual of Disciplinary Guidelines and Model Disciplinary Orders

BE AWARE & TAKE CARE:
Talk to your pharmacist!

California State Board of Pharmacy
Department of Consumer Affairs
(Rev. 10/2007 9/2012)
Additional copies of these disciplinary guidelines may be downloaded from the board’s website.
# TABLE OF CONTENTS

Introduction ................................................................................................................. 1  
Factors to be Considered in Determining Penalties ..................................................... 3  
Mitigating Evidence 4  

**Pharmacist/Intern Pharmacist Individual Licensees** .................................................. 5  
Terms of Probation – Pharmacist/Intern Pharmacist Individual Licensees ...................... 5  
Categories of Violation and Recommended Penalties ................................................... 5  
Category I – Penalty ...................................................................................................... 6  
Category II – Penalty ..................................................................................................... 11  
Category III – Penalty .................................................................................................... 15  
Category IV – Penalty .................................................................................................... 18  
Model Disciplinary Language – Pharmacist/Intern Pharmacist Individual Licensees ... 19  
Standard Conditions .................................................................................................... 23  
Optional Conditions ..................................................................................................... 27  

**Pharmacy Technician** ............................................................................................... 43  
Terms of Probation – Pharmacy Technician .................................................................. 43  
Category III – Penalty ................................................................................................... 44  
Model Disciplinary Language – Pharmacy Technician .................................................. 44  
Standard Conditions ................................................................................................... 48  
Optional Conditions .................................................................................................... 52  

**Designated Representative** ..................................................................................... 55  
Terms of Probation – Designated Representative .......................................................... 55  
Category III – Penalty .................................................................................................. 55  
Model Disciplinary Language – Designated Representative ......................................... 56  
Standard Conditions .................................................................................................... 60  
Optional Conditions .................................................................................................... 64  

**Premises** .................................................................................................................. 67  
Terms of Probation – Premises ..................................................................................... 67  
Category I – Penalty ..................................................................................................... 68  
Category II – Penalty .................................................................................................... 73  
Category III – Penalty .................................................................................................... 77  
Category IV – Penalty .................................................................................................... 79  
Model Disciplinary Language – Premises .................................................................... 80  
Standard Conditions .................................................................................................... 84  
Optional Conditions .................................................................................................... 87
INTRODUCTION

The Board of Pharmacy (board) is responsible for the enforcement of statutes and regulations related to the practice of pharmacy (the Pharmacy Law) and to the regulation of controlled substances (the Uniform Controlled Substances Act). The board serves the public by:

- protecting the health, safety, and welfare of the people of California with integrity and honesty;
- advocating the highest quality of affordable pharmaceutical care;
- providing the best available information on pharmaceutical care; and
- promoting education, wellness and quality of life.

Pharmacists are patient advocates who provide pharmaceutical care and exercise clinical judgment for the citizens of California for their patients, enlightening them about their drug therapy through effective communicating and listening, assessing, collaborating, understanding and intervening. Enforcement officials act quickly, consistently and efficiently in the public’s interest to ensure the safe, effective delivery of these services.

The board recognizes the importance of ensuring the safe and effective delivery of dangerous drugs and controlled substances for therapeutic purposes. At the same time, and given the historical and current abuse and diversion of drugs, particularly controlled substances, the board believes there should be no tolerance for licensees who traffic in drugs or who, in the absence of appropriate evidence of rehabilitation, personally abuse drugs or alcohol.

In accordance with Section 1760 of the California Code of Regulations, the board has produced this booklet for those involved in and affected by the disciplinary process: the general public, board licensees, attorneys from the Office of the Attorney General, administrative law judges from the Office of Administrative Hearings, defense attorneys, board licensees, the courts, board staff and board members who review and vote on proposed decisions and stipulations.

These guidelines are to be followed in Board of Pharmacy disciplinary actions. Subject to judicial review, the board has the final authority over the disposition of its cases, and, to complete its work, it uses the services of the Office of the Attorney General and the Office of Administrative Hearings. The board recognizes that individual cases may necessitate a departure from these guidelines. In such cases, the mitigating or aggravating circumstances shall be detailed in any proposed decision or any transmittal memorandum accompanying a proposed stipulation, especially where Category III or IV violations are involved.

In general, the position of the board is that revocation should always be an option whenever grounds for discipline are found to exist. Board policy is that revocation is generally an appropriate order where a respondent is in default, such as when he or she fails to file a notice of defense or fails to appear at a disciplinary hearing.
Board policy is that a suspension, where imposed, should be at least 30 days for an individual and at least 14 days for a licensed premises.

The board seeks recovery of all investigative and prosecution costs up to the hearing in all disciplinary cases. This includes all charges of the Office of the Attorney General, including, but not limited to, those for legal services, and includes charges by expert consultants. The board believes that the burden of paying for disciplinary cases should fall on those whose conduct requires investigation and prosecution, not upon the profession as a whole.

The board recognizes there may be situations where an individual licensee deserves a stronger penalty than the pharmacy for which he or she works, but the board also believes in holding a pharmacy owner, manager, and/or pharmacist-in-charge responsible for the acts of pharmacy personnel. Similarly, the board recognizes that in some cases a licensed premises may well be more culpable than any individual licensed by or registered with the board.

For purposes of these guidelines “board” includes the board and/or its designees.
FACTORS TO BE CONSIDERED IN DETERMINING PENALTIES

Section 4300 of the Business and Professions Code provides that the board may discipline the holder of, and suspend or revoke, any certificate, license or permit issued by the board.

In determining whether the minimum, maximum, or an intermediate penalty is to be imposed in a given case, factors such as the following should be considered:

1. actual or potential harm to the public
2. actual or potential harm to any consumer
3. prior disciplinary record, including level of compliance with disciplinary order(s)
4. prior warning(s), including but not limited to citation(s) and fine(s), letter(s) of admonishment, and/or correction notice(s)
5. number and/or variety of current violations
6. nature and severity of the act(s), offense(s) or crime(s) under consideration
7. aggravating evidence
8. mitigating evidence
9. rehabilitation evidence
10. compliance with terms of any criminal sentence, parole, or probation
11. overall criminal record
12. if applicable, evidence of proceedings for case being set aside and dismissed pursuant to Section 1203.4 of the Penal Code
13. time passed since the act(s) or offense(s)
14. whether the conduct was intentional or negligent, demonstrated incompetence, or, if the respondent is being held to account for conduct committed by another, the respondent had knowledge of or knowingly participated in such conduct
15. financial benefit to the respondent from the misconduct.

No single one or combination of the above factors is required to justify the minimum and/or maximum penalty in a given case, as opposed to an intermediate one.
MITIGATING EVIDENCE

A respondent is permitted to present mitigating circumstances at a hearing or in the settlement process and has the burden of demonstrating any rehabilitative or corrective measures he or she has taken. The board does not intend, by the following references to written statements, letters, and reports, to waive any evidentiary objections to the form or admissibility of such evidence. The respondent must produce admissible evidence in the form required by law in the absence of a stipulation to admissibility by the complainant.

The following are examples of appropriate evidence a respondent may submit to demonstrate his or her rehabilitative efforts and competency:

a. Recent, dated, written statements and/or performance evaluations from persons in positions of authority who have on-the-job knowledge of the respondent's current competence in the practice of pharmacy including the period of time and capacity in which the person worked with the respondent. Such reports must be signed under penalty of perjury and will be subject to verification by board staff.

b. Recent, dated, letters from counselors regarding the respondent's participation in a rehabilitation or recovery program, which should include at least a description and requirements of the program, a psychologist's diagnosis of the condition and current state of recovery, and the psychologist's basis for determining rehabilitation. Such letters and reports will be subject to verification by board staff.

c. Recent, dated, letters describing the respondent's participation in support groups, (e.g., Alcoholics Anonymous, Narcotics Anonymous, professional support groups, etc.). Such letters and reports will be subject to verification by board staff.

d. Recent, dated, laboratory analyses or drug screen reports, confirming abstention from drugs and alcohol. Such analyses and reports will be subject to verification by board staff.

e. Recent, dated, physical examination/ or assessment report(s) by a licensed physician, confirming the absence of any physical impairment that would prohibit the respondent from practicing safely. Such assessments and report(s) will be subject to verification by board staff.

f. Recent, dated, letters from probation or parole officers regarding the respondent's participation in and/or compliance with terms and conditions of probation or parole, which should include at least a description of the terms and conditions, and the officer's basis for determining compliance. Such letters and reports will be subject to verification by board staff.

g. Recent, dated, letters from persons familiar with respondent in either a personal or professional capacity regarding their knowledge of: the respondent's character; the respondent's rehabilitation, if any; the conduct of which the respondent is accused; or any other pertinent facts that would enable the board to better decide the case. Such letters must be signed under penalty of perjury and will be subject to verification by board staff.
TERMS OF PROBATION – PHARMACIST/INTERN PHARMACIST INDIVIDUAL LICENSEES (PHARMACIST, INTERN PHARMACIST, PHARMACY TECHNICIAN, DESIGNATED REPRESENTATIVE)

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORIES OF VIOLATIONS AND RECOMMENDED PENALTIES

The California Pharmacy Law identifies offenses for which the board may take disciplinary action against the license. Included among grounds for discipline are violations of the Pharmacy Law itself, violations of regulations promulgated by the board, and violations of other state or federal statutes or regulations.

For those licenses issued to individuals (pharmacists, intern pharmacists, pharmacy technicians, and designated representatives), the board has identified four (4) categories of violations and their associated recommended minimum and maximum penalties. These categories of violations are arranged in ascending order from the relatively minor (Category I) to the most serious (Category IV), although any single violation in any category, or any combination of violation(s) in one or more categories, may merit revocation. For pharmacy technicians and designated representatives, the board believes an order of revocation is typically the appropriate penalty when any grounds for discipline are established, and that if revocation is not imposed that a minimum Category III level of discipline should be imposed.

The following are categories of possible violations used by the board to determine appropriate disciplinary penalties. These categories represent the judgment of the board as to the perceived seriousness of particular offenses.

Under each category, the board has grouped statutes and regulations where violations would typically merit the recommended range of minimum to maximum penalties for that category. These lists are representative, and are not intended to be comprehensive or exclusive. For each violation category, the board has given offense descriptions and examples where violations would typically merit the recommended range of minimum to maximum penalties for that category. These descriptions and examples are representative, and are not intended to be comprehensive or exclusive. Where a violation not included in these lists is a basis for disciplinary action, the appropriate penalty for that violation may be best derived by comparison to any analogous violation(s) that are included. Where no such analogous violation is listed, the category descriptions may be consulted.
These categories assume a single violation of each listed statute or regulation. For multiple violations, the appropriate penalty shall increase accordingly. Moreover, if an individual has committed violations in more than one category, the minimum and maximum penalties shall be those recommended in the highest category.

The board also has the authority, pursuant to Business and Professions Code section 4301(n), to impose discipline based on disciplinary action taken by another jurisdiction. The discipline imposed by the board will depend on the discipline imposed by the other jurisdiction, the extent of the respondent's compliance with the terms of that discipline, the nature of the conduct for which the discipline was imposed, and other factors set forth in these guidelines.

**CATEGORY I**

Minimum: Revocation; Revocation stayed; one year probation. All standard terms and conditions shall be included and optional terms and conditions as appropriate.

Maximum: Revocation

Category I discipline is recommended for violations which are relatively minor but are potentially harmful. These may include:

- violations which are relatively minor but are potentially harmful of recordkeeping requirements, scope of practice requirements, or inventory control requirements;
- repeated violations of a relatively minor nature: smaller or isolated failure(s) to abide by or enforce prescription or refill requirements, drug-substitution requirements, or labeling requirements;
- violation(s) of obligations to supply or update information to the board, or to other enforcement or regulatory agencies;
- failure(s) to adequately supervise staff or ensure security and sanitation of premises, dangerous drugs, or controlled substances; and
- violation(s) of packaging requirements, security control requirements, or reporting requirements.

Violations of the following codes are representative of this category:

**BUSINESS AND PROFESSIONS CODE**

**Article 3. Scope of Practice and Exemptions**

4052.1 Skin Puncture by Pharmacist; Conditions Permitting
4052.5 Pharmacist May Select Different Form of Medication with Same Active Chemical Ingredients; Exceptions
4052.7 Repackage Previously Dispensed Drugs; Requirements
4053 Exemptee Supervisor of Manufacturer, etc.: Requirements
4054 Supply by Manufacturer, etc. of Certain Dialysis Drugs and Devices
4055 Sale of Devices to Licensed Clinics, etc.
4056 Purchase of Drugs at Wholesale — Hospital Containing 100 Beds or Less
4057 Exceptions to Application of this Chapter
4058 Display of Original License
4062 Furnishing Dangerous Drugs During Emergency
4064 Emergency Refill of Prescription Without Prescription Authorization
Article 4. Requirements for Prescription

4070      Reduction of Oral or Electronic Prescription to Writing
4071      Prescriber May Authorize Agent to Transmit Prescription; Schedule II Excluded
4072      Oral or Electronic Transmission of Prescription – Health Care Facility
4073      Substitution of Generic Drug – Requirements and Exceptions
4074      Drug Risk: Informing Patient; Providing Consultation for Discharge Medications
4076      Prescription Container – Requirements for Labeling
4077      Dispensing Dangerous Drug in Incorrectly Labeled Container

Article 5. Authority of Inspectors

4082      Names of Owners, Managers and Employees Open for Inspection

Article 6. General Requirements

4100      Change of Address or Name – Notification to Board
4103      Blood Pressure – Taking by Pharmacist

Article 7. Pharmacies

4114      Intern Pharmacist: Activities Permitted
4119      Furnish Prescription Drug to Licensed Health Care Facility – Secured
4119.1    Pharmacy May Provide Services to Health Facility
4119.5    Transfer or Repackaging Dangerous Drugs by Pharmacy
4121      Advertisement for Prescription Drug: Requirements; Restrictions
4122      Required Notice at Availability of Prescription Price Information; General Product
          Availability, Pharmacy Services; Providing Drug Price Information; Limitations on
          Price Information Requests
4123      Compounding Drug for Other Pharmacy for Parenteral Therapy; Notice to Board
4124      Dispensing Replacement Contact Lenses: Requirements; Patient Warnings;
          Registration with Medical Board; Application of Section to Nonresident Pharmacies

Article 9. Hypodermic Needles and Syringes

4141      Furnishing Without License
4142      Prescription Required
4143      Exemption: Sale to Other Entity, Physician, etc.
4144      Industrial Use Exception
4145      Exception: Furnishing for Administration of Insulin, Adrenaline, or Specified Animal
          Uses; Conditions
4148      Confiscation if Found Outside Licensed Premises
4149      Sale by Distributor

Article 10. Pharmacy Corporations
Article 11. Wholesalers and Manufacturers

4161. Nonresident Wholesaler: When License Required; Application
4162. Issuance or Renewal of Wholesaler License; Surety Bond
4163. Unauthorized Furnishing by Manufacturer or Wholesaler
4164. Sale or Transfer of Dangerous Drug or Device Into State: Furnishing Records to Authorized Officer on Demand; Citation for Non-compliance
4165. Shipping of Dangerous Drugs or Devices — Wholesaler or Distributor
4166. Wholesaler: Bar on Obtaining Dangerous Drugs or Devices It Cannot Maintain on Licensed Premises

Article 13. Non-Profit or Free Clinics

4180. Purchase of Drugs at Wholesale Only with License: Eligible Clinics
4181. License Requirements; Policies and Procedures; Who May Dispense
4182. Duties of Professional Director; Consulting Pharmacist Required
4183. No Professional Dispensing Fee
4184. Dispensing Schedule II Substance Prohibited
4186. Automated Drug Delivery Systems

Article 14. Surgical Clinics

4190. Purchase of Drugs at Wholesale: Permitted Uses of Drugs; Required Records and Policies; License Required
4191. Compliance with Department of Health Services Requirements; Who May Dispense Drugs
4192. Duties of Professional Director; Providing Information to Board
4193. Clinic Not Eligible for Professional Dispensing Fee; Ban on Offering Drugs for Sale
4194. Dispensing of Schedule II Substance by Clinic Prohibited; Physician May Dispense; Administration Authorized in Clinic

Article 15. Veterinary Food-Animal Drug Retailers

4196. License Required: Temporary License on Transfer of Ownership; Persons Authorized in Storage Area
4197. Minimum Standards: Security; Sanitation; Board Regulations; Waivers
4198. Written Policies and Procedures Required: Contents; Training of Personnel; Quality Assurance; Consulting Pharmacist

Article 17. Continuing Education

4231. Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New Licensee
4232. Content of Course
Article 18. Poisons

4240 Application of Act

Article 20. Prohibitions and Offenses

4341 Advertisement of Prescription Drugs or Devices
4343 Buildings: Prohibition Against Use of Certain Signs Unless Licensed Pharmacy Within

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1704 Change of Address
1705 Notification of Bankruptcy, Receivership or Liquidation
1708.2 Discontinuance of Business
1708.4 Pharmacist Handling Radioactive Drugs
1708.5 Pharmacy Furnishing Radioactive Drugs
1709 Names of Owners and Pharmacist in Charge
1712 Use of Pharmacist Identifiers
1714 Operational Standards and Security
1715.6 Reporting Drug Loss
1716 Variation From Prescriptions
1717 Pharmaceutical Practice
1717.1 Common Electronic Files
1717.4 Electronic Transmission of Prescriptions
1718.1 Manufacturer’s Expiration Date
1726 Supervision of Intern Pharmacists
1728 Requirements for Examination
1732.1 Requirements for Accredited Providers
1732.3 Requirements for Continuing Education Courses
1732.4 Provider Audit Requirements
1732.5 Renewal Requirements for Pharmacist
1744 Drug Warnings
1746 Emergency Contraception
1751 Sterile Injectable Compounding Area
1751.01 Facility and Equipment Standards for Sterile Injectable Compounding from Non-Sterile Ingredients
1751.02 Policies and Procedures
1751.1 Laminar Flow Biological Safety Cabinet
1751.2 Labeling Requirements
1751.3 Recordkeeping Requirements
1751.4 Attire
1751.5 Training of Staff, Patient, and Caregiver
1751.6 Disposal of Waste Material
1751.7 Quality Assurance and Process Evaluation
1751.9 Reference Materials
1751.11 Furnishing to Home Health Agencies and Licensed Hospices
1751.12 Obligations of a Pharmacy Furnishing Portable Containers
1771 Posting Notice of Suspension
1772 Disciplinary Condition of Suspension
HEALTH AND SAFETY CODE

11100 Report of Certain Chemical: Chemicals Included; Exclusions; Penalties
11100.1 Report of Chemicals Received from Outside State; Penalties
11151 Limitation on Filling Prescriptions From Medical Students
11158 Prescription Required for Schedule II, III, IV, or V Controlled Substance; Exception
   for Limited Dispensing; Administration
11159 Chart Order Exemption for Patient in County or Licensed Hospital; Maintaining
   Record for Seven Years
11159.1 Chart Order Exemption for Clinic Patient; Maintaining Record for Seven Years
11159.2 Exception to Triplicate Prescription Requirement
11167 Emergency Dispensing of Schedule II Substance: Circumstances and Requirements
11167.5 Oral or Electronic Prescriptions for Scheduled II Controlled Substances for Specified
   Inpatients, Residents, and Home Hospice Patients; Requirements
11171 Prescribing, etc. Controlled Substance Only as Authorized
11172 Antedating or Postdating Prescription Prohibited
11175 Prohibition on Obtaining or Possessing Nonconforming Prescription; Prohibition on
   Obtaining Controlled Substance by Nonconforming Prescription
11180 Prohibition on Controlled Substance Obtained or Possessed by Nonconforming
   Prescription
11200 Restrictions on Dispensing or Refilling; Refill of Schedule II Prescription Barred
11201 Emergency Refill of Schedule III, IV, or V Prescription; Circumstances; Requirements
11205 Maintenance andRetention of Records in Separate File
11206 Required information on Prescription
11209 Delivery and Receiving Requirements for Schedule II, III, and IV Substances; Violation
11210 Issuing Prescription: By Whom; For What Purpose; Quantity to Be Prescribed
11250 Authorized Retail Sale by Pharmacists to Physicians, etc.; Required Order Form
11251 Authorized Wholesale Sale by Pharmacists
11252 Preservation of Federally Required Forms
11253 Duration of Retention
11255 Actions Constituting Sale
11256 Required Report of Order By or Sale to Out-of-State Wholesaler or Manufacturer
11256.5 to
11265 Adulterated or Misbranded Drugs or Devices

CODE OF FEDERAL REGULATIONS, TITLE 21

1301.11 Persons required to register.
1301.12 Separate registrations for separate locations.
1301.71 Security requirements generally.
1301.72 Physical security controls for non-practitioners; narcotic treatment programs and compounders for narcotic treatment programs; storage areas.
1301.73 Physical security controls for non-practitioners; compounders for narcotic treatment programs; manufacturing and compounding areas.
1301.74 Other security controls for non-practitioners; narcotic treatment programs and compounders for narcotic treatment programs.
1301.75 Physical security controls for practitioners.
1301.76 Other security controls for practitioners.
1301.90 Employee screening procedures.
1301.91 Employee responsibility to report drug diversion.
1301.92 Illicit activities by employees.
1302.03 Symbol required; exceptions.
1302.04 Location and size of symbol on label and labeling.
1302.05 Effective dates of labeling requirements.
1302.06 Sealing of controlled substances.
1302.07 Labeling and packaging requirements for imported and exported substances.
1304.11 Inventory requirements.
1304.21 Inventories of importers and exporters
1304.31 Reports from manufacturers importing narcotic raw materials.
1304.32 Reports of manufacturers importing coca leaves.
1304.33 Reports to ARCOS.
1305.03 Distributions requiring a Form 222 or a digitally signed electronic order.
1305.04 Persons entitled to order Schedule I and II controlled substances.
1305.05 Power of attorney.
1305.06 Persons entitled to fill orders for Schedule I and II controlled substances.
1305.11 Procedure for obtaining DEA Forms 222.
1305.12 Procedure for executing DEA Forms 222.
1305.14 Procedure for endorsing DEA Forms 222.
1305.15 Unaccepted and defective DEA Forms 222.
1305.16 Lost and stolen DEA Forms 222.
1306.03 Persons entitled to issue prescriptions.
1306.05 Manner of issuance of prescriptions.
1306.14 Labeling of substances and filling of prescriptions.
1306.24 Labeling of substances and filing of prescriptions.
1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes.
1306.26 Dispensing without a prescription.
1307.11 Distribution by dispenser to another practitioner or reverse distributor.
1307.12 Distribution to supplier or manufacture.
1307.13 Incidental manufacture of controlled substances.
1307.21 Procedure for disposing of controlled substances.
1700.1 to 1707.15 Child-resistant containers.

**CATEGORY II**

Minimum: Revocation; Revocation stayed, three years probation (five years probation where self-administration or diversion of controlled substances is involved). All
standard terms and conditions shall be included and optional terms and conditions as appropriate.

Maximum: Revocation

Category II discipline is recommended for violations with serious potential for harm, as well as for violations involving disregard for public safety or for the laws or regulations pertaining to pharmacy and/or to dispensing or distributing of dangerous drugs or controlled substances, violations that reflect on ethics, competence, or diligence, and criminal convictions not involving alcohol, dangerous drugs, or controlled substances. Violations in this category may include:

- failure(s) to abide by prohibitions on referral rebates or discounts (kickbacks) and/or volume or percentage-based lease agreements;
- violation(s) of advertising or marketing limitations, including use of false or misleading advertising or marketing;
- repeat or serious violation(s) of recordkeeping requirements, scope of practice requirements, or inventory control requirements;
- violation(s) of controlled substance secure prescription requirements, inventory controls, or security requirements;
- failure(s) to meet compliance requirements, including pharmacist-in-charge or designated representative-in-charge designation and duties;
- violation(s) of monitoring and reporting requirements with regard to chemically, mentally, or physically impaired licensees or employees;
- repeat or serious failure(s) to adequately supervise staff or ensure security and sanitation of premises, dangerous drugs, or controlled substances;
- violation(s) of law governing dangerous drugs and controlled substances, including smaller cases of diversion or self-administration;
- unlawful possession(s) of dangerous drugs, controlled substances, hypodermic needles and syringes, or drug paraphernalia;
- smaller scale dispensing or furnishing of dangerous drug(s) or device(s) via the internet without valid prescription(s);
- purchasing, trading, selling, or transferring dangerous drug(s) or devise(s) to or from unauthorized person(s);
- failure(s) to make required reports to board or other regulatory agencies, including CURES obligations and reporting to DEA;
- violation(s) of quality assurance and self-assessment obligations, failure(s) to clarify erroneous or uncertain prescription(s);
- gross immorality, incompetence, gross negligence, clearly excessive furnishing of controlled substances, moral turpitude, dishonest, or fraud;
- criminal conviction(s) not involving alcohol, dangerous drugs, or controlled substances;
- violating, or assisting in or abetting violation of, or conspiring to violate the laws and regulation governing pharmacy; and
- subverting or attempting to subvert an investigation conducted by the board.

Violations which involve greater disregard for pharmacy law and public safety

Violations which reflect on ethics, care exercised or competence or a criminal conviction not involving dangerous drugs or controlled substances or involving possession or use of dangerous drugs or controlled substances.
Violations of the following codes are representative of this category:

**BUSINESS AND PROFESSIONS CODE**

650 Rebates or Discounts for Referral Prohibited
650.1 Lease Prohibition – Hospitals or Prescribers
651 Professional Advertising Requirements

**Article 3. Scope of Practice and Exemptions**

4051(b) Conduct Authorized by Pharmacist
4062 Furnishing to Prescriber; Permissible Procedures by Pharmacist in Health Care Facility or Clinic or for Other Health Care Provider
4060 Controlled Substance — Prescription Required; Exceptions
4061 Distribution of Drug as Sample; Written Request Required
4063 Refill of Prescription for Dangerous Drug or Device; Prescriber Authorization
4067 Internet; Dispensing Dangerous Drugs or Devices without Prescription
4075 Proof of Identity Required — Oral or Electronic Prescription
4078 False or Misleading Label on Prescription

**Article 6. General Requirements**

4101 Pharmacist in Charge, Exemptee: Termination of Employment; Notification to Board
4104 Licensed Employee, Theft or Impairment: Pharmacy Procedures
4105 Retaining Records of Dangerous Drugs and Devices on Licensed Premises; Temporary Removal; Waivers; Access to Electronically Maintained Records

**Article 7. Pharmacies**

4112 Nonresident Pharmacy: Registration; Provision of Information to Board; Maintaining Records; Patient Consultation
4113 Pharmacist in Charge: Notification to Board; Responsibilities
4115 Pharmacy Technician: Activities Permitted; Required Supervision; Activities Limited to Pharmacist; Registration; Requirements for Registration; Ratios
4115.5 Pharmacy Technician Trainee; Placement; Supervisions; Requirements
4116 Security of Dangerous Drugs and Devices in Pharmacy: Pharmacist Responsibility for Individuals on Premises; Regulations
4117 Admission to Area Where Narcotics are Stored, etc. — Who May Enter
4120 Nonresident Pharmacy: Registration Required
4125 Pharmacy Quality Assurance Program Required; Records Considered Peer Review Documents

**Article 9. Hypodermic Needle and Syringes**

4140 Unlawful Possession
4147 Disposal of Needle or Syringe

**Article 11. Wholesalers and Manufacturers**

4160 Wholesaler: License Required
4163 Unauthorized Furnishing by Manufacturer or Wholesaler
Article 13. Non-Profit of Free Clinics

Article 14. Surgical Clinics

Article 19. Disciplinary Proceedings

Article 20. Prohibitions and Offenses

Article 22. Unfair Trade Practices
CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707.1  Duty to Maintain Medication Profiles (Patient Medication Records)
1707.2  Notice to Consumers and Duty to Consult
1707.3  Duty to Review Drug Therapy and Patient Medication Record Prior to Delivery
1709.1  Designation of Pharmacist in Charge
1714.1  Pharmacy Operations During the Temporary Absence of a Pharmacist
1715  Self-Assessment of a Pharmacy by the Pharmacist-in-Charge
1716.1  Compounding Unapproved Drugs for Prescriber Office Use
1716.2  Record Requirements—Compounding for Future Furnishing
1717.3  Preprinted, Multiple Checkoff Prescription Blanks
1723.1  Confidentiality of Examination Questions
1745  Partial Filling of Schedule II Prescriptions
1751.10 Furnishing to Parenteral Patient at Home
1761(a)  Erroneous or Uncertain Prescriptions
1764  Unauthorized Disclosure of Prescriptions
1765  Commissions, Gratuities, and Rebates
1766  False or Misleading Advertising
1775.3  Compliance with Orders of Abatement
1782  Reporting Sales of Drugs Subject to Abuse
1783  Manufacturer or Wholesaler Furnishing Drugs or Devices
1793.1  Duties of a Pharmacist
1793.2  Duties of a Pharmacy Technician
1793.3  Other Non-Licensed Pharmacy Personnel
1793.7  Requirements for Pharmacies Employing Pharmacy Technicians
1793.8  Technicians in Hospitals with Clinical Pharmacy Programs

HEALTH AND SAFETY CODE

11103  Report of Theft, Lose, or Shipping Discrepancy
11150  Persons Authorized to Write or Issue a Prescription
11152  Nonconforming Prescriptions Prohibited
11154  Prescription, etc., Must Be for Treatment; Knowing Solicitation of Unlawful Prescription, etc.
11156  Prescribing, etc., Controlled Substances to Addict Only as Authorized
11164  Prescriptions for Schedule II, III, IV and V Controlled Substances: Form and Content; Record of Practitioner Dispensing Schedule II Controlled Substances
11166  Time Limit for Filling Schedule II Prescription; Knowingly Filling Mutilated, Forged, or Altered Prescription Prohibited
11170  Prohibition on Prescribing, etc., Controlled Substance for Self
11179  Retention of Controlled Substance Prescription
11207  Only Pharmacist or Intern Authorized to Fill Prescription
11209  Delivery and Receiving Requirements for Schedule II, III, and IV Substances; Violation
11350  Possession of Specified Controlled Substance
11377  Unlawful Possession of Specified Substance
14165(d)  CURES Transmission
150204  Surplus Medication Collection and Distribution Program
CODE OF FEDERAL REGULATIONS, TITLE 21

1304.03 Persons required to keep records and file reports.
1304.04 Maintenance of records and inventories.
1304.11 Inventory requirements.
1304.21 General requirements for continuing records.
1304.22 Records for manufacturers.
1305.07 Special procedure for filling certain orders.
1305.13 Procedure for filling DEA Forms 222.
1306.04 Purpose of issue of prescription.
1306.06 Persons entitled to fill prescriptions.
1306.07 Administering or dispensing of narcotic drugs.
1306.11 Requirement of prescription.
1306.12 Refilling prescription.
1306.13 Partial filling of prescriptions.
1306.21 Requirement of prescription.
1306.22 Refilling of prescriptions.
1306.23 Partial filling of prescriptions.

CATEGORY III

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three to five years probation (five years probation where self-administration or diversion of controlled substances is involved). All standard terms and conditions and optional terms and conditions as appropriate.

Maximum: Revocation

Category III discipline is recommended for violations where potential for harm is greater, more imminent, or more serious than it is for Category II violations, as well as for violations that involve knowingly or willfully violating laws or regulations pertaining to pharmacy and/or to the dispensing or distributing of dangerous drugs or controlled substances, and most criminal convictions involving alcohol, dangerous drugs or controlled substances, and most criminal convictions involving alcohol, dangerous drugs, or controlled substances. Violations in this category may include:

- violation(s) involving creation, manipulation, perpetuation, or disregard of drug shortages;
- failure(s) to deploy or abide by electronic pedigree requirements for dangerous drugs;
- violation(s) of licensee’s corresponding responsibility to ensure the proper prescribing and dispensing of controlled substances;
- dispensing or furnishing without valid prescription, dispensing or furnishing to unauthorized person(s);
- violation(s) involving fraudulent acts committed in connection with the licensee’s practice;
- repeat or serious violation(s) of controlled substance secure prescription requirements, inventory controls, or security requirements;
- violation(s) of laws governing dangerous drugs and controlled substances, including repeat or serious diversion or self-administration;
- repeat or serious unlawful possession(s) of dangerous drugs, controlled substances, hypodermic needles or syringes, or drug paraphernalia.
larger scale dispensing or furnishing or dangerous drug(s) or device(s) via the internet, without valid prescription(s);
- purchasing, trading, selling, or transferring adulterated, misbranded, or expired dangerous drug(s) or device(s);
- removal, sale, or disposal of embargoed dangerous drug(s) or device(s);
- failing to maintain record(s) of acquisition and disposition of dangerous drug(s) or device(s);
- resale(s) of preferentially priced drugs, contract bid diversion, or other instances of improper sale(s) or resale(s);
- repeat or serious violation(s) of quality assurance and self-assessment obligations, failure(s) to ensure properly trained staff and conduct practice safely;
- repeat or serious failure(s) to perform drug utilization reviews, monitor patient medication profiles, or promote safety and efficacy of prescribed drugs;
- forgery of prescriptions, passing of forged prescriptions, or other unlawful means of acquiring dangerous drug(s) or controlled substance(s);
- repeat or serious acts violating, assisting in or abetting violation of, or conspiring to violate the laws and regulations governing pharmacy; and
- violation(s) involving providing or offering to provide controlled substance(s) to addict(s).

Violations of the following codes are representative of this category:

**BUSINESS AND PROFESSIONS CODE**

**Article 3. Scope of Practice and Exemptions**

4034 Pedigree
4051(a) Conduct Limited To Pharmacist
4059 Furnishing Dangerous Drugs or Devices Prohibited Without Prescription: Exceptions
4059.5 Who May Order Dangerous Drugs or Devices: Exceptions

**Article 5. Authority of Inspectors**

4080 Stock of Dangerous Drugs and Devices Kept Open for Inspection
4081 Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory
4085(a) Unlawful to Remove, Sell, Dispose of Embargoed Dangerous Drug or Dangerous Device

**Article 6. General Requirements**

4105 Retaining Records of Dangerous Drugs and Devices on Licensed Premises; Temporary Removal; Waivers; Access to Electronically Maintained Records

**Article 7. Pharmacies**
Article 11. Wholesalers and Manufacturers

4169(a)(2) to 4169(a)(5) Prohibited Acts

Article 15. Veterinary Food-Animal Retailers

4199 Labeling Requirements; Maintaining Prescription Records

Article 19. Disciplinary Proceedings

4301 Unprofessional Conduct—subsections (i)–(k) and (o)
4307 Prohibition of Association of Individual with Entity License by Board: Length of Prohibition; Individuals Covered; Imposition of Prohibition Through Administrative Act Proceeding
4308 Prohibited Association: Notification of Affected Licensees Known to Board

Article 20. Prohibitions and Offenses

4322 Misdemeanor or Infraction: False Representations to Secure License for Self or Others; False Representation of Licensure; Penalties
4323 Misdemeanor: False Representation of Self as Physician, Agent of Physician, etc. to Obtain Drug
4324 Felony or Misdemeanor: Forgery of Prescription; Possession of Drugs Obtained Through Forged Prescription
4325 Misdemeanor: Manufacture, Possession, etc. of False Prescription Blank
4327 Misdemeanor: Sale, Dispensing, or Compounding While Under the Influence of Drugs or Alcoholic Beverages
4329 Misdemeanor: Non-pharmacist Acting as Manager, Compounding, Dispensing or Furnishing Drugs
4332 Misdemeanor: Failure or Refusal to Maintain or Produce Required Drug or Device Records; Willful Production of False Records
4335 Voided License: Knowing Failure to Arrange for Disposition of Stock as Misdemeanor
4336 Felony: Knowing or Willful Use of Minor to Violate Specified Sections of Pharmacy Law: Exception for Pharmacist Furnishing Pursuant to a Prescription

Article 22. Unfair Trade Practices

4380 Resale of Preferentially Priced Drugs: Prohibition; Exceptions

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707 Waiver Requirements for Off-Site Storage of Records
1718 Current Inventory Defined
1761(b) Erroneous or Uncertain Prescriptions
1771 Posting of Notice of Suspension
1772 Disciplinary Condition of Suspension
1773 Disciplinary Conditions of Probation of Pharmacist
1774 Disciplinary Conditions of Probation of Permit

HEALTH AND SAFETY CODE

11104 Providing Chemical for Illicit Manufacturing; Evasion of Reporting Requirements; Penalties
11105 False Statement in Report
11150 Persons Authorized to Write or Issue a Prescription
11153 Responsibility for Legitimacy of Prescription; Corresponding Responsibility of Pharmacist; Knowing Violation
11153.5 Wholesaler or Manufacturer Furnishing Controlled Substance Other Than for Legitimate Medical Purpose; Knowing Violation; Factors in Assessing Legitimacy
11157 No False or Fictitious Prescriptions
11162.5 Counterfeiting or Possession of Counterfeit Triplicate Prescription Blank; Penalty
11173 Fraud, Deceit, Misrepresentation or False Statement; False Representation; False Label
11174 Prohibition on Providing False Name or Address in Connection with Prescription, etc.
11351 Possession or Purchase for Sale of Specified Controlled Substance
11368 Forged or Altered Prescriptions
11375 Possession for Sale or Selling Specified Substance
11378 Possession for Sale
11550 Using or Being Under Influence of Controlled Substance
11167.5 Pharmacy Generated Prescription for Schedule II Controlled Substances in a Skilled Nursing Facility
111295 Manufacturing, Selling, or Offering for Sale an Adulterated Drug or Device
111300 Unlawful to Adulterate a Drug
111305 Unlawful to Receive in Commerce an Adulterated Drug
111440 Unlawful Manufacturer, Selling a Misbranded Drug
111445 Unlawful for a Person to Misbrand
111450 Unlawful to Receive into Commerce a Drug that is Misbranded

CATEGORY IV
Penalty: Revocation

Category IV discipline (Revocation) is recommended for the most serious violations of laws or regulations pertaining to pharmacy and/or to the dispensing or distributing of dangerous drugs or controlled substances. Violations in this category may include: the Uniform Controlled Substance Act (Health and Safety Code 11000 et seq.) involving:
- possession for sale violations involving possession for sale, transportation, importation, and/or use of a minor for unlawful sale of controlled substances;
- transportation criminal convictions involving the above, or repeat convictions involving diversion or abuse of alcohol, dangerous drugs, or controlled substances; and
- repeated or serious example(s) of conduct described in Category I, Category II, or Category III.
importation
sale
use of a minor for the unlawful sale of controlled substances

Revocation is also recommended when: where a respondent fails to file a notice of defense to an accusation or to appear at a disciplinary hearing, where a respondent violates the terms and conditions of probation from a previous disciplinary order, or where prior discipline has been imposed on the license:

- a respondent fails to file a notice of defense or to appear at a disciplinary hearing where the board has requested revocation in the accusation
- a respondent violates the terms and conditions of probation from a previous disciplinary order
- prior discipline has been imposed, as progressive discipline unless the respondent can demonstrate satisfactory evidence of rehabilitation.

Violations of the following codes are representative of this category:

**HEALTH AND SAFETY CODE**

11352 Importing, Selling, Furnishing Controlled Substance
11353 Adult Inducing Minor to Violate Provisions
11379 Transporting, Importing, Selling Controlled Substance
11380 Adult Using, Soliciting or Intimidating Minor for Violation
MODEL DISCIPLINARY LANGUAGE - PHARMACIST/INTERN PHARMACIST INDIVIDUAL LICENSEEES (PHARMACIST, INTERN PHARMACIST, PHARMACY TECHNICIAN, DESIGNATED REPRESENTATIVE)

The following standardized language shall be used in every decision where the order or condition is imposed.

Revocation

License number ________________, issued to respondent ___________________, is revoked.

Respondent shall relinquish his or her [his/her] wall license, including any indicia of licensure issued by the board, and pocket renewal license to the board within 10 days of the effective date of this decision. Respondent may not reapply or petition the board for reinstatement of his or her revoked license for three years from the effective date of this decision.

Respondent shall pay to the board its costs of investigation and prosecution in the amount of $__________ within fifteen (15) days of the effective date of this decision.

Option: As a condition precedent to reinstatement of his or her revoked license, respondent shall reimburse the board for its costs of investigation and prosecution in the amount of $__________. Said amount shall be paid in full prior to the reapplication or reinstatement of his or her license unless otherwise ordered by the board.

Option: Respondent shall pay to the board its costs of investigation and prosecution in the amount of $__________ within fifteen (15) days of the effective date of this decision.

Suspension

As part of probation, respondent is suspended from the practice as a [insert license type] for _____ [day(s)/month(s)/year(s)] of pharmacy for ____________ beginning the effective date of this decision.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.
Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this *any such* suspension shall be considered a violation of probation.

**Standard Stay/Probation Order**

License number ____________, issued to respondent is revoked; however, the revocation is stayed and respondent is placed on probation for ______________ years upon the following terms and conditions:

**Issuance of Probationary License** *(In cases where a Statement of Issues has been filed.)*

Upon satisfaction of all statutory and regulatory requirements for issuance of a *[insert license type]* license, a *[insert license type]* license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for ______ years upon the following terms and conditions:

**Option: (Pharmacist Interns Only)**

Should the board subsequently issue a license to practice as a pharmacist during the period of probation, said license shall be immediately revoked. The revocation of such license shall be stayed, and the probation imposed by this decision and order will continue. Respondent shall be subject to the same terms and conditions imposed by this disciplinary order. Notwithstanding this provision, the Board reserves the right to deny respondent's application for the pharmacist licensure exam. If the board issues a pharmacist license to respondent, the following additional terms and conditions shall be included as part of the disciplinary order:

**Surrender**

Respondent surrenders license number __________ as of the effective date of this decision. Respondent shall relinquish his or her wall license, including any indicia of licensure issued by the board, and/or pocket renewal license to the board within ten (10) days of the effective date of this decision.

The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board.

Respondent understands and agrees that if he or she *[he/she]* ever files an application for licensure or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.

Respondent may not apply for any license, permit, or registration from the board for three years from the effective date of this decision. Respondent stipulates that should he or she *[he/she]* apply for any license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, correct
and admitted by respondent when the board determines whether to grant or deny the application. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board, including, but not limited to taking and passing the California Pharmacist Licensure Examination prior to the issuance of a new license. Respondent is required to report this surrender as disciplinary action.

Respondent further stipulates that he or she [he/she] shall reimburse the board for its costs of investigation and prosecution in the amount of $_________ within ________ days of the effective date of this decision.

Option: Respondent stipulates that should he or she [he/she] apply for any license from the board on or after the effective date of this decision the investigation and prosecution costs in the amount of $_________ shall be paid to the board prior to issuance of the new license.

Public Reprimand

It is hereby ordered that a public reprimand be issued against licensee, ____________.

Respondent is required to report this reprimand as a disciplinary action.

License Reinstatement Order with Conditions Prior to Issuing License

It is hereby ordered that the petition for reinstatement filed by ____________ is hereby granted and Petitioner’s License No. _________ will be reinstated upon the following conditions precedent:

a. Petitioner shall take and pass the North American Pharmacist Licensure Examination (NAPLEX) and/or the California Practice Standards and Jurisprudence Examination for Pharmacists (CPJE)/Pharmacy Technician Certification Board exam within one (1) year of the effective date of this order.

b. Petitioner must pay the fee in place at the time for these examinations.

c. Petitioner must pay a reinstatement fee in the amount of $__________.

Option: Petitioner pays the Board’s cost recovery or fine amount owed to the Board in the amount of $_______.

Upon completion of the conditions precedent above, Petitioner’s license shall be REINSTATED. Upon reinstatement, Petitioner’s license shall be REVOKED. However, said revocation shall be STAYED, and Petitioner shall be placed on PROBATION for a period of _____ year(s) under the following terms and conditions:

License Reinstatement

It is hereby ordered that the petition for reinstatement filed by ____________ is hereby GRANTED and Petitioner’s license shall be REINSTATED. Upon reinstatement, Petitioner’s license shall be REVOKED. However, said revocation shall be STAYED, and Petitioner shall be placed on PROBATION for a period of _____ years under the following terms and conditions:
Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.
STANDARD CONDITIONS - To be included in all probation decisions/orders.

1. Obey All Laws
2. Report to the Board
3. Interview with the Board
4. Cooperate with Board Staff
5. Continuing Education
6. Reporting of Employment and Notice to Employers
7. Notification of Change(s) in Name, Employment, Address(es), or Phone Number(s)
8. No Supervision of Interns, Serving as Pharmacist-In-Charge (PIC), or Serving as a Consultant
9. Restrictions on Supervision and Oversight of Licensed Facilities
10. Reimbursement of Board Costs
11. Probation Monitoring Costs
12. Status of License
13. License Surrender While on Probation/Suspension
14. Notification of a Change in Name, Residence Address, Mailing Address or Employment
15. Certification Prior to Resuming Work
16. Notification of Departure
17. Tolling of Probation License Practice Requirement - Tolling
18. Violation of Probation
19. Completion of Probation

OPTIONAL CONDITIONS

18. Suspension
19. Restricted Practice
20. Pharmacist Examination
21. Mental Health Examination Clinical Diagnostic Evaluation
22. Psychotherapy
23. Medical Evaluation
24. Pharmacists Recovery Program (PRP)
25. Random Drug Screening Drug and Alcohol Testing
26. Abstain from Drugs and Alcohol Use
27. Prescription Coordination and Monitoring of Prescription Use
28. Facilitated Group Recovery and/or Support Meetings
29. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
30. Work Site Monitor
31. Community Service Program
32. Restitution
33. Remedial Education
34. Pharmacy Self-Assessment Mechanism (PSAM)
35. Intern Pharmacist Experience
36. Supervised Practice
37. No Supervision of Ancillary Personnel
38. No Ownership or Management of Licensed Premises
39. Separate File of Controlled Substances Records
40. Report of Controlled Substances
41. No Access to Controlled Substances
42. Criminal Probation/Parole Reports
43. Consultant for Owner or Pharmacist-In-Charge
44. Tolling of Suspension
39.42. Surrender of DEA Permit
40.43. Ethics Course
STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

1. Obey All Laws

Respondent shall obey all state and federal laws and regulations.

Respondent shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent's [fill in] license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

3. Interview with the Board

Upon receipt of reasonable prior notice, respondent shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

4. Cooperate with Board Staff

Respondent shall timely cooperate with the board's inspection program and with the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her [his/her] probation, including but not limited to: timely responses to requests for information by board staff; timely compliance with directives from board staff regarding requirements of any term or condition of probation; and timely completion of documentation pertaining to a term or condition of probation. Failure to timely cooperate shall be considered a violation of probation.

5. Continuing Education (Pharmacists Only)
Respondent shall provide evidence of efforts to maintain skill and knowledge as a pharmacist as directed by the board or its designee.

6. Reporting of Employment and Notice to Employers

During the period of probation, respondent shall provide the board with written consent authorizing communication with all employers and shall notify all present and prospective employers of the decision in case number ________ and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of undertaking any new employment, respondent shall report to the board in writing the name, physical address, and mailing address of all of [his/her] employer(s), and the name(s) and telephone number(s) of all of [his/her] direct supervisor(s), as well as any pharmacist(s)-in-charge, designated representative(s)-in-charge, or other compliance supervisor(s). Respondent shall sign and return to the board a written consent authorizing the board or its designee to communicate with all of respondent's employer(s) and supervisor(s), and authorizing those employer(s) or supervisor(s) to communicate with the board or its designee, concerning respondent's work status, performance, and monitoring. Failure to comply with the requirements or deadlines of this condition shall be considered a violation of probation.

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause (a) his or her [his/her] direct supervisor, (b) his or her pharmacist-in-charge, designated representative-in-charge, or other compliance supervisor, (including each new pharmacist-in-charge employed during respondent's tenure of employment) and (c) the owner or owner representative of his or her employer, to report to the board in writing acknowledging that the listed individual(s) has/have read the decision in case number ________, and terms and conditions imposed thereby. If one person serves in more than one role described in (a), (b), or (c), the acknowledgment shall so state. It shall be the respondent's responsibility to ensure that these acknowledgement(s) are timely submitted to the board. In the event of a change in the person(s) serving the role(s) described in (a), (b), or (c) during the term of probation, respondent shall cause the person(s) taking over the role(s) to report to the board in writing within fifteen (15) days of the change acknowledging that he or she has read the decision in case number ________, and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his or her employer(s) and supervisor(s) submit timely acknowledgment(s) to the board.

If respondent works for or is employed by or through a pharmacy an employment service, respondent must notify the person(s) described in (a), (b), and (c) above at every entity licensed by the board, of the decision in case number ________, and the terms and conditions imposed thereby in advance of respondent commencing work at each licensed entity. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy an employment service, respondent shall cause the person(s) described in (a), (b), and (c) above his or her direct supervisor with the pharmacy at the employment service to report to the board in writing
acknowledging that he or she has read the decision in case number ______, and the terms and conditions imposed thereby. It shall be respondent’s responsibility to ensure that these acknowledgment(s) are timely submitted to the board his or her employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or failure to cause the identified person(s) with that/those employer(s) to submit timely written acknowledgments to the board shall be considered a violation of probation.

"Employment" within the meaning of this provision shall includes any full-time, part-time, temporary, relief, or employment/management service position as a [insert license type], or any position for which a [insert license type] license or pharmacy management service as a pharmacist or any position for which a pharmacist license is a requirement or criterion for employment, whether the respondent is an employee, independent contractor or volunteer.

7. **Notification of Change(s) in Employment, Name, Address(es), or Phone Number(s)**

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule, if known. Respondent shall further notify the board in writing within ten (10) days of any change in name, residence address, mailing address, or phone number.

Failure to timely notify the board of any change in employer, name, address, or phone number shall be considered a violation of probation.

78. **No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as Designated Representative-in-Charge, or Serving as a Consultant Restrictions on Supervision and Oversight of Licensed Facilities**

During the period of probation, respondent shall not supervise any intern pharmacist, be the pharmacist-in-charge, or designated representative-in-charge, or other compliance supervisor of any entity licensed by the board, nor serve as a consultant unless otherwise specified in this order. Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.

**Option 1:** During the period of probation, respondent shall not supervise any ancillary personnel, including, but not limited to, pharmacy technicians or designated representatives in any entity licensed by the board. Assumption of any such unauthorized ancillary personnel supervision responsibilities shall be considered a violation of probation.

**Option 2a:** During the period of probation, respondent shall not supervise any intern pharmacist or serve as a consultant to any entity licensed by the board. Respondent may be a pharmacist-in-charge, designated representative-in-charge, or other compliance supervisor of

---

1 This term was renamed and renumbered from previous term 12.
2 This term was renamed and consolidated with two additional terms: No Supervision of Ancillary Personnel and Consultant for Owner of Pharmacist-in-Charge.
any single entity licensed by the board, but only if respondent or that entity retains, at his/her/its expense, an independent consultant who shall be responsible for reviewing the operations of the entity on a [monthly/quarterly] basis for compliance by respondent and the entity with state and federal laws and regulations governing the practice of the entity, and compliance by respondent with the obligations of his or her supervisory position. Respondent may serve in such a position at only one entity licensed by the board. The consultant shall be a pharmacist licensed by and not on probation with the board, who has been approved by the board or its designee to serve in this position. Respondent shall submit the name of the proposed consultant to the board or its designee for approval within thirty (30) days of the effective date of the decision. Assumption of any unauthorized supervision responsibilities shall be considered a violation of probation. In addition, failure to timely seek approval for, timely retain, or ensure timely reporting by the consultant shall be considered a violation of probation.

Option 2b: During the period of probation, respondent shall not supervise any intern pharmacist or serve as a consultant to any entity licensed by the board. Respondent may be a pharmacist-in-charge, designated representative-in-charge, or other compliance supervisor of any single entity licensed by the board, but only if respondent or that entity retains, at his/her/its expense, an independent consultant who shall be responsible for reviewing the operations of the entity on a [monthly/quarterly] basis for compliance by respondent and the entity with state and federal laws and regulations governing the practice of the entity, and compliance by respondent with the obligations of his or her supervisory position. Respondent may serve in such a position at only one entity licensed by the board, who has been approved by the board or its designee to serve in this position. Respondent shall submit the name of the proposed consultant to the board or its designee for approval within thirty (30) days of the effective date of the decision. Assumption of any unauthorized supervision responsibilities shall be considered a violation of probation. In addition, failure to timely seek approval for, timely retain, or ensure timely reporting by the consultant shall be considered a violation of probation.

Option 2c: During the period of probation, respondent shall not supervise any intern pharmacist or serve as a consultant to any entity licensed by the board. Respondent may be a pharmacist-in-charge, designated representative-in-charge, or other compliance supervisor of any single entity licensed by the board, but only if respondent or that entity retains, at his/her/its expense, an independent consultant who shall be responsible for reviewing the operations of the entity on a [monthly/quarterly] basis for compliance by respondent and the entity with state and federal laws and regulations governing the practice of the entity, and compliance by respondent with the obligations of his or her supervisory position. Respondent may serve in such a position at only one entity licensed by the board, and only if respondent is already serving in such a position at the time of the effective date of this decision. The consultant shall be a pharmacist licensed by and not on probation with the board, who has been approved by the board or its designee to serve in this position. Respondent shall submit the name of the proposed consultant to the board or its designee for approval within thirty (30) days of the effective date of the decision. Assumption of any unauthorized supervision responsibilities shall be considered a violation of probation. In addition, failure to timely seek approval for, timely retain, or ensure timely reporting by the consultant shall be considered a violation of probation.

89. Reimbursement of Board Costs
As a condition precedent to successful completion of probation, respondent shall pay to the board its costs of investigation and prosecution in the amount of $________. Respondent shall make said payments as follows: __________________.

There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

**Option:** Respondent shall be permitted to pay these costs in a payment plan approved by the board or its designee, so long as full payment is completed no later than one (1) year prior to the end date of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

**910. Probation Monitoring Costs**

Respondent shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

**4011. Status of License**

Respondent shall, at all times while on probation, maintain an active, current [insert license type] license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current [insert license type] license shall be considered a violation of probation.

If respondent's [insert license type] license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication respondent's [insert license type] license shall be subject to all terms and conditions of this probation not previously satisfied.

**4112. License Surrender While on Probation/Suspension**

Following the effective date of this decision, should respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her [insert license type] license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the [insert license type] license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent's license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his or her pocket and/or wall license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent may not reapply for any license from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board, including any outstanding costs.
12. **Notification of a Change in Name, Residence Address, Mailing Address or Employment**

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule if known. Respondent shall further notify the board in writing within ten (10) days of a change in name, residence address, mailing address, or phone number(s).

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

13. **Certification Prior to Resuming Work (Pharmacy Technicians Only)**

Respondent shall be suspended, and shall not work as a pharmacy technician, until [he/she] has been certified as defined by Business and Professions Code section 4202, subdivision (a)(4), has submitted proof of certification to the board, and has been notified by the board or its designee that [he/she] may begin work. Failure to achieve certification within six (6) months shall be considered a violation of probation. Respondent shall not resume working as a pharmacy technician until notified by the board.

During any such suspension, respondent shall not enter any pharmacy area or any portion of any other board licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs) which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or assist any licensee of the board. Respondent shall not have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

During any such suspension, respondent shall not engage in any activity that requires licensure as a pharmacy technician. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacture, distribution, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

Failure to comply with this any such suspension shall be considered a violation of probation.

**Option**: Respondent shall maintain an active, current certification as defined by Business and Professions Code section 4202, subdivision (a)(4), for the entire period of probation, and shall submit proof of re-certification or renewal of certification to the board within ten (10) days of receipt. Failure to maintain active, current certification or to timely submit proof of same shall be considered a violation of probation.

14. **Notification of Departure**

---

3 This probationary term is not new, but is rather being moved from the “Model Disciplinary language - - Pharmacy Technician” Standard Terms and Conditions for purposes of consolidation.

4 This probationary term is not new, but is rather being moved from the “Model Disciplinary language - - Pharmacy Technician” for purposes of consolidation.
Prior to leaving the probationary geographic area designated by the board or its designee for a period greater than twenty-four (24) hours, respondent shall notify the board verbally and in writing of the dates of departure and return. Failure to comply with this provision shall be considered a violation of probation.

### 13.15. Tolling of Probation License Practice Requirement - Tolling

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a pharmacist [insert license type] in California for a minimum of _________ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation, unless the respondent is notified in writing by the board or its designee.

Should respondent, regardless of residency, for any reason (including vacation) cease practicing as a pharmacist for a minimum of _________ hours per calendar month in California, respondent shall notify the board in writing within ten (10) days of the cessation of practice, and must further notify the board in writing within ten (10) days of the resumption of practice conclusion of that calendar month. This notification shall include at least: the date(s), locations(s), and hours of last practice; the reason(s) for the interruption or decline in practice; and the anticipated date(s) on which respondent will resume practice at the required level. Respondent shall further notify the board in writing within ten (10) days following the next calendar month during which respondent practices as a [insert license type] in California for a minimum of _________ hours. Any failure to timely provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a total period, counting consecutive and non-consecutive months, exceeding thirty-six (36) months.

“Cessation of practice” means any calendar month during which respondent is not practicing as a pharmacist for at least _________ hours, as defined by Business and Professions Code section 4000 et seq. “Resumption of practice” means any calendar month during which respondent is practicing as a pharmacist for at least _________ hours as a pharmacist as defined by Business and Professions Code section 4000 et seq.

**Option 1:** As a condition precedent to successful completion of probation, during the period of probation respondent shall practice as a [insert license type] in a licensed _________ in California that dispenses dangerous drugs for a minimum of one (1) year. After the first year of probation, the board or its designee may consider a modification of this requirement. Failure to comply with this requirement (or as modified) shall be considered a violation of probation. Respondent is required to practice as a pharmacist in a licensed pharmacy setting that dispenses medication for a minimum of one year prior to the completion of probation. After the first year of probation, the board or its designee may consider a modification of this requirement.
If respondent fails to comply with this requirement or a subsequent modification thereto, such failure shall be considered a violation of probation.

**Option 2: (First-year pharmacist interns only)** During respondent's first academic year of enrollment in a school or college of pharmacy, no minimum practice hours shall be required. Instead, respondent shall report to the board quarterly in writing, in a format and schedule as directed by the board or its designee, on [his/her] compliance with academic and vocational requirements, and on [his/her] academic progress. This exemption shall apply only once, and only during respondent's first academic year. Respondent must comply with all other terms and conditions of probation, unless notified in writing by the board or its designee.

14.16. Violation of Probation

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction and the period of probation shall be automatically extended until the petition to revoke probation or accusation is heard and decided.

15.17. Completion of Probation

Upon written notice by the board or its designee indicating successful completion of probation, respondent's license will be fully restored.

OPTIONAL CONDITIONS OF PROBATION

18. Suspension

As part of probation, respondent is suspended from practice as a [insert license type] for _________ [day(s)/month(s)/year(s)] beginning the effective date of this decision.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices or controlled substances.
During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

Failure to comply with any such suspension shall be considered a violation of probation.

Option 1: During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of ten (10) days during the period of suspension shall be considered a violation of probation, and shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation, unless notified in writing by the board or its designee.

Respondent shall notify the board or its designee in writing within ten (10) days of any departure from California, for any period, and shall further notify the board or its designee in writing within ten (10) days of return. Failure to timely provide such notification(s) shall be considered a violation of probation. Upon such departure and return, respondent shall not resume the practice of pharmacy until notified by the board or its designee that the period of suspension has been satisfactorily completed.

16.19. Restricted Practice

Respondent’s practice as a [insert license type] of pharmacy shall be restricted to [specify setting or type of practice] for the first ______ year(s) of probation. Respondent shall submit proof satisfactory to the board or its designee in writing of compliance with this term of probation.

Option: Respondent shall not prepare, oversee, or participate in the preparation of injectable sterile products during the first _____ year(s) of probation. Upon request, respondent shall submit to the board or its designee on writing, satisfactory proof satisfactory of compliance with this restriction, including but not limited to a written acknowledgment of this restriction signed by (a) respondent’s direct supervisor, (b) the pharmacist-in-charge, and (c) the owner or owner representative of his or her employer, which explains whether the workplace in question compounds drug products and how this restriction will be enforced term of probation. Failure to abide by this restriction or to timely submit proof to the board or its designee of compliance therewith shall be considered a violation of probation.

17.20. Pharmacist Examination (Pharmacists Only)

Respondent shall take and pass the [California Pharmacist Jurisprudence Examination (CPJE) and/or the North American Pharmacist Licensure Examination (NAPLEX)] within six (6) months of the effective date of this decision. If respondent fails to take and pass the examination(s) within six (6) months after the effective of this decision, respondent shall be automatically suspended from practice. Respondent shall not resume the practice of pharmacy until he or she takes and passes the [CPJE and/or NAPLEX] and is notified, in writing, that he or she has passed the examination(s) and may resume practice. Respondent shall bear all costs of the examination(s) required by the board.
During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices and controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

If respondent fails to take and pass the [CPJE and/or NAPLEX] after four attempts, respondent shall successfully complete, at a minimum, sixteen (16) additional semester units of pharmacy education as approved by the board. The respondent shall submit in writing to the board or its designee satisfactory proof of completion of sixteen (16) additional semester units of pharmacy education. Failure to complete coursework or provide proof of such completion as required shall be considered a violation of probation.

Failure to take and pass the examination(s) within one (1) year six (6) months of the effective date of this decision shall be considered a violation of probation.

18.20. Mental Health Examination Clinical Diagnostic Evaluation  (Appropriate for those cases where evidence demonstrates that mental illness psychiatric disorders (mental illness, emotional disturbance, gambling addiction), substance abuse, or disability was a contributing cause of the violation(s).)

Within thirty (30) days of the effective date of this decision, and on a periodic basis thereafter if as may be required by the board or its designee, respondent shall undergo, at his or her [his/her] own expense, psychiatric clinical diagnostic evaluation(s) by a board-appointed or board-approved licensed mental health practitioner selected or approved prior to the evaluation by the board or its designee. The approved evaluator shall be provided with a copy of the board’s [accusation, or petition to revoke probation, or other pleading] and decision. Respondent shall sign a release authorizing the evaluator to furnish the board with a current diagnosis and a written report regarding the respondent's judgment and ability to function independently as a pharmacist [insert license type] with safety to the public. Respondent shall comply with all the recommendations of the evaluator if directed by the board or its designee. If the evaluator recommends restrictions or conditions on respondent’s practice, including but not limited to, other terms and conditions listed in these guidelines (e.g., required psychotherapy, prescription coordination and monitoring, restricted practice), the board or its designee may by
written notice to respondent adopt these restrictions or conditions as additional probation terms and conditions, violation of which shall be considered a violation of probation.

If the evaluator recommends, and the board or its designee directs, respondent shall undergo psychotherapy. Within thirty (30) days of notification by the board that a recommendation for psychotherapy has been accepted, respondent shall submit to the board or its designee, for prior approval, the name and qualification of a licensed mental health practitioner of respondent’s choice. Within thirty (30) days of approval thereof by the board, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved licensed mental health practitioner. Should respondent, for any reason, cease treatment with the approved licensed mental health practitioner, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment therewith, submit the name of a replacement licensed mental health practitioner of respondent’s choice to the board for its prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved replacement. Failure to comply with any requirement or deadline stated by this paragraph shall be considered a violation of probation.

Upon approval of the initial or any subsequent licensed mental health practitioner, respondent shall undergo and continue treatment with that therapist, at respondent’s own expense, until the therapist recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further psychotherapy is necessary. Upon receipt of such recommendation from the treating therapist, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent’s expense, a mental health evaluation by a separate board-appointed or board-approved evaluator. If the approved evaluator recommends that respondent continue psychotherapy, the board or its designee may require respondent to continue psychotherapy.

Psychotherapy shall be at least once a week unless otherwise approved by the board. Respondent shall provide the therapist with a copy of the board’s [accusation or petition to revoke probation] and decision no later than the first therapy session. Respondent shall take all necessary steps to ensure that the treating therapist submits written quarterly reports to the board concerning respondent’s fitness to practice, progress in treatment, and other such information as may be required by the board or its designee.

If at any time the approved evaluator or therapist determines that respondent is unable to practice safely or independently as a pharmacist, the licensed mental health practitioner shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

**Option 1:** (Appropriate for those cases where evidence demonstrates substance abuse): The evaluation(s) shall be conducted in accordance with acceptable professional standards for alcohol or substance abuse clinical diagnostic evaluations. The written report(s) shall set forth, at least, the opinions of the evaluator as to: whether respondent has an alcohol or substance abuse problem; whether respondent is a threat to him/herself or others; and recommendations for alcohol or substance abuse treatment, practice restrictions, or other steps related to respondent’s rehabilitation and safe practice. If the evaluator determines during the evaluation process that respondent is a threat to him/herself or others, the evaluator shall notify the board within twenty-four (24) hours.
Commencing on the effective date of this decision, respondent is suspended from practice and shall not practice as a [insert license type] until:

- Respondent has undergone and completed clinical diagnostic evaluation(s);
- The report(s) of the evaluation(s) has/have been received by the board or its designee;
- One or more report(s) has concluded that respondent is safe to return to practice as a [insert license type];
- Respondent has submitted to observed bodily fluid testing for the presence of alcohol, dangerous drugs, or controlled substances [pursuant to Term and Condition 24] at least twice per week for at least thirty (30) days;
- During the testing period, respondent has not had a confirmed positive test result for alcohol, or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment, for at least thirty (30) days;
- The board or its designee has determined that respondent is safe to return to either full-time or part-time practice as a [insert license type], after considering the evaluation report(s), the results of the fluid testing, and criteria including the license type, respondent’s history, respondent’s documented period of sobriety or documented time since last use, respondent’s scope and pattern of use, respondent’s treatment history, respondent’s medical history and current medical condition, the nature, duration, and severity of respondent’s alcohol or substance abuse, and whether respondent is a threat to him/herself or others; and
- Respondent receives written notice from the board or its designee that practice may resume.

The board or its designee shall select or approve evaluator(s) holding a valid, unrestricted license to practice, with a scope of practice that includes the conduct of clinical diagnostic evaluations and at least three (3) years experience conducting such evaluations of health professionals with alcohol or substance abuse problems. The evaluator(s) shall not have a financial relationship, personal relationship, or business relationship with respondent within the last five (5) years. The evaluator(s) shall provide an objective/ unbiased, and independent evaluation of respondent.

For all such evaluations, a final written report shall be provided to the board no later than ten (10) days from the date the evaluator is assigned the matter unless the evaluator requests additional information to complete the evaluation, not to exceed thirty (30) days.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and controlled substances.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs or devices or controlled substances.
During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

Should the evaluator’s diagnosis indicate that the respondent is substance abusing, all provisions contained is in Section ?? shall apply during the term of probation.

Option 2: Commencing on the effective date of this decision, respondent is suspended from practice and shall not engage in the practice of pharmacy as a [insert license type] until notified in writing by the board that respondent has been deemed psychologically fit to practice pharmacy safely, and the board or its designee approves said recommendation. The evaluator recommends that respondent return to practice, this recommendation is accepted by the board or its designee, and respondent receives written notice from the board or its designee that practice may resume. The final written report of the evaluation shall be provided to the board no later than ten (10) days from the date the evaluator is assigned the matter unless the evaluator requests additional information to complete the evaluation, not to exceed thirty (30) days.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices and or controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

(Option language to be used in addition to standard language)

Option 3: If recommended by the evaluating licensed mental health practitioner and approved by the board, respondent shall be suspended from practicing pharmacy until respondent’s treating therapist recommends, in writing, stating the basis therefor, that respondent can safely practice pharmacy, and the board or its designee approves said recommendation. The evaluator, the board or its designee may suspend respondent from practice as a [insert license type] by providing written notice of suspension to the respondent. Upon suspension, respondent shall
not resume practice as a [insert license type] until: 1) another evaluation done at respondent’s expense by a licensed practitioner selected or approved by the board or its designee; 2) the evaluator recommends that respondent return to practice; 3) the board or its designee accepts the recommendation; 4) and the board notifies the respondent in writing that practice may resume.

The report(s) from any such additional evaluation(s) shall be provided to the board or its designee in writing by the evaluator no later than ten (10) days from the date the evaluator is assigned the matter unless the evaluator requests additional information to complete the evaluation, not to exceed thirty (30) days.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices or and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

19.21. Psychotherapy (Appropriate for those cases where the evidence demonstrates mental illness psychiatric disorders (mental illness, emotional disturbance, gambling addiction) or alcohol or drug abuse was involved in the violation(s).)

Within thirty (30) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, the name and qualifications of a licensed mental health practitioner of respondent’s choice. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved licensed mental health practitioner. Should respondent, for any reason, cease treatment with the approved licensed mental health practitioner, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement psychotherapist or licensed mental health practitioner of respondent’s choice to the board for its prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved replacement. Failure to comply with any requirement or deadline stated by this paragraph shall be considered a violation of probation.
Upon approval of the initial or any subsequent licensed mental health practitioner, respondent shall undergo and continue treatment with that therapist, at respondent's own expense, until the therapist recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further psychotherapy is necessary. Upon receipt of such recommendation from the treating therapist, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent's own expense, a mental health evaluation by a board-appointed or board-approved psychiatrist or psychologist. If the approved evaluator recommends that respondent continue psychotherapy, the board or its designee may require respondent to continue psychotherapy.

Psychotherapy shall be at least once a week unless otherwise approved by the board. Respondent shall provide the therapist with a copy of the board's accusation and decision no later than the first therapy session. Respondent shall take all necessary steps to ensure that the treating therapist submits written quarterly reports to the board concerning respondent's fitness to practice, progress in treatment, and such other information as may be required by the board or its designee.

If at any time the treating therapist determines that respondent cannot practice safely or independently, the therapist shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices or and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with any such this suspension shall be considered a violation of probation.

20.22. Medical Evaluation (Appropriate for those cases where the evidence demonstrates that the respondent has had a physical problem/disability which was a contributing cause of
Within thirty (30) days of the effective date of this decision, and on a periodic basis thereafter as may be required by the board or its designee, respondent shall undergo a medical evaluation, at respondent's own expense, by a board-appointed or board-approved physician who shall furnish a medical report to the board. The approved physician shall be provided with a copy of the board’s [accusation or petition to revoke probation] and decision. A record of this notification must be provided to the board upon request. Respondent shall sign a release authorizing the physician to furnish the board with a current diagnosis and a written report regarding the respondent's ability to function independently as a pharmacist [insert license type] with safety to the public. Respondent shall comply with all the recommendations of the physician if directed by the board or its designee.

If the physician recommends, and the board or its designee directs, that respondent undergo medical treatment, respondent shall, within thirty (30) days of written notice from the board, submit to the board or its designee, for prior approval, the name and qualifications of a licensed physician of respondent’s choice. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of treatment with the approved physician. Should respondent, for any reason, cease treatment with the approved physician, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement physician of respondent’s choice to the board or its designee for prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of treatment with the approved replacement. Failure to comply with any deadline stated by this paragraph shall be considered a violation of probation.

Upon approval of the initial or any subsequent physician, respondent shall undergo and continue treatment with that physician, at respondent’s own expense, until the treating physician recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further treatment is necessary. Upon receipt of such recommendation from the treating physician, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent’s own expense, a medical evaluation by a separate board-appointed or board-approved physician. If the approved evaluating physician recommends that respondent continue treatment, the board or its designee may require respondent to continue treatment.

Respondent shall take all necessary steps to ensure that any treating physician submits written quarterly reports to the board concerning respondent’s fitness to practice, progress in treatment, and other such information as may be required by the board or its designee.

If at any time an approved evaluating physician or respondent’s approved treating physician determines that respondent is unable to practice safely or independently as a pharmacist [insert license type], the evaluating or treating physician shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not
practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices or and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

*(Option language to be used in addition to standard language)*

**Option 1:** Commencing on the effective date of this decision, respondent shall not engage in the practice of pharmacy as a [insert license type] until notified in writing by the board that respondent has been deemed medically fit to practice safely and independently, and the board or its designee approves said recommendation.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy as a [insert license type] nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

*(Option language to be used in addition to standard language)*

**Option 2:** If recommended by the evaluating physician and approved by the board, respondent shall be suspended from practicing pharmacy as a [insert license type] until the treating
physician recommends, in writing, stating the basis therefor, that respondent can safely and independently resume the practice of a pharmacist, and the board or its designee approves said recommendation. Respondent shall not resume practice until notified by the board that practice may be resumed.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy as a [insert license type] nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and or devices or controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

21.23. Pharmacists Recovery Program (PRP) (Appropriate for those cases where evidence demonstrates substance abuse chemical dependency (alcohol, drugs), or psychiatric disorders (mental illness, emotional disturbance, gambling addiction) (Pharmacists and Pharmacist Interns Only)

By no later than ten (10) days after Within thirty (30) days of the effective date of this decision, respondent shall have completed all of the following: contacted the Pharmacists Recovery Program (PRP) for evaluation; enrolled in the PRP; completed, signed, and returned the treatment contract plus any addendums required or suggested by the PRP; successfully completed registration for any drug or alcohol testing mandated by the treatment contract and/or by enrollment in the PRP; and begun compliance with the drug or alcohol testing protocol(s). contact the Pharmacists Recovery Program (PRP) for evaluation, and shall immediately thereafter enroll, successfully participate in, and complete the treatment contract and any subsequent addendums as recommended and provided by the PRP and as approved by the board or its designee. Respondent shall successfully participate in and complete his or her current contract and any subsequent addendums with the PRP.

If respondent is currently enrolled in the PRP, said participation is now mandatory and as of the effective date of this decision is no longer considered a self-referral under Business and Professions Code section 4362(c) (a)(2). Respondent shall successfully participate in and complete his or her current contract and any subsequent addendums with the PRP.
Failure to timely contact or enroll in the PRP, complete the treatment contract and any addendums, complete testing registration, comply with testing, and/or successfully participate in and complete the treatment contract and/or any addendums, shall result in the automatic suspension of practice by respondent and shall be considered a violation of probation. Respondent shall not resume practice until notified in writing by the board or its designee.

Probation shall be automatically extended until respondent successfully completes the PRP. Any person terminated from the PRP program shall be automatically suspended by the board. Respondent may not resume the practice of pharmacy until notified by the board in writing.

Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall result in the automatic suspension of practice by respondent and shall be considered a violation of probation. Respondent may not resume the practice of pharmacy until notified by the board in writing.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy as a [insert license type] nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and or devices or controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with any such this suspension shall be considered a violation of probation.

Respondent shall pay administrative fees as invoiced by the PRP or its designee. Fees not timely paid to the PRP shall constitute a violation for probation. The board will collect unpaid administrative fees as part of the annual probation monitoring costs if not submitted to the PRP.

(Option language to be used in addition to standard language)

Option: Respondent shall work in a pharmacy setting with access to controlled substances for six (6) consecutive months before successfully completing probation the PRP. If respondent fails to do so, probation shall be automatically extended until this condition has been met. Failure to satisfy this condition within six (6) months beyond the original date of expiration of the term of probation shall be considered a violation of probation.
22. 24. Random-Drug-Screening Drug and Alcohol Testing (If PRP provision is required, this term is also to be included to allow for continued fluid monitoring by the Board in cases where a respondent successfully completes the PRP before completion of the probation period; terms is also appropriate for those cases where the evidence demonstrates that the respondent may have a problem with chemical dependency (drugs, alcohol) but where the PRP is not required—(Appropriate for those cases where the evidence demonstrates substance abuse.)

Respondent, at his or her [his/her] own expense, shall participate in random testing, including but not limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other drug screening program as directed by the board or its designee. Respondent may be required to participate in testing for the entire probation period and the frequency of testing will be determined by the board or its designee. At all times, respondent shall fully cooperate with the board or its designee, and shall, when directed, submit to such tests and samples for the detection of alcohol, narcotics, hypnotics, controlled substances, and dangerous drugs, or other controlled substances as the board or its designee may direct. Failure to timely submit to testing as directed shall be considered a violation of probation. Upon request of the board or its designee, respondent shall provide documentation from a licensed practitioner that the prescription for a detected drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall be considered a violation of probation and shall result in the automatic suspension of practice of pharmacy by respondent. Respondent may not resume the practice of pharmacy until notified by the board in writing.

Testing protocols may include biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other testing protocols as directed by the board or its designee. All testing must be pursuant to an observed testing protocol, unless respondent is informed otherwise in writing by the board or its designee. Respondent may be required to participate in testing for the entire probation period and frequency of testing will be determined by the board or its designee.

By no later than thirty (30) days after the effective date of this decision, respondent shall have completed all of the following tasks: enrolled and registered with an approved drug and alcohol testing vendor; provided that vendor with any necessary information and documentation, and any information necessary for payment by respondent; commenced testing protocols, including all required contacts with the testing vendor to determine testing date(s); and begun testing. At all times, respondent shall fully cooperate with the testing vendor, and with the board or its designee, with regard to enrollment, registration, and payment for, and compliance with, testing. Any failure to cooperate timely shall be considered a violation of probation.

Respondent may be required to test on any day, including weekends and holidays. Respondent is required to make daily contact with the testing vendor to determine if a test is required, and if a test is required must submit to testing on the same day.

Any detection through testing of alcohol, or of a controlled substance or dangerous drug absent documentation that the detected substance was taken pursuant to a legitimate prescription and a necessary treatment, may cause the board or its designee to increase the frequency of testing, in addition to any other action including but not limited to further disciplinary action.

Prior to any vacation or other period of absence from the geographic area of the approved testing vendor, respondent shall seek and receive approval from the board or its designee of an alternate testing vendor in the geographic area to be visited or resided in by respondent. Upon approval, respondent shall enroll and register with the approved alternate drug testing vendor,
provide that alternate vendor with any necessary information and documentation, including any necessary payment by respondent. During the period of visitation or residence in the alternate geographic area, respondent shall commence testing protocols with the alternate vendor, including required daily contacts with the testing vendor to determine if testing is required, and required testing. Any failure to timely seek or receive approval from the board or its designee, or to timely enroll and register with, timely commence testing protocols with, or timely undergo testing with, the alternate testing vendor, shall be considered a violation of probation.

Upon detection through testing of a controlled substance or dangerous drug, the board or its designee may require respondent to timely provide documentation from a licensed practitioner authorized to prescribe the detected substance demonstrating that the substance was administered or ingested pursuant to a legitimate prescription issued as a necessary part of treatment. All such documentation shall be provided by respondent within ten (10) days of being requested.

Any of the following shall be considered a violation of probation and shall result in respondent being immediately suspended from practice as a [insert license type] until notified by the board in writing that [he/she] may resume practice: failure to timely complete all of the steps required for enrollment/registration with the drug testing vendor, including making arrangements for payment; failure to timely commence drug testing protocols; failure to contact the drug testing vendor as required to determine testing date(s); failure to test as required; failure to timely supply documentation demonstrating that a detected substance was taken pursuant to a legitimate prescription issued as a necessary part of treatment; and/or detection through testing of alcohol, or of a controlled substance or dangerous drug absent documentation that the detected substance was taken pursuant to a legitimate prescription and a necessary treatment. In the event of a suspension ordered after detection through testing of alcohol, or of a controlled substance or dangerous drug absent documentation that the detected substance was taken pursuant to a legitimate prescription and a necessary treatment, the board or its designee shall inform respondent of the suspension and inform [him/her] to immediately leave work, and shall notify respondent’s employer(s) and work site monitor(s) of the suspension.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a pharmacist [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

---

2. The Terms of Probation Designated Representative are now consolidated into “Terms of Probation – Individual Licensees.”
Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

23.25. Abstain from Drugs and Alcohol Use

Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs, or and their associated paraphernalia, except when possessed or used pursuant to a legitimate prescription issued as a necessary part of treatment, the drugs are lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon request of the board or its designee, respondent shall provide documentation from the licensed practitioner that the prescription for the drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she [he/she] is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, dangerous drugs or controlled substances, or their associated paraphernalia not supported by for which a legitimate prescription has been issued as a necessary part of treatment, the documentation timely provided, and/or or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

24.26. Prescription Coordination and Monitoring of Prescription Use (Appropriate for those cases where the evidence demonstrates substance abuse, chemical dependency (alcohol, drugs), or psychiatric disorders (mental illness, emotional disturbance, gambling addiction)

Within thirty (30) days of the effective date of this decision, respondent shall submit to the board, for its prior approval, the name and qualifications of a single physician, nurse practitioner, physician assistant, or psychiatrist of respondent's choice, who shall be aware of the respondent's history [with the use of alcohol, controlled substances, and/or dangerous drugs, and/or of mental illness, and/or of gambling addiction] and who will coordinate and monitor any prescriptions for respondent for dangerous drugs, controlled substances or mood-altering drugs. The approved practitioner shall be provided with a copy of the board's [accusation or petition to revoke probation] and decision. A record of this notification must be provided to the board upon request. Respondent shall sign a release authorizing the practitioner to communicate with the board or its designee about respondent's treatment(s). The coordinating physician, nurse practitioner, physician assistant, or psychiatrist shall report to the board on a quarterly basis for the duration of probation regarding respondent's compliance with this condition. If any substances considered addictive have been prescribed, the report shall identify a program for the time limited use of any such substances. The board or its designee may require that the single coordinating physician, nurse practitioner, physician assistant or psychiatrist be a specialist in addictive medicine, or consult a specialist in addictive medicine. Should respondent, for any reason, cease supervision by the approved practitioner, respondent shall notify the board or its designee immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement physician, nurse practitioner, physician assistant, or psychiatrist of respondent's choice to the board or its designee for its prior approval. Failure to timely submit the selected practitioner or replacement practitioner to the board or its designee for approval, or to ensure the required reporting thereby on the quarterly reports, shall be
considered a violation of probation.

If at any time an approved practitioner determines that respondent is unable to practice safely or independently as a [insert license type], the practitioner shall notify the board or its designee immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice as a [insert license type] until notified by the board or its designee that practice may be resumed.

During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs or devices and controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment and/or licensure as a [insert license type] of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with any such this suspension shall be considered a violation of probation.

25.27. Community Services Program

Within sixty (60) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, a community service program in which respondent shall provide free [insert type of service e.g., health-care related services] on a regular basis to a community or charitable facility or agency for at least ______ hours per ______ for the first ______ of probation. Within thirty (30) days of board approval thereof, respondent shall submit documentation to the board or its designee demonstrating commencement of the community service program. A record of this notification must be provided to the board upon request. Respondent shall report on progress with the community service program in the quarterly reports and provide satisfactory documentary evidence of such progress to the board or its designee upon request. Failure to timely submit, commence, or comply with the program shall be considered a violation of probation.

26.28. Restitution (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)
Within _____ days of the effective date of this decision, respondent shall pay restitution to ___________ in the amount of $ ___________. Failure to make restitution by this deadline shall be considered a violation of probation.

27.29. Remedial Education

Within [thirty (30), sixty (60), ninety (90)] days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, an appropriate program of remedial education related to [the grounds for discipline]. The program of remedial education shall consist of at least _______ hours, which shall be completed within _______ months/year at respondent's own expense. All remedial education shall be in addition to, and shall not be credited toward, continuing education (CE) courses used for license renewal purposes for pharmacists.

Failure to timely submit for approval or complete the approved remedial education shall be considered a violation of probation. The period of probation will be automatically extended until such remedial education is successfully completed and written proof, in a form acceptable to the board, is provided to the board or its designee.

Following the completion of each course, the board or its designee may require the respondent, at his or her [his/her] own expense, to take an approved examination to test the respondent's knowledge of the course. If the respondent does not achieve a passing score on the examination, this failure shall be considered a violation of probation. Any such examination failure shall require respondent to take another course approved by the board in the same subject area.

Option: Respondent shall be restricted from the practice of [areas where a serious deficiency has been identified] until the remedial education program has been successfully completed.

28. Pharmacy Self-Assessment Mechanism

Within the first year of probation, respondent shall complete the Pharmacist Self-Assessment Mechanism (PSAM) examination provided by the National Association of Boards of Pharmacy (NABP). Respondent shall submit a record of completion to the board demonstrating he/she has completed this examination. Respondent shall bear all costs for the examination. Continuing education hours received for this examination shall not be used as part of the required continuing education hours for renewal purposes.

Failure to timely complete the PSAM or submit documentation thereof shall be considered a violation of probation.

Option A: Respondent shall waive any rights to confidentiality and provide examination results to the board or its designee.

Option B: (This term must be accompanied by the “Remedial Education” term. [Include/Modify Remedial Education Term to Conform].) Respondent shall waive any rights to confidentiality and provide examination results to the board or its designee. Based on the results of the examination, the board shall determine which courses are appropriate for remedial education.

29. 30. Intern Pharmacist Experience (Pharmacist Interns Only)
Within ninety (90) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, a pharmacy intern training program consisting of ________ hours to be served as an intern pharmacist in a community and/or institutional pharmacy as directed. Respondent shall successfully complete the intern hours within the first year of probation and shall, by no later than one (1) year and ten (10) days from the effective date of this decision, submit proof satisfactory to the board of completion of this experience signed under penalty of perjury by both the respondent and supervising pharmacist. Failure to timely complete or document the required intern experience shall be considered a violation of probation.

30. 31. Supervised Practice (Pharmacists, Pharmacist Interns and Designated Representatives Only)

During the period of probation, respondent shall practice only under the supervision of a licensed pharmacist not on probation with the board. Upon and after the effective date of this decision, respondent shall not practice pharmacy and his or her license shall be automatically suspended until a supervisor is approved by the board or its designee. The supervision shall be, as required by the board or its designee, either: Within thirty (30) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, the name of a [insert license type] licensed by and not on probation with the board, to serve as respondent’s practice supervisor. As part of the documentation submitted, respondent shall cause the proposed practice supervisor to report to the board in writing acknowledging that he or she has read the decision in case number [insert case number], and is familiar with the terms and conditions imposed thereby, including the level of supervision required by the board or its designee. This level will be determined by the board or its designee, will be communicated to the respondent on or before the effective date of this decision and shall be one of the following:

- Continuous – At least 75% of a work week
- Substantial - At least 50% of a work week
- Partial - At least 25% of a work week
- Daily Review - Supervisor's review of probationer's daily activities within 24 hours

Respondent may practice only under the required level of supervision by an approved practice supervisor. If, for any reason, including change of employment, respondent is no longer supervised at the required level by an approved practice supervisor, within ten (10) days of this change in supervision respondent shall submit to the board or its designee, for prior approval, the name of a [insert license type] licensed by and not on probation with the board, to serve as respondent’s replacement practice supervisor. As part of the documentation submitted, respondent shall cause the proposed replacement practice supervisor to report to the board in writing acknowledging that he or she has read the decision in case number [insert case number], and is familiar with the terms and conditions imposed thereby, including the level of supervision required.

Any of the following shall be considered a violation of probation: failure to timely nominate either an initial or a replacement practice supervisor; failure to cause the practice supervisor to timely report to the board in writing acknowledging the decision, terms and conditions, and supervision level; practicing in the absence of an approved practice supervisor after lapse of the nomination period; and/or failure to adhere to the level of supervision required by the board or its designee. If any of these obligations or prohibitions is not met, respondent shall be automatically suspended from practice as a [insert license type] and may not resume such practice until notified by the board or its designee in writing.
Within thirty (30) days of the effective date of this decision, respondent shall have his or her supervisor submit notification to the board in writing stating that the supervisor has read the decision in case number _________ and is familiar with the required level of supervision as determined by the board or its designee. It shall be the respondent’s responsibility to ensure that his or her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to the board. Failure to cause the direct supervisor and the pharmacist-in-charge to submit timely acknowledgements to the board shall be considered a violation of probation.

If respondent changes employment, it shall be the respondent’s responsibility to ensure that his or her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to the board. Respondent shall have his or her new supervisor, within fifteen (15) days after employment commences, submit notification to the board in writing stating the direct supervisor and pharmacist-in-charge have read the decision in case number _________ and is familiar with the level of supervision as determined by the board. Respondent shall not practice pharmacy and his or her license shall be automatically suspended until the board or its designee approves a new supervisor. Failure to cause the direct supervisor and the pharmacist-in-charge to submit timely acknowledgements to the board shall be considered a violation of probation.

Within ten (10) days of leaving employment, respondent shall notify the board in writing. During any such suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and or devices or controlled substances. Respondent shall not resume practice until notified by the board.

During any such suspension, respondent shall not engage in any activity that requires the professional judgment and/or licensure as a [insert license type]of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy or of the manufacture, distribution, wholesaling, or retailing of dangerous drugs or devices or controlled substances. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this any such suspension shall be considered a violation of probation.

31. No Supervision of Ancillary Personnel

During the period of probation, respondent shall not supervise any ancillary personnel, including, but not limited to, pharmacy technicians or designated representatives in any entity licensed by the board.
Failure to comply with this provision shall be considered a violation of probation.

32. **No Ownership or Management of Licensed Premises**

Respondent shall not own, have any legal or beneficial interest in, or nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90) days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.

**Option:** Respondent shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If respondent currently owns or has any legal or beneficial interest in, or serves as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, respondent may continue to serve in such capacity or hold that interest, but only to the extent of that position or interest as of the effective date of this decision. Violation of this restriction shall be considered a violation of probation.

33. **Separate File of Controlled Substances Records** *(For pharmacist, pharmacist owners and pharmacists-in-charge)*

Respondent shall maintain and make available for inspection a separate file of all records pertaining to the acquisition or disposition of all controlled substances. Failure to maintain such file or make it available for inspection shall be considered a violation of probation.

34. **Report of Controlled Substances** *(For pharmacist, pharmacist owners and pharmacists-in-charge)*

Respondent shall submit quarterly reports to the board detailing the total acquisition and disposition of such controlled substances as the board or its designee may direct. Respondent shall specify the manner of disposition (e.g., by prescription, due to burglary, etc.) or acquisition (e.g., from a manufacturer, from another retailer, etc.) of such controlled substances. Respondent shall report on a quarterly basis or as directed by the board or its designee. The report shall be delivered or mailed to the board no later than ten (10) days following the end of the reporting period as determined by the board or its designee. Failure to timely prepare or submit such reports shall be considered a violation of probation.

35. **No Access to Controlled Substances**

During the period of probation and as directed by the board or its designee, respondent shall not order, possess, dispense or otherwise have access to any controlled substance(s) in Schedules I, II, III, IV or V (Health and Safety Code sections 11055-11058 inclusive). Respondent shall not order, receive or retain any security prescription forms. Failure to comply with this restriction shall be considered a violation of probation.
36. Criminal Probation/Parole Reports

Respondent shall provide a copy of the conditions of any criminal probation/parole to the board, in writing, within ten (10) days of the issuance or modification of those conditions. Respondent shall provide the name of his or her probation/parole officer to the board, in writing, within ten (10) days after that officer is designated or a replacement for that officer is designated. Respondent shall provide a copy of all criminal probation/parole reports to the board within ten (10) days after respondent receives a copy of such a report. Failure to timely make any of the submissions required hereby shall be considered a violation of probation.

37. Consultant for Owner or Pharmacist-In-Charge

(Option #1 for pharmacist owners – primarily intended for appropriate cases where the respondent is the sole owner and pharmacist-in-charge of his or her own pharmacy, the standard language should be used in most cases.)

During the period of probation, respondent shall not supervise any intern pharmacist or serve as a consultant to any entity licensed by the board. Respondent may be a pharmacist-in-charge. However, if during the period of probation respondent serves as a pharmacist-in-charge, respondent shall retain an independent consultant at his or her own expense who shall be responsible for reviewing pharmacy operations on a [monthly/quarterly] basis for compliance by respondent with state and federal laws and regulations governing the practice of pharmacy and for compliance by respondent with the obligations of a pharmacist-in-charge. The consultant shall be a pharmacist licensed by and not on probation with the board and whose name shall be submitted to the board or its designee, for prior approval, within thirty (30) days of the effective date of this decision. Respondent shall not be a pharmacist-in-charge at more than one pharmacy or at any pharmacy of which he or she is not the sole owner. Failure to timely retain, seek approval of, or ensure timely reporting by the consultant shall be considered a violation of probation.

(Option #2 – appropriate for pharmacists who are not pharmacy owners, but who wish, because of their current employment, to remain as the pharmacist-in-charge, and have provided documented mitigating evidence to warrant this option.)

During the period of probation, respondent shall not supervise any intern pharmacist, or serve as a consultant to any entity licensed by the board. In the event that the respondent is currently the pharmacist-in-charge of a pharmacy, the pharmacy shall retain an independent consultant at its own expense who shall be responsible for reviewing pharmacy operations on a [monthly/quarterly] basis for compliance by respondent with state and federal laws and regulations governing the practice of pharmacy and for compliance by respondent with the obligations of a pharmacist-in-charge. The consultant shall be a pharmacist licensed by and not on probation with the board and whose name shall be submitted to the board or its designee, for prior approval. Within thirty (30) days of the effective date of this decision. Respondent shall not be a pharmacist-in-charge at more than one pharmacy or at any pharmacy of which he or she is not the current PIC. The board may, in case of an employment change by respondent or for other reasons as deemed appropriate by the board or its designee, preclude the respondent from acting as a pharmacist-in-charge. Failure to timely retain, seek approval of, or ensure timely reporting by the consultant shall be considered a violation of probation.

6 This term was consolidated in new term 8 – Restrictions on Supervision and Oversight of Licensed Facilities.
38. **Tolling of Suspension**

During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of the (10) days during suspension shall be considered a violation of probation. Moreover, any absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not resume the practice of pharmacy until notified by the board that the period of suspension has been satisfactorily completed.

39. **Surrender of DEA Permit (Pharmacists and Pharmacist Interns Only)**

Within thirty (30) days of the effective date of this decision, respondent shall surrender his or her federal Drug Enforcement Administration (DEA) permit to the DEA, for cancellation. Respondent shall provide documentary proof of such cancellation to the board or its designee. Respondent is prohibited from prescribing, dispensing, furnishing, or otherwise providing dangerous drugs or devices or controlled substances until the board has received satisfactory proof of cancellation. Thereafter, respondent shall not apply/reapply for a DEA registration number without the prior written consent of the board or its designee.

**Option 1:** Respondent may obtain a DEA permit restricted to Schedule(s) _______ controlled substance(s).

**Option 2:** Respondent shall not order, receive, or retain any federal order forms, including DEA form 222 forms, for controlled substances.

40. **Ethics Course (Pharmacists and Pharmacist Interns Only)**

Within sixty (60) calendar days of the effective date of this decision, respondent shall enroll in a course in ethics, at respondent’s expense, approved in advance by the board or its designee that complies with Title 16 California Code of Regulations section 1773.5. Respondent shall provide proof of enrollment upon request. Within five (5) days of completion, respondent shall submit a copy of the certificate of completion to the board or its designee. Failure to timely enroll in an approved ethics course, to initiate the course during the first year of probation, to successfully and complete it before the end of within the second year of probation, or to timely submit proof of completion to the board or its designee, shall be considered a violation of probation.

Respondent shall submit a certificate of completion to the board or its designee within five days after completing the course.

39. **Facilitated Group Recovery and/or Support Meetings** (Appropriate for those cases where the evidence demonstrates substance abuse.)
Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a group recovery and/or support meeting that approved in advance by the board or its designee. The required frequency of group meeting attendance shall be determined by the board or its designee.

The facilitator shall, upon request by the board or its designee, provide the board with a dated document signed by the facilitator that includes respondent’s name, the group’s name, if any, the date and time of its regular meeting(s), respondent’s attendance record, and respondent’s participation level and progress. Respondent shall provide signed and dated documentation of attendance as required with each quarterly report. Failure to attend as required or to submit documentation of attendance shall be considered a violation of probation.

40. **Attend Substance Abuse Recovery Relapse Prevention and Support Groups**  
(Appropriate for those cases where the evidence demonstrates substance abuse.)

Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a recognized and established substance abuse recovery support group in California (e.g., Alcoholics Anonymous, Narcotics Anonymous, etc.) which has been approved by the board or its designee. Respondent must attend at least one group meeting per week unless otherwise directed by the board or its designee. Respondent shall continue regular attendance and submit signed and dated documentation confirming attendance with each quarterly report for the duration of probation. Failure to attend or submit documentation thereof shall be considered a violation of probation.

41. **Work Site Monitor** (Appropriate for those cases where the evidence demonstrates substance abuse.)

Within ten (10) days of the effective date of this decision, respondent shall identify a work site monitor, for prior approval by the board or its designee, who shall be responsible for supervising respondent during working hours. Respondent shall be responsible for ensuring that the work site monitor reports in writing to the board monthly or on another schedule as directed by the board or its designee. Should the designated work site monitor suspect at any time during the probationary period that respondent has abused alcohol or drugs, he or she shall notify the board immediately.

The initial notification shall be made orally within one (1) business day of the occurrence, and shall be followed by written notification within two (2) business days of the occurrence. If, for any reason, including change of employment, respondent is no longer able to be monitored by the approved work site monitor within ten (10) days respondent shall designate a new work site monitor for approval by the board or its designee. Failure to timely identify an acceptable initial or replacement work site monitor, or to ensure monthly reports are submitted to the board by the monitor, shall be considered a violation of probation.

---

7 This probationary term is not new, but is being moved from the previous section “Pharmacy Technician – Standard Terms and Conditions” for purposes of consolidation. The language of this term is also changing from the previous version.
The written reports submitted to the board or its designee by the work site monitor shall include at least the following information: respondent’s name and license number; the monitor’s name, license number (if applicable) and work site location; the date(s) the monitor had face-to-face contact with respondent; the staff interviewed, if applicable; an attendance report; notes on any changes in respondent’s behavior or personal habits; notes on any indicators that may lead to substance abuse; and the work site monitor’s signature.

Respondent shall complete any required consent forms and sign any required agreement with the work site monitor and/or the board to allow the board or its designee to communicate freely on the subject of respondent’s work performance and sobriety with the work site monitor.

Option for respondents enrolled in PRP or who are given the PRP enrollment term: It is a condition of respondent’s enrollment in the Pharmacists Recovery Program (PRP) that [he/she] is required to have a work site monitor approved by the PRP who shall be responsible for supervising respondent during working hours. Respondent shall be responsible for ensuring that the work site monitor reports in writing to the PRP monthly or on another schedule as directed by the PRP. Should the designated work site monitor suspect at any time during the probationary period that respondent has abused alcohol or drugs, he or she shall notify the PRP immediately. The initial notification shall be made orally within one (1) business day of the occurrence, and shall be followed by written notification within two (2) business days of the occurrence. If, for any reason, including change of employment, respondent is not longer able to be monitored by the approved work site monitor, within ten (10) days of commencing new employment for prior approval by the PRP. Failure to identify an acceptable initial or replacement work site monitor, or to ensure monthly reports are submitted to the PRP by the work site monitor, shall be considered a violation of probation.

The work site monitor shall not have a financial, personal, familial or other relationship with the respondent that could reasonably be expected to compromise the ability of the monitor to render impartial and unbiased reports to the PRP. If it is impractical for anyone but respondent’s employer to serve as work site monitor, this requirement may be waived by the PRP; however, under no circumstances shall respondent’s work site monitor be respondent’s employee.

The work site monitor shall hold a license with a scope of practice including the scope of practice of the respondent’s license, shall be another health care professional if no monitor with like practice is available, or, as approved by the PRP, shall be a person in a position of authority who is capable of monitoring respondent while at work.

The written reports submitted to the PRP by the work site monitor shall include at least the following information: respondent’s name and license number; the monitor’s name, license number (if applicable) and work site location; the date(s) the monitor had face-to-face contact with respondent; the staff interviewed, if applicable; an attendance report; notes on any changes in respondent’s behavior or personal habits; notes on any indicators that may lead to substance abuse; and the work site monitor’s signature.

Respondent shall complete any required consent forms and sign any required agreement with the work site monitor and/or the PRP to allow the PRP to communicate freely on the subject of respondent’s work performance and sobriety with the work site monitor.
PHARMACY TECHNICIAN

The board files cases against pharmacy technicians where the violation(s) involve significant misconduct on the part of the licensee. The board believes that revocation is typically the appropriate penalty when grounds for discipline are found to exist. Grounds for discipline include, but are not limited to the following violation(s) of law(s) involving:

- Possession of dangerous drugs and/or controlled substances
- Use of dangerous drugs and/or controlled substances
- Possession for sale of dangerous drugs and/or controlled substances
- Personal misuse of drugs or alcohol

If revocation is not imposed, the board recommends a minimum Category III level of discipline be imposed on the pharmacy technician. This would include suspension and probation.

In addition, a pharmacy technician would be required to obtain certification as defined by Business and Professions Code section 4202(a)(4) prior to resuming work as a pharmacy technician. The board believes that certification prior to resuming work is always warranted in cases where a pharmacy technician license is disciplined but not revoked.

Pharmacy technicians are issued a license based on minimal education, training requirements or certification. No examination is required for issuance of the registration. Pharmacy technicians are not independent practitioners and must work under the supervision of a pharmacist. To place a pharmacy technician on probation places an additional burden on the pharmacist (who may or may not be on probation) to ensure that the respondent pharmacy technician complies with the terms and conditions of his or her probation.

TERMS OF PROBATION—PHARMACY TECHNICIAN

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.
CATEGORY OF VIOLATIONS AND RECOMMENDED PENALTIES

CATEGORY III—Penalty

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three years probation. All standard terms and conditions shall be included and optional terms and conditions as appropriate.

Maximum: Revocation

Applies to all applicable statutes and regulations

MODEL DISCIPLINARY LANGUAGE—PHARMACY TECHNICIAN

The following standardized language shall be used in every decision where the order of condition is imposed.

Revocation

Pharmacy technician license number ___________, issued to respondent ____________ is revoked. Respondent shall relinquish his or her technician license to the board within ten (10) days of the effective date of this decision. Respondent may not reapply or petition the board for reinstatement of his or her revoked technician license for three (3) years from the effective date of this decision.

A condition of reinstatement shall be that the respondent is certified as defined in Business and Professions Code section 4202(a)(4) and provides satisfactory proof of certification to the board.

Respondent shall pay to the board its costs of investigation and prosecution in the amount of $________ within fifteen (15) days of the effective date of this decision.

Option: As a condition precedent to reinstatement of his or her revoked technician license respondent shall reimburse the board for its costs of investigation and prosecution in the amount of $________. Said amount shall be paid in full prior to the reapplication or reinstatement of his or her revoked technician license, unless otherwise ordered by the board.

Suspension

As part of probation, respondent is suspended from working as a pharmacy technician for ____________ beginning the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of or any other board licensed premises (wholesaler, veterinary food-animal drug retailer or any other distributor of drugs) any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or assist any licensee of the board. Respondent shall not have

8 All information specific to Pharmacy Technician is being removed and consolidated into Terms of Probation – Individual Licensees.
access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

Respondent shall not direct, control or perform any aspect of the practice of pharmacy. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

Standard Stay/Probation Order

Pharmacy technician license number ______________ is revoked; however the revocation is stayed and respondent is placed on probation for ____________ years upon the following terms and conditions:

Issuance of Probationary License (In cases where a Statement of Issues has been filed.)

Upon satisfaction of all statutory and regulatory requirements for issuance of a license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for ______ years upon the following terms and conditions:

Surrender

Respondent surrenders pharmacy technician license number _____________ as of the effective date of this decision. Respondent shall relinquish his or her pharmacy technician license to the board within ten (10) days of the effective date of this decision.

The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board.

Respondent understands and agrees that if he or she ever files an application for licensure or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.

Respondent may not apply for any license, permit, or registration from the board for three (3) years from the effective date of this decision. Respondent stipulates that should he or she apply for any license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, correct and admitted by respondent when the board determines whether to grant or deny the application. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board, including, but not limited to certification by a nationally recognized body prior to the issuance of a new license. Respondent is required to report this surrender as disciplinary action.

Respondent further stipulates that he or she shall reimburse the board for its costs of investigation and prosecution in the amount of $____________ within ____________ days of the effective date of this decision.
Option: Respondent stipulates that should he or she apply for any license from the board on or after the effective date of this decision, investigation and prosecution costs in the amount of $____________ shall be paid to the board prior to issuance of the license.

Public Reprimand

It is hereby ordered that a public reprimand be issued against pharmacy technician license, ____________. Respondent is required to report this reprimand as a disciplinary action.

Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.
STANDARD CONDITIONS — To be included in all probation decisions/orders:

1. Certification Prior to Resuming Work
2. Obey All Laws
3. Report to the Board
4. Interview with the Board
5. Cooperate with Board Staff
6. Notice to Employers
7. Reimbursement of Board Costs
8. Probation Monitoring Costs
9. Status of License
10. License Surrender While on Probation/Suspension
11. Notification of a Change in Name, Residence Address, Mailing Address or Employment
12. Tolling of Probation
13. Violation of Probation
14. Completion of Probation

OPTIONAL CONDITIONS

15. No Ownership of Licensed Premises
16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
17. Random Drug Screening
18. Work Site Monitor
19. Notification of Departure
20. Abstain from Drugs and Alcohol Use
21. Tolling of Suspension
22. Restitution
STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

1. Certification Prior to Resuming Work

Respondent shall be automatically suspended from working as a pharmacy technician until he or she is certified as defined by Business and Professions Code section 4202(a)(4) and provides satisfactory proof of certification to the board. Respondent shall not resume working as a pharmacy technician until notified by the board. Failure to achieve certification within one (1) year shall be considered a violation of probation. Respondent shall not resume working as a pharmacy technician until notified by the board.

During suspension, respondent shall not enter any pharmacy area or any portion of any other board licensed premises (wholesaler, veterinary food-animal drug retailer or any other distributor of drugs), any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or assist any licensee of the board. Respondent shall not have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances. Respondent shall not resume work until notified by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises by the board in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

2. Obey All Laws

Respondent shall obey all state and federal laws and regulations.

Respondent shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent’s _____ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

3. Report to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports
in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

4. Interview with the Board

Upon receipt of reasonable prior notice, respondent shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear at two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

5. Cooperate with Board Staff

Respondent shall cooperate with the board’s inspection program and with the board’s monitoring and investigation of respondent’s compliance with the terms and conditions of his or her probation. Failure to cooperate shall be considered a violation of probation.

6. Notice to Employers

During the period of probation, respondent shall notify all present and prospective employers of the decision in case number ________ and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his or her direct supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent’s tenure of employment) and owner to report to the board in writing acknowledging that the listed individual(s) has/have read the decision in case number ________ and the terms and conditions imposed thereby. It shall be respondent’s responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgement(s) to the board.

If respondent works for or is employed by or through a pharmacy employment service, respondent must notify his or her direct supervisor, pharmacist-in-charge and owner at every pharmacy of the terms and conditions of the decision in case number ________ in advance of the respondent commencing work at each pharmacy. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy employment service, respondent shall cause his or her direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he or she has read the decision in case number ________ and the terms and conditions imposed thereby. It shall be respondent’s responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgements to the board shall be considered a violation of probation.
“Employment” within the meaning of this provision shall include any full-time, part-time, temporary or relief service or pharmacy management service as a pharmacy technician or in any position for which a pharmacy technician license is a requirement or criterion for employment, whether the respondent is considered an employee, independent contractor or volunteer.

7. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, respondent shall pay to the board its costs of investigation and prosecution in the amount of $_________. Respondent shall make said payments as follows: ___________. There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

8. Probation Monitoring Costs

Respondent shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

9. Status of License

Respondent shall, at all times while on probation, maintain an active, current pharmacy technician license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If respondent's pharmacy technician license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication respondent’s license shall be subject to all terms and conditions of this probation not previously satisfied.

10. License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent cease work due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her pharmacy technician license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent’s license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his or her pharmacy technician license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent may not reapply for any license, permit, or registration from the board for three (3) years from the effective date of the surrender. Respondent shall meet all
requirements applicable to the license sought as of the date the application for that license is submitted to the board.

11. **Notification of a Change in Name, Residence Address, Mailing Address or Employment**

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule if known. Respondent shall further notify the board in writing within ten (10) days of a change in name, residence address and mailing address, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

12. **Tolling of Probation**

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a pharmacy technician in California for a minimum of _________ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

Should respondent, regardless of residency, for any reason (including vacation) cease working as a pharmacy technician for a minimum of _________ hours per calendar month in California, respondent must notify the board in writing within ten (10) days of cessation of work and must further notify the board in writing within ten (10) days of the resumption of the work. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a total period, counting consecutive and non-consecutive months, exceeding thirty-six (36) months.

"Cessation of work" means calendar month during which respondent is not working for at least _________ hours as a pharmacy technician, as defined in Business and Professions Code section 4115. "Resumption of work" means any calendar month during which respondent is working as a pharmacy technician for at least _________ hours as a pharmacy technician as defined by Business and Professions Code section 4115.

13. **Violation of Probation**

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a
violation thereof may lead to automatic termination of the stay and/or revocation of the license.
If a petition to revoke probation or an accusation is filed against respondent during probation,
the board shall have continuing jurisdiction, and the period of probation shall be automatically
extended until the petition to revoke probation or accusation is heard and decided.

14. Completion of Probation

Upon written notice by the board indicating successful completion of probation, respondent’s
pharmacy technician license will be fully restored.

OPTIONAL CONDITIONS OF PROBATION

15. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager,
administrator, member, officer, director, trustee, associate, or partner of any business, firm,
partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell
or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90)
days following the effective date of this decision and shall immediately thereafter provide written
proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide
documentation thereof shall be considered a violation of probation.

Option: Respondent shall not acquire any new ownership, legal or beneficial interest nor serve
as a manager, administrator, member, officer, director, trustee, associate, or partner of any
additional business, firm, partnership, or corporation licensed by the board. If respondent
currently owns or has any legal or beneficial interest in, or serve as a manager, administrator,
member, officer, director, trustee, associate, or partner of any business, firm, partnership, or
corporation currently or hereinafter licensed by the board, respondent may continue to serve in
such capacity or hold that interest, but only to the extent of that position or interest as of the
effective of this decision. Violation of this restriction shall be considered a violation of probation.

16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
(Appropriate for those cases with chemical dependency (alcohol, drugs))

Within thirty (30) days of the effective date of this decision, respondent shall begin regular
attendance at a recognized and established substance abuse recovery support group in
California, (e.g., Alcoholics Anonymous, Narcotics Anonymous, etc.) which has been approved
by the board or its designee. Respondent must attend at least one group meeting per week
unless otherwise directed by the board or its designee. Respondent shall continue regular
attendance and submit signed and dated documentation confirming attendance with each
quarterly report for the duration of probation. Failure to attend or submit documentation thereof
shall be considered a violation of probation.

17. Random Drug Screening (Appropriate for those cases with chemical dependency
(alcohol, drugs))

Respondent, at his or her own expense, shall participate in random testing, including but not
limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other drug
screening program as directed by the board or its designee. Respondent may be required to
participate in testing for the entire probation period and the frequency of testing will be
determined by the board or its designee. At all times respondent shall fully cooperate with the
board or its designee, and shall, when directed, submit to such tests and samples for the
detection of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as
the board or its designee may direct. Failure to timely submit to testing as directed shall be
considered a violation of probation. Upon request of the board or its designee, respondent shall
provide documentation from a licensed practitioner that the prescription for a detected drug was
legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely
provide such documentation shall be considered a violation of probation. Any confirmed
positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part
of a documented medical treatment shall be considered a violation of probation and shall result
in the automatic suspension of work by respondent. Respondent may not resume work as a
pharmacy technician until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of or any other
board licensed premises (wholesaler, veterinary food animal drug retailer or any other
distributor of drugs) any drug manufacturer, or any other location where dangerous drugs and
devices or controlled substances are maintained. Respondent shall not do any act involving
drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall
respondent manage, administer, or assist any licensee of the board. Respondent shall not have
access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices
or controlled substances. Respondent shall not resume work until notified by the board.

Respondent shall not direct, control or perform any aspect of the practice of pharmacy. Subject
to the above restrictions, respondent may continue to own or hold an interest in any licensed
premises in which he or she holds an interest at the time this decision becomes effective unless
otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

18. Work Site Monitor (Appropriate for those cases with chemical dependency (alcohol,
drugs))

Within ten (10) days of the effective date of this decision, respondent shall identify a work site
monitor, for prior approval by the board, who shall be responsible for supervising respondent
during working hours. Respondent shall be responsible for ensuring that the work site monitor
reports in writing to the board quarterly. Should the designated work site monitor determine at
any time during the probationary period that respondent has not maintained sobriety, he or she
shall notify the board immediately, either orally or in writing as directed. Should respondent
change employment, a new work site monitor must be designated, for prior approval by the
board, within ten (10) days of commencing new employment. Failure to identify an acceptable
initial or replacement work site monitor, or to ensure quarterly reports are submitted to the
board, shall be considered a violation of probation.

19. Notification of Departure (Appropriate for those cases with chemical dependency
(alcohol, drugs))

Prior to leaving the probationary geographic area designated by the board or its designee for a
period greater than twenty-four (24) hours, respondent shall notify the board verbally and in
writing of the dates of departure and return. Failure to comply with this provision shall be
considered a violation of probation.
20. **Abstain from Drugs and Alcohol Use** (Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs and their associated paraphernalia except when the drugs are lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon request of the board or its designee, respondent shall provide documentation from the licensed practitioner that the prescription for the drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia not supported by the documentation timely provided, and/or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

21. **Tolling of Suspension**

During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of ten (10) days during suspension shall be considered a violation of probation. Moreover, any absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not return to work until notified by the board that the period of suspension has been satisfactorily completed.

22. **Restitution** (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)

Within ______ days of the effective date of this decision, respondent shall pay restitution to __________ in the amount of $ __________. Failure to make restitution by this deadline shall be considered a violation of probation.
DESIGNATED REPRESENTATIVE

The board files cases against designated representatives where the violation(s) involve significant misconduct on the part of the licensee. The board believes that revocation is typically the appropriate penalty when grounds for discipline are found to exist. Grounds for discipline include, but are not limited to, the following violation(s) of law(s) involving:

- Possession of dangerous drugs and/or controlled substances
- Use of dangerous drugs and/or controlled substances
- Possession for sale of dangerous drugs and/or controlled substances
- Personal misuse of drugs or alcohol

If revocation is not imposed, the board recommends a minimum Category III level of discipline be imposed on the designated representative. This would include suspension and probation.

TERMS OF PROBATION – DESIGNATED REPRESENTATIVE

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORY OF VIOLATIONS AND RECOMMENDED PENALTIES

CATEGORY III – Penalty

 Minimum: Revocation; Revocation stayed, 90 days actual suspension, three years probation. All standard terms and conditions shall be included and optional terms and conditions as appropriate.

 Maximum: Revocation

 Applies to all applicable statutes and regulations

---

9 All information specific to Designated Representative is being removed and consolidated into Terms of Probation – Individual Licensees.
MODEL DISCIPLINARY LANGUAGE – DESIGNATED REPRESENTATIVE

The following standardized language shall be used in every decision where the order of condition is imposed.

Revocation

Designated Representative license number ____________, issued to respondent ____________ is revoked. Respondent shall relinquish his or her designated representative license to the board within ten (10) days of the effective date of this decision. Respondent may not petition the board for reinstatement of his or her revoked designated representative license for three (3) years from the effective date of this decision.

Respondent shall pay to the board its costs of investigation and prosecution in the amount of $________ within fifteen (15) days of the effective date of this decision.

Option: As a condition precedent to reinstatement of his or her revoked designated representative license respondent shall reimburse the board for its costs of investigation and prosecution in the amount of $________. Said amount shall be paid in full prior to the reinstatement of his or her revoked designated representative license, unless otherwise ordered by the board.

Suspension

As part of probation, respondent is suspended from working as a designated representative for ___________ beginning the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs licensed by the board, or any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not perform any of the duties of a designated representative, nor do any act involving drug selection, selection of stock, manufacturing, dispensing; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices and controlled substances. Respondent shall not resume work until notified by the board.

Respondent shall not direct, control or perform any aspect involving the distribution of dangerous drugs and devices and controlled substances. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed entity in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

Standard Stay/Probation Order

Designated representative license number ______________ is revoked; however, the revocation is stayed and respondent is placed on probation for ____________ years upon the following terms and conditions:
Issuance of Probationary License (In cases where a Statement of Issues has been filed.)

Upon satisfaction of all statutory and regulatory requirements for issuance of a license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for ______ years upon the following terms and conditions:

Surrender

Respondent surrenders designated representative license number __________ as of the effective date of this decision. Respondent shall relinquish his or her designated representative license to the board within ten (10) days of the effective date of this decision.

The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board.

Respondent understands and agrees that if he or she ever files an application for licensure or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.

Respondent may not apply for any license, permit or registration from the board for three (3) years from the effective date of this decision. Respondent stipulates that should he or she apply for any license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, correct and admitted by respondent when the board determines whether to grant or deny the application. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board prior to issuance of a new license. Respondent is required to report this surrender as disciplinary action.

Respondent further stipulates that he or she shall reimburse the board for its costs of investigation and prosecution in the amount of $__________ within _________ days of the effective date of this decision.

Option: Respondent stipulates that should he or she apply for any license from the board on or after the effective date of this decision, investigation and prosecution costs in the amount of $____________ shall be paid to the board prior to issuance of the new license.

Public Reprimand

It is hereby ordered that a public reprimand be issued against designated representative license, ____________. Respondent is required to report this reprimand as a disciplinary action.
Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.
STANDARD CONDITIONS—To be included in all probation decisions/orders:

1. Obey All Laws
2. Report to the Board
3. Interview with the Board
4. Cooperate with Board Staff
5. Notice to Employers
6. No Being Designated Representative-in-Charge
7. Reimbursement of Board Costs
8. Probation Monitoring Costs
9. Status of License
10. License Surrender While on Probation/Suspension
11. Notification of a Change in Name, Residence Address, Mailing Address or Employment
12. Tolling of Probation
13. Violation of Probation
14. Completion of Probation

OPTIONAL CONDITIONS

15. No Ownership of Licensed Premises
16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
17. Random Drug Screening
18. Work Site Monitor
19. Notification of Departure
20. Abstain from Drugs and Alcohol Use
21. Tolling of Suspension
22. Restitution
STANDARD CONDITIONS - TO BE INCLUDED IN ALL PROBATIONS

1. Obey All Laws

Respondent shall obey all state and federal laws and regulations.

Respondent shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- an arrest or issuance of a criminal complaint for violation of any state or federal law
- a plea of guilty or nolo contendere in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent’s license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distribution or billing or charging for of any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

3. Interview with the Board

Upon receipt of reasonable prior notice, respondent shall appear in person for interviews with the board or its designee, upon request at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

4. Cooperate with Board Staff

Respondent shall cooperate with the board’s inspection program and with the board’s monitoring and investigation of respondent’s compliance with the terms and conditions of his or her probation. Failure to cooperate shall be considered a violation of probation.
5. Notice to Employers

During the period of probation, respondent shall notify all present and prospective employers of the decision in case number ________ and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his or her direct supervisor, designated representative-in-charge (including each new designated representative-in-charge employed during respondent’s tenure of employment) and owner to report to the board in writing acknowledging that the listed individual(s) has/have read the decision in case number __________ and terms and conditions imposed thereby. It shall be respondent’s responsibility to ensure that his or her employer(s) and or supervisor(s) submit timely acknowledgement(s) to the board.

If respondent works for or is employed by or through a pharmacy employment service, respondent must notify his or her direct supervisor, designated representative-in-charge and owner at each entity licensed by the board of the terms and conditions of the decision in case number _______ in advance of the respondent commencing work at each licensed entity. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy employment service, respondent shall cause his or her direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he or she has read the decision in case number _____ and the terms and conditions imposed thereby. It shall be the respondent’s responsibility to ensure that his or her employer(s) and or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgements to the board shall be considered a violation of probation.

“Employment” within the meaning of this provision shall include any full-time, part-time, temporary or relief service or pharmacy management service as a designated representative or in any position for which a designated representative license is a requirement or criterion for employment, whether the respondent is considered an employee or independent contractor or volunteer.

6. No Being Designated Representative-in-Charge

During the period of probation, respondent shall not be the designated representative-in-charge of any entity licensed by the board unless otherwise specified in this order. Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.

7. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, respondent shall pay to the board its costs of investigation and prosecution in the amount of $___________. Respondent shall make said payments as follows: ___________. There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.
The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

8. **Probation Monitoring Costs**

Respondent shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

9. **Status of License**

Respondent shall, at all times while on probation, maintain an active, current designated representative license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If respondent’s designated representative license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication respondent’s license shall be subject to all terms and conditions of this probation not previously satisfied.

10. **License Surrender While on Probation/Suspension**

Following the effective date of this decision, should respondent cease work due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her designated representative license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent’s license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his or her designated representative license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent may not reapply for any license, permit, or registration from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

11. **Notification of a Change in Name, Residence Address, Mailing Address or Employment**

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving and the address of the new employer, supervisor and owner and work schedule, if known. Respondent shall further notify the board in writing within ten (10) days of a change in name, residence address and mailing address, or phone number. Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.
12. **Tolling of Probation**

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a designated representative in California for a minimum of _________ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

Should respondent, regardless of residency, for any reason (including vacation) cease working as a designated representative for a minimum of _______ hours in California, respondent must notify the board in writing within ten (10) days of cessation of work and must further notify the board in writing within ten (10) days of the resumption of work. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a total period, counting consecutive and non-consecutive months, exceeding thirty-six (36) months.

"Cessation of work" means any calendar month during which respondent is not working as a designated representative for at least ________ hours as a designated representative as defined by Business and Professions Code section 4053.

"Resumption of work" means any calendar month during which respondent is working as a designated representative for at least _______ hours as a designated representative as defined by Business and Professions Code section 4053.

13. **Violation of Probation**

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction, and the period of probation shall be automatically extended, until the petition to revoke probation or accusation is heard and decided.

14. **Completion of Probation**

Upon written notice by the board indicating successful completion of probation, respondent's designated representative license will be fully restored.
OPTIONAL CONDITIONS OF PROBATION

15. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90) days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.

Option: Respondent shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If respondent currently owns or has any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, respondent may continue to serve in such capacity or hold that interest, but only to the extent of that position or interest as of the effective date of this decision. Violation of this restriction shall be considered a violation of probation.

16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups

(Appropriate for those cases with chemical dependency (alcohol, drugs))

Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a recognized and established substance abuse recovery support group in California, (e.g., Alcoholics Anonymous, Narcotics Anonymous, etc.) which has been approved by the board or its designee. Respondent must attend at least one group meeting per week unless otherwise directed by the board or its designee. Respondent shall continue regular attendance and submit signed and dated documentation confirming attendance with each quarterly report for the duration of probation. Failure to attend or submit documentation thereof shall be considered a violation of probation.

17. Random Drug Screening

(Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent, at his or her own expense, shall participate in random testing, including but not limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other drug screening program as directed by the board or its designee. Respondent may be required to participate in testing for the entire probation period and the frequency of testing will be determined by the board or its designee. At all times respondent shall fully cooperate with the board or its designee, and shall, when directed, submit to such tests and samples for the detection of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as the board or its designee may direct. Failure to timely submit to testing as directed shall be considered a violation of probation. Upon request of the board or its designee, respondent shall provide documentation from a licensed practitioner that the prescription for a detected drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall be considered a violation of probation and shall result
in the automatic suspension of work by respondent. Respondent may not resume work as a
designated representative until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed
premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs
licensed by the board, or any drug manufacturer, or any other location where dangerous drugs
and devices or controlled substances are maintained. Respondent shall not perform any of the
duties of a designated representative, nor do any act involving drug selection, selection of stock,
manufacturing, dispensing; nor shall respondent manage, administer, or be a consultant to any
licensee of the board, or have access to or control the ordering, manufacturing or dispensing of
dangerous drugs and devices and controlled substances. Respondent shall not resume work
until notified by the board.

Respondent shall not direct, control or perform any aspect involving the distribution of
dangerous drugs and devices and controlled substances. Subject to the above restrictions,
respondent may continue to own or hold an interest in any licensed entity in which he or she
holds an interest at the time this decision becomes effective unless otherwise specified in this
order.

Failure to comply with this suspension shall be considered a violation of probation.

18.—— Work Site Monitor (Appropriate for those cases with chemical dependency (alcohol,
drugs))

Within ten (10) days of the effective date of this decision, respondent shall identify a work site
monitor, for prior approval by the board, who shall be responsible for supervising respondent
during working hours. Respondent shall be responsible for ensuring that the work site monitor
reports in writing to the board quarterly. Should the designated work site monitor determine at
any time during the probationary period that respondent has not maintained sobriety, he or she
shall notify the board immediately, either orally or in writing as directed. Should respondent
change employment, a new work site monitor must be designated, for prior approval by the
board, within ten (10) days of commencing new employment. Failure to identify an acceptable
initial or replacement work site monitor, or to ensure quarterly reports are submitted to the
board, shall be considered a violation of probation.

19.—— Notification of Departure (Appropriate for those cases with chemical dependency
(alcohol, drugs))

Prior to leaving the probationary geographic area designated by the board or its designee for a
period greater than twenty-four (24) hours, respondent shall notify the board verbally and in
writing of the dates of departure and return. Failure to comply with this provision shall be
considered a violation of probation.

20.—— Abstain from Drugs and Alcohol Use (Appropriate for those cases with chemical
dependency (alcohol, drugs))

Respondent shall completely abstain from the possession or use of alcohol, controlled
substances, dangerous drugs and their associated paraphernalia except when the drugs are
lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon
request of the board or its designee, respondent shall provide documentation from the licensed
practitioner that the prescription for the drug was legitimately issued and is a necessary part of
the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia not supported by the documentation timely provided, and/or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

21. **Tolling of Suspension**

   During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of ten (10) days during suspension shall be considered a violation of probation. Moreover, any absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

   Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not resume work until notified by the board that the period of suspension has been satisfactorily completed.

22. **Restitution** (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)

   Within _______ days of the effective date of this decision, respondent shall pay restitution to _________ in the amount of $___________. Failure to make restitution by this deadline shall be considered a violation of probation.
TERM OF PROBATION – PREMISES

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of dangerous drugs or devices or controlled substances has occurred at a licensed premises. Terms and conditions are imposed to provide consumer protection. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORIES OF VIOLATIONS AND RECOMMENDED PENALTIES

The California Pharmacy Law identifies offenses for which the board may take disciplinary action against a license. Included among grounds for discipline are violations of the Pharmacy Law itself, violations of regulations promulgated by the board, and violations of other state or federal statutes or regulations.

The following are categories of possible violations used by the board to determine appropriate disciplinary penalties. These categories represent the judgment of the board as to the perceived seriousness of particular offenses.

For those licenses issued to premises (pharmacies and wholesalers, resident and nonresident), the board has identified four (4) categories of violations and associated recommended minimum and maximum penalties for each. These categories of violations are arranged in ascending order from the relatively minor (Category I) to the most serious (Category IV), although any violation in any category, or any combination of violation(s) in one or more categories, may merit revocation.

Under each category, the board has grouped statutes and regulations where violations would typically merit the recommended range of minimum to maximum penalties for that category. These lists are representative, and are not intended to be comprehensive or exclusive. For each violation category, the board has given offense descriptions and examples where violations would typically merit the recommended range of minimum to maximum penalties for that category. These descriptions and examples are representative, and are not intended to be comprehensive or exclusive. Where a violation not included in these lists is a basis for disciplinary action, the appropriate penalty for that violation may be best derived by comparison to any analogous violation(s) that are included. Where no such analogous violation is listed, the category descriptions may be consulted.

These categories assume a single violation of each listed statute or regulation. For multiple violations, the appropriate penalty shall increase accordingly. Moreover, if an individual has committed violations in more than one category, the minimum and maximum penalties shall be those recommended in the highest category.
The board also has the authority, pursuant to Business and Professions Code section 4301(n), to impose discipline based on disciplinary action taken by another jurisdiction. The discipline imposed by the board will depend on the discipline imposed by the other jurisdiction, the extent of the respondent's compliance with the terms of that discipline, the nature of the conduct for which the discipline was imposed, and other factors set forth in these guidelines.

**CATEGORY I**

Minimum: Revocation; Revocation stayed; one-year probation. All standard terms and conditions shall be included and may include optional terms and conditions, as appropriate.

Maximum: Revocation

Category I discipline is recommended for violations which are relatively minor but are potentially harmful:

- violation(s) of recordkeeping requirements, scope of practice requirements, or inventory control requirements;
- smaller or isolated failure(s) to abide by or enforce prescription or refill requirements, drug-substitution requirements, or labeling requirements;
- violation(s) of obligations to supply or update information to the board, or to other enforcement or regulatory agencies;
- failure(s) to adequately supervise staff to ensure security and sanitation of premises, dangerous drugs or devices or controlled substances;
- violation(s) of packaging requirements, security control requirements, or reporting requirements; and
- failure(s) to display original license(s), or to supply name(s) of owner(s), manager(s), or employee(s).
- violations which are relatively minor but are potentially harmful
- repeated violations of a relatively minor nature

Violations of the following codes are representative of this category:

**BUSINESS AND PROFESSIONS CODE**

**Article 3. Scope of Practice and Exemptions**

4053 Exemptee Supervisor of Manufacturer, etc.: Requirements
4054 Supply by Manufacturer, etc. of Certain Dialysis Drugs and Devices
4056 Purchase of Drugs at Wholesale – Hospital Containing 100 Beds or Less
4057 Exceptions to Application of this Chapter
4058 Display of Original License
4062 Furnishing Dangerous Drugs During Emergency
4064 Emergency Refill of Prescription Without Prescriber Authorization
4065 Injection Card System; Requirements for Administration
4066 Furnishing Dangerous Drugs to Master or First Officer of Vessel
Article 4. Requirements for Prescription

4070 Reduction of Oral or Electronic Prescription to Writing
4071 Prescriber May Authorize Agent to Transmit Prescription; Schedule II Excluded
4072 Oral or Electronic Transmission of Prescription - Health Care Facility
4073 Substitution of Generic Drug – Requirements and Exceptions
4074 Drug Risk: Informing Patient; Providing Consultation for Discharge Medications
4076 Prescription Container – Requirements for Labeling
4077 Dispensing Dangerous Drug in Incorrectly Labeled Container

Article 5. Authority of Inspectors

4082 Names of Owners, Managers and Employees Open for Inspection

Article 6. General Requirements

4100 Change of Address or Name – Notification to Board
4103 Blood Pressure – Taking by Pharmacist

Article 7. Pharmacies

4114 Intern Pharmacist: Activities Permitted
4119.5 Transfer or Repackaging Dangerous Drugs by Pharmacy
4120 Nonresident Pharmacy: Registration Required
4121 Advertisement for Prescription Drug: Requirements; Restrictions
4122 Required Notice at Availability of Prescription Price Information, General Product Availability, Pharmacy Services; Providing Drug Price Information; Limitations on Price Information Requests
4123 Compounding Drug for Other Pharmacy for Parenteral Therapy; Notice to Board
4124 Dispensing Replacement Contact Lenses: Requirements; Patient Warnings; Registration with Medical Board; Application of Section to Nonresident Pharmacies

Article 9. Hypodermic Needles and Syringes

4141 Furnishing Without License
4142 Prescription Required
4143 Exemption: Sale to Other Entity, Physician, etc.
4144 Industrial Use Exception
4145 Exception: Furnishing for Administration of Insulin, Adrenaline, or Specified Animal Uses; Conditions
4148 Confiscation if Found Outside Licensed Premises
4149 Sale by Distributor

Article 10. Pharmacy Corporations

4151 Licensure Requirements
4152 Corporate Name Requirements
4153 Shareholder Income While Disqualified
4156 Unprofessional Conduct by Corporation
Article 11. Wholesalers and Manufacturers

4161 Nonresident Wholesaler: When License Required; Application
4162 Issuance or Renewal of Wholesaler License; Surety Bond
4164 Reports Required
4165 Sale or Transfer of Dangerous Drug or Device Into State: Furnishing Records to Authorized Officer on Demand; Citation for Non-compliance
4166 Shipping of Dangerous Drugs or Devices — Wholesaler or Distributor
4167 Wholesaler: Bar on Obtaining Dangerous Drugs or Devices It Cannot Maintain on Licensed Premises

Article 13. Non-Profit or Free Clinics

4180 Purchase of Drugs at Wholesale Only with License: Eligible Clinics
4181 License Requirements; Policies and Procedures; Who May Dispense
4182 Duties of Professional Director; Consulting Pharmacist Required
4183 No Professional Dispensing Fee
4184 Dispensing Schedule II Substance Prohibited
4186 Automated Drug Delivery Systems

Article 14. Surgical Clinics

4190 Purchase of Drugs at Wholesale: Permitted Uses of Drugs; Required Records and Policies; License Required
4191 Compliance with Department of Health Services Requirements; Who May Dispense Drugs
4192 Duties of Professional Director; Providing Information to Board
4193 Clinic Not Eligible for Professional Dispensing Fee; Ban on Offering Drugs for Sale
4194 Dispensing of Schedule II Substance by Clinic Prohibited; Physician May Dispense; Administration Authorized in Clinic

Article 15. Veterinary Food-Animal Drug Retailers

4196 License Required: Temporary License on Transfer of Ownership; Persons Authorized in Storage Area
4197 Minimum Standards: Security; Sanitation; Board Regulations; Waivers
4198 Written Policies and Procedures Required: Contents; Training of Personnel; Quality Assurance; Consulting Pharmacist

Article 17. Continuing Education

4231 Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New Licensee
4232 Content of Courses

Article 18. Poisons

4240 Application of Act

Article 20. Prohibitions and Offenses
CALIFORNIA CODE OF REGULATIONS, TITLE 16

1704 Change of Address
1705 Notification of Bankruptcy, Receivership or Liquidation
1708.2 Discontinuance of Business
1708.4 Pharmacist Handling Radioactive Drugs
1708.5 Pharmacy Furnishing Radioactive Drugs
1709 Names of Owners and Pharmacist in Charge
1714 Operational Standards and Security
1715.6 Reporting Drug Loss
1716 Variation from Prescriptions
1717 Pharmaceutical Practice
1717.1 Common Electronic Files
1717.4 Electronic Transmission of Prescriptions
1718.1 Manufacturer’s Expiration Date
1726 Supervision of Intern Pharmacists
1728 Requirements for Examination
1732.1 Requirements for Accredited Providers
1732.3 Requirements for Continuing Education Courses
1732.4 Provider Audit Requirements
1732.5 Renewal Requirements for Pharmacist
1744 Drug Warnings
1751 Sterile Injectable Compounding Area
1751.01 Facility and Equipment Standards for Sterile Injectable Compounding from Non-Sterile Ingredients
1751.02 Policies and Procedures
1751.11 Furnishing to Home Health Agencies and Licensed Hospices
1751.12 Obligations of a Pharmacy Furnishing Portable Containers
1771 Posting of Notice of Suspension
1772 Disciplinary Condition of Suspension
1780 Minimum Standards for Wholesalers
1780.1 Minimum Standards for Veterinary Food-Animal Drug Retailers
1781 Exemption Certificate
1786 Exemptions
1787 Authorization to Distribute Hemodialysis Drugs and Devices
1790 Assembling and Packaging
1791 Labeling
1792 Receipt for Shipment

HEALTH AND SAFETY CODE

11100 Report of Certain Chemical: Chemicals Included; Exclusions; Penalties
11100.1 Report of Chemicals Received from Outside State; Penalties
11151 Limitation on Filling Prescriptions From Medical Students
11158 Prescription Required for Schedule II, III, IV, or V Controlled Substance; Exception for Limited Dispensing, Administration

11159 Chart Order Exemption for Patient in County or Licensed Hospital; Maintaining Record for Seven Years

11159.1 Chart Order Exemption for Clinic Patient; Maintaining Record for Seven Years

11159.2 Exception to TriPLICATE Prescription Requirement

11167 Emergency Dispensing of Schedule II Substance: Circumstances and Requirements

11167.5 Oral or Electronic Prescriptions for Schedule II Controlled Substance for Specified Inpatients, Residents, and Home Hospice Patients; Requirements

11171 Prescribing, etc. Controlled Substance Only as Authorized

11172 Antedating or Postdating Prescription Prohibited

11175 Prohibition on Obtaining or Possessing Nonconforming Prescription; Prohibition on Obtaining Controlled Substance by Nonconforming Prescription

11180 Prohibition on Controlled Substance Obtained or Possessed by Nonconforming Prescription

11200 Restrictions on Dispensing or Refilling; Refill of Schedule II Prescription Barred

11201 Emergency Refill of Schedule III, IV, or V Prescription; Circumstances; Requirements

11205 Maintenance and Retention of Records in Separate File

11206 Required Information on Prescription

11209 Delivery and Receiving Requirements for Schedule II, III, and IV Substances; Violation

11210 Issuing Prescription: By Whom; For What Purpose; Quantity to Be Prescribed

11250 Authorized Retail Sale by Pharmacists to Physicians, etc.; Required Order Form

11251 Authorized Wholesale Sale by Pharmacists

11252 Preservation of Federally Required Forms

11253 Duration of Retention

11255 Actions Constituting Sale

11256 Required Report of Order By or Sale to Out-of-State Wholesaler or Manufacturer

11225 to

111655 Adulterated or Misbranded Drugs or Devices

CODE OF FEDERAL REGULATIONS, TITLE 21

1301.13 Application for registration; time for application; expiration date; registration for independent activities; application forms, fees, contents and signature; coincident activities.

1301.14 Filing of application; acceptance for filing; defective applications.

1301.71 Security requirements generally.

1301.72 Physical security controls for non-practitioners; narcotic treatment programs and compounders for narcotic treatment programs; storage areas.

1301.73 Physical security controls for non-practitioners; compounders for narcotic treatment programs; manufacturing and compounding areas.

1301.74 Other security controls for non-practitioners; narcotic treatment programs and compounders for narcotic treatment programs.

1301.77 Security controls for freight forwarding facilities.

1301.90 Employee screening procedures.

1301.91 Employee responsibility to report drug diversion.

1301.92 Illicit activities by employees.

1302.03 Symbol required; exceptions.
1302.04 Location and size of symbol on label and labeling.
1302.05 Effective dates of labeling requirements.
1302.06 Sealing of controlled substances.
1302.07 Labeling and packaging requirements for imported and exported substances.
1304.11 Inventory requirements.
1304.31 Reports from manufacturers importing narcotic raw material.
1304.32 Reports of manufacturers importing coca leaves.
1304.33 Reports to ARCOS.
1305.03 Distributions requiring a Form 222 or a digitally signed electronic order.
1305.04 Persons entitled to order Schedule I and II controlled substances.
1305.05 Power of attorney.
1305.06 Persons entitled to fill orders for Schedule I and II controlled substances.
1305.11 Procedure for obtaining DEA Forms 222.
1305.12 Procedure for executing DEA Forms 222.
1305.14 Procedure for endorsing DEA Forms 222.
1305.15 Unaccepted and defective DEA Forms 222.
1305.16 Lost and stolen DEA Forms 222.
1306.03 Persons entitled to issue prescriptions.
1306.05 Manner of issuance of prescriptions.
1306.14 Labeling of substances and filling of prescriptions.
1306.24 Labeling of substances and filing of prescriptions.
1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes.
1306.26 Dispensing without a prescription.
1307.11 Distribution by dispenser to another practitioner or reverse distributor.
1307.12 Distribution to supplier or manufacturer.
1307.13 Incidental manufacture of controlled substances.
1307.21 Procedure for disposing of controlled substances.
1700.1 to 1707.15 Child-resistant containers.

CATEGORY II

Minimum: Revocation; Revocation stayed, three years probation (five years probation where self-administration or diversion of dangerous drugs or devices or controlled substances occurred at the licensed premises). All standard terms and conditions shall be included and may include optional terms and conditions, as appropriate.

Maximum: Revocation

Category II discipline is recommended for violations with serious potential for harm, as well as for violations involving disregard for public safety or for laws or regulations pertaining to pharmacy and/or to the dispensing or distributing of dangerous drugs or devices or controlled substances, violations that reflect on ethics, competency, or diligence, and criminal convictions not involving alcohol, dangerous drugs or devices or controlled substances. Violations in this category may include:
- failure(s) to abide by prohibitions on referral rebates or discounts (kickbacks) and/or volume or percentage-based lease agreements;
violation(s) of advertising or marketing limitations, including use of false or misleading advertising or marketing;
repeat or serious violation(s) of recordkeeping requirements, scope of practice requirements, or inventory control requirements;
violation(s) of controlled substance secure prescription requirements, inventory controls, or security requirements;
failure(s) to meet compliance requirements, including pharmacist-in-charge or designated representative-in-charge designation and duties;
violation(s) of monitoring and reporting requirements with regard to chemically, mentally, or physically impaired licensees or employees;
repeat or serious failure(s) to adequately supervise staff or ensure security and sanitation of premises, dangerous drugs or devices or controlled substances;
violation(s) of laws governing dangerous drugs or devices and controlled substances, including smaller cases of diversion or self-administration;
unlawful possession(s) of dangerous drugs or devices, controlled substances, hypodermic needles or syringes, or drug paraphernalia;
smaller scale dispensing or furnishing of dangerous drugs or devices via the internet, without valid a prescription;
purchasing, trading, selling, or transferring dangerous drugs or devises to or from unauthorized person(s);
failure(s) to make required reports to the board or to other regulatory agencies, including CURES obligations and reporting to the DEA;
violation(s) of quality assurance and self-assessment obligations, failure(s) to ensure properly trained staff and conduct practice safely;
failure(s) to perform drug utilization reviews, monitor patient medication profiles, or promote safety and efficacy of prescribed drugs or devices or controlled substances;
repeat or serious deviation(s) from the requirements of prescription(s) or failure(s) to clarify erroneous or uncertain prescription(s);
gross immorality, incompetence, gross negligence, clearly excessive furnishing of controlled substances, moral turpitude, dishonestly, or fraud;
criminal conviction(s) not involving alcohol, dangerous drugs or devices or controlled substances;
violating, assisting in or abetting violation of, or conspiring to violate the laws and regulations governing pharmacy; and
subverting or attempting to subvert an investigation conducted by the board.

Violations of the following codes are representative of this category:

BUSINESS AND PROFESSIONS CODE

650 Rebates or Discounts for Referral Prohibited
650.1 Lease Prohibition – Hospitals or Prescribers
651 Professional Advertising Requirements

Article 3. Scope of Practice and Exemptions
4051(b) — Conduct Authorized by Pharmacist
4052 — Furnishing to Prescriber; Permissible Procedures by Pharmacist in Health Care Facility or Clinic or for Other Health Care Provider
4060 — Controlled Substance — Prescription Required; Exceptions
4061 — Distribution of Drug as Sample; Written Request Required
4064 — Emergency Refill of Prescription Without Prescriber Authorization
4067 — Internet; Dispensing Dangerous Drugs or Devices without Prescription
4075 — Proof of Identity Required — Oral or Electronic Prescription
4078 — False or Misleading Label on Prescription

Article 6. General Requirements

4101 — Pharmacist in Charge, Exemptee: Termination of Employment; Notification to Board
4104 — Licensed Employee, Theft or Impairment: Pharmacy Procedures
4105 — Retaining Records of Dangerous Drugs and Devices on Licensed Premises; Temporary Removal; Waivers; Access to Electronically Maintained Records

Article 7. Pharmacies

4112 — Nonresident Pharmacy: Registration; Provision of Information to Board; Maintaining Records; Patient Consultation
4113 — Pharmacist in Charge: Notification to Board; Responsibilities
4115 — Pharmacy Technician: Activities Permitted; Required Supervision; Activities Limited to Pharmacist; Registration; Requirements for Registration; Ratios
4115.5 — Pharmacy Technician Trainee; Placement; Supervision; Requirements
4116 — Security of Dangerous Drugs and Devices in Pharmacy: Pharmacist Responsibility for Individuals on Premises; Regulations
4117 — Admission to Area Where Narcotics are Stored, etc. — Who May Enter
4120 — Nonresident Pharmacy: Registration Required
4125 — Pharmacy Quality Assurance Program Required; Records Considered Peer Review Documents

Article 9. Hypodermic Needle and Syringes

4140 — Unlawful Possession
4147 — Disposal of Needle or Syringe

Article 11. Wholesalers and Manufacturers

4161 — Nonresident Wholesaler: When License Required; Application
4163 — Unauthorized Furnishing by Manufacturer or Wholesale
4164 — Reports Required
4169(a)(1) — Prohibited Acts

Article 13. Non-Profit of Free Clinics

4185 — Inspection Permitted

Article 14. Surgical Clinics

4195 — Inspection Permitted
Article 19. Disciplinary Proceedings

4301 Unprofessional Conduct—subsections (a)-(h), (j), and (l) (q)
4302 Discipline of Corporate Licensee for Conduct of Officer, Director, Shareholder
4303 Nonresident Pharmacy: Grounds for Discipline
4304 Out-of-state Distributor: Authority to Discipline
4305 Disciplinary Grounds: Failure of Pharmacy, Pharmacist to Notify Board of Termination of Pharmacist in Charge; Continuing to Operate Without Pharmacist
4305.5 Disciplinary Grounds: Failure of Other Entity Licensed by Board, of Pharmacist or Exemptee to Notify Board of Termination of Pharmacist in Charge or Exemptee; Continuing to Operate Without Pharmacist or Exemptee
4306 Violation of Professional Corporation Act as Unprofessional Conduct
4306.5 Misuse of Education, etc. by Pharmacist Outside Course of Practice of Pharmacy as Unprofessional Conduct

Article 20. Prohibitions and Offenses

4326 Misdemeanor: Obtaining Needle or Syringe by Fraud, etc.; Unlawful Use of Needle or Syringe Obtained from Another
4328 Misdemeanor: Permitting Compounding, Dispensing, or Furnishing by Non-pharmacist
4330 Misdemeanor: Non-pharmacist Owner Failing to Place Pharmacist in Charge, Dispensing or Compounding Except by Pharmacist, Interfering with Pharmacist in Charge
4331 Misdemeanor: Medical Device Retailer, Wholesaler, Veterinary Food-Animal Drug Retailer Failing to Place Pharmacist or Exemptee in Charge, Permitting Dispensing or Compounding Except by Pharmacist or Exemptee
4333 Maintaining Prescriptions, Other Drug Records on Premises, Open to Inspection; Waiver; Willful Failure to Keep or Permit Inspection of Records of Prescriptions, Other Records as Misdemeanor
4340 Unlawful Advertising by Nonresident Pharmacy Not Registered with Board

Article 22. Unfair Trade Practices

4380 Resale of Preferentially Priced Drugs; Prohibition; Exceptions
4382 Board May Audit Sales to Walk-in Customers

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707.1 Duty to Maintain Medication Profiles (Patient Medication Records)
1707.2 Notice to Consumers and Duty to Consult
1707.3 Duty to Review Drug Therapy and Patient Medication Record Prior to Deliver
1709.1 Designation of Pharmacist in Charge
1714.1 Pharmacy Operation During Temporary Absence of a Pharmacist
1715 Self-Assessment of a Pharmacy by the Pharmacist-in-Charge
1715.5 Implementation of Electronic Monitoring of Schedule II Prescriptions
1716.1 Compounding Unapproved Drugs for Prescriber Office Use
1716.2 Record Requirements—Compounding for Future Furnishing
1717.2 Notice of Electronic Prescription Files
1717.3 Preprinted, Multiple Checkoff Prescription Blanks
1723.1 Confidentiality of Examination Questions
1745 Partial Filling of Schedule II Prescriptions
1751.10 Furnishing to Parenteral Patient at Home
1761(a) Erroneous or Uncertain Prescriptions
1764 Unauthorized Disclosure of Prescriptions
1765 Commissions, Gratuities, and Rebates
1766 False or Misleading Advertising
1775.3 Compliance with Orders of Abatement
1782 Reporting Sales of Drugs Subject to Abuse
1783 Manufacturer or Wholesaler Furnishing Drugs or Devices
1793.1 Duties of a Pharmacist
1793.2 Duties of a Pharmacy Technician
1793.3 Other Non-Licensed Pharmacy Personnel
1793.4 Qualifications for Registration as a Pharmacy Technician
1793.7 Requirements for Pharmacies Employing Pharmacy Technicians
1793.8 Technicians in Hospitals with Clinical Pharmacy Programs

HEALTH AND SAFETY CODE

11103 Report of Theft, Loss, or Shipping Discrepancy
11150 Persons Authorized to Write or Issue a Prescription
11152 Nonconforming Prescriptions Prohibited
11154 Prescription, etc. Must Be for Treatment; Knowing Soliciting of Unlawful Prescription, etc.
11156 Prescribing, etc. Controlled Substances to Addict Only as Authorized
11164 Prescriptions for Schedule II, III, IV and V Controlled Substance: Form and Content; Record of Practitioner Dispensing Schedule II Controlled Substance
11165(d) CURES Transmission
11166 Time Limit for Filling Schedule II Prescription; Knowingly Filling Mutilated, Forged, or Altered Prescription Prohibited
11170 Prohibition on Prescribing, etc. Controlled Substance for Self
11179 Retention of Controlled Substance Prescription
11207 Only Pharmacist or Intern Authorized to Fill Prescription
11209 Delivery and Receiving Requirements for Schedule II, III, and IV Substances; Violation
11350 Possession of Specified Controlled Substance
11377 Unlawful Possession of Specified Substance

CODE OF FEDERAL REGULATIONS, TITLE 21

1304.03 Persons required to keep records and file reports.
1304.04 Maintenance of records and inventories.
1304.11 Inventory requirements.
1304.21 General requirements for continuing records.
1304.22 Records for manufacturers, distributors, dispensers, researchers, importers and exporters.
1305.07 Special procedures for filling certain orders.
1305.13 Procedure for filling DEA Forms 222.
1306.04 Purpose of issue of prescription.
1306.06 Persons entitled to fill prescriptions.
1306.11 Requirement prescription.
1306.12 Refilling prescriptions.
1306.13 Partial filling of prescriptions.
1306.21 Requirement of prescription.
1306.22 Refilling of prescriptions.
1306.23 Partial filling of prescriptions.

CATEGORY III

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three to five years probation (five years probation where self-administration or diversion of dangerous drugs or devices or controlled substances occurred at the licensed premises). All standard terms and conditions shall be included and may include optional terms and conditions as appropriate.

Maximum: Revocation

Category III discipline is recommended for violations where potential for harm is greater, more imminent, or more serious than it is for Category II violations, as well as for violations that involve knowingly or willfully violating laws or regulations pertaining to pharmacy and/or to the dispensing or distributing of dangerous drugs or devices or controlled substances, and most criminal convictions involving alcohol, dangerous drugs or controlled substances. Violations in this category may include:

- violation(s) involving creation, manipulation, perpetuation, or disregard of drug shortages;
- failure(s) to deploy or abide by electronic pedigree requirements for dangerous drugs;
- violation(s) of licensee’s corresponding responsibility to ensure the proper prescribing and dispensing of controlled substances;
- dispensing or furnishing without valid prescription, dispensing or furnishing to unauthorized person(s);
- violation(s) involving fraudulent acts committed in connection with the licensee’s practice;
- repeat or serious unlawful possession(s) of dangerous drugs or dangerous devices, controlled substances, hypodermic needles or syringes, or drug paraphernalia;
- larger scale dispensing or furnishing of dangerous drug(s) or device(s) via the internet, without valid prescription(s);
- purchasing, trading, selling, or transferring adulterated, misbranded, or expired dangerous drug(s) or device(s);
- removal, sale, or disposal of embargoed dangerous drug(s) or device(s);
- failing to maintain record(s) of acquisition and disposition of dangerous drug(s) or devise(s) or controlled substances
- resale(s) of preferentially prices drugs, contract bid diversion, or other instances of improper sale(s) or resale(s);
- repeat or serious violation(s) of quality assurance and self-assessment obligations, failure(s) to ensure properly trained staff and conduct practice safely;
- repeat or serious failure(s) to perform drug utilization reviews, monitor patient medication profiles, or promote safety and efficacy of prescribed drugs;
- forgery of prescriptions, passing of forged prescriptions, or other unlawful means of acquiring dangerous drug(s) or device(s) or controlled substances(s);
- repeat or serious acts violating, assisting in or abetting violation of, or conspiring to violate the laws and regulations governing pharmacy; and
- violation(s) involving providing or offering to provide controlled substance(s) to addict(s).
- most criminal convictions involving dangerous drugs or controlled substances
- knowing or willfully violating laws or regulations pertaining to dispensing or distributing dangerous drugs or controlled substances
- fraudulent acts committed in connection with the licensee’s practice
- drug shortages
- violation of a licensee’s corresponding responsibility.

Violations of the following codes are representative of this category:

**BUSINESS AND PROFESSIONS CODE**

**Article 3. Scope of Practice and Exemptions**

4051(a) Conduct Limited to Pharmacist
4059 Furnishing Dangerous Drugs or Devices Prohibited Without Prescription: Exceptions
4059.5 Who May Order Dangerous Drugs or Devices: Exceptions

**Article 5. Authority of Inspectors**

4080 Stock of Dangerous Drugs and Devices Kept Open for Inspection
4081 Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory
4085(a) Unlawful to Remove, Sell, Dispose of Embargoed Dangerous Drug or Dangerous Device

**Article 7. Pharmacies**

4110 License Required; Temporary Permit Upon Transfer of Ownership
4111 Restrictions on Prescriber Ownership

**Article 11. Wholesalers and Manufacturers**

4169(a)(2) to
4169(a)(5) Prohibited Acts

**Article 15. Veterinary Food-Animal Retailers**

4199 Labeling Requirements; Maintaining Prescription Records

**Article 19. Disciplinary Proceedings**

4301 Unprofessional Conduct - subsections (i) - (k) and (o)
4307 Prohibition of Association of Individual with Entity License by Board: Length of Prohibition; Individuals Covered; Imposition of Prohibition Through Administrative Act Proceeding
Article 20. Prohibitions and Offenses

4308—Prohibited Association: Notification of Affected Licensees Known to Board

Article 20. Prohibitions and Offenses

4322—Misdemeanor or Infraction: False Representations to Secure License for Self or Others; False Representation of Licensure; Penalties
4323—Misdemeanor: False Representation of Self as Physician, Agent of Physician, etc. to Obtain Drug
4324—Felony or Misdemeanor: Forgery of Prescription; Possession of Drugs Obtained Through Forged Prescription
4325—Misdemeanor: Manufacture, Possession, etc. of False Prescription Blank
4327—Misdemeanor: Sale, Dispensing, or Compounding While Under the Influence of Drugs or Alcoholic Beverages
4329—Misdemeanor: Non-pharmacist Acting as Manager, Compounding, Dispensing or Furnishing Drugs
4332—Misdemeanor: Failure or Refusal to Maintain or Produce Required Drug or Device Records; Willful Production of False Records
4335—Voided License: Knowing Failure to Arrange for Disposition of Stock as Misdemeanor
4336—Felony: Knowing or Willful Use of Minor to Violate Specified Sections of Pharmacy Law: Exception for Pharmacist Furnishing Pursuant to a Prescription

Article 22. Unfair Trade Practices

4380—Resale of Preferentially Priced Drugs: Prohibition; Exceptions

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1718—Current Inventory Defined
1761(b)—Erroneous or Uncertain Prescriptions
1771—Posting of Notice of Suspension
1772—Disciplinary Condition of Suspension
1773—Disciplinary Conditions of Probation of Pharmacist
1774—Disciplinary Conditions of Probation of Permit

HEALTH AND SAFETY CODE

11104—Providing Chemical for Illicit Manufacturing; Evasion of Reporting Requirements; Penalties
11105—False Statement in Report
11150—Persons Authorized to Write or Issue a Prescription
11153—Responsibility for Legitimacy of Prescription; Corresponding Responsibility of Pharmacist
11153.5—Wholesaler or Manufacturer Furnishing Controlled Substance Other Than for Legitimate Medical Purpose; Knowing Violation; Factors in Assessing Legitimacy
11157—No False or Fictitious Prescriptions
11162.5—Counterfeiting or Possession of Counterfeit Triplicate Prescription Blank; Penalty
11167.5—Pharmacy Generated Prescription for Schedule II Controlled Substance in a Skilled Nursing Facility
11173 Fraud, Deceit, Misrepresentation or False Statement; False Representation; False Label

11174 Prohibition on Providing False Name or Address in Connection with Prescription, etc.

11351 Possession or Purchase for Sale of Specified Controlled Substance

11368 Forged or Altered Prescriptions

11375 Possession for Sale or Selling Specified Substance

11378 Possession for Sale

11550 Using or Being Under Influence of Controlled Substance

111295 Manufacturing, Selling or Offering for Sale an Adulterated Drug or Device

111300 Unlawful to Adulterate a Drug

111305 Unlawful to Receive in Commerce an Adulterated Drug

111440 Unlawful Manufacturer, selling a misbranded Drug

111445 Unlawful for a Person to Misbrand

111450 Unlawful to Receive into Commerce a Drug that is Misbranded

CATEGORY IV

Penalty: Revocation

Category IV discipline (Revocation revocation) is recommended for the most serious violations of the Uniform Controlled Substance Act (Health and Safety Code 11000 et seq.) involving laws or regulations pertaining to pharmacy and/or to the dispensing or distributing of dangerous drugs or devices or controlled substances. Violations in this category may include:

- violation(s) involving possession for sale, transportation, importation, and/or use of a minor for unlawful acquisition of sale of controlled substances;
- criminal conviction(s) involving the above, or repeat convictions involving diversion or abuse of alcohol, dangerous drugs or devices, or controlled substances; and
- repeat or serious example(s) of conduct described in Category I, Category II, or Category III.

- possession for sale
- transportation
- importation
- sale
- use of a minor for the unlawful sale of controlled substances

Revocation is also recommended when where a respondent fails to file a notice of defense to an Accusation or to appear at a disciplinary hearing, where a respondent violates the terms and conditions of probation from a previous disciplinary order, or where prior discipline has been imposed on the license:

- a respondent fails to file a notice of defense or to appear at a disciplinary hearing where the board has requested revocation in the accusation
- a respondent violates the terms and conditions of probation from a previous disciplinary order
- prior discipline has been imposed, as progressive discipline unless the respondent can demonstrate satisfactory evidence of rehabilitation.

Violations of the following codes are representative of this category:
HEALTH AND SAFETY CODE

11352 Importing, Selling, Furnishing Controlled Substance
11353 Adult Inducing Minor to Violate Provisions
11379 Transporting, Importing, Selling Controlled Substance
11380 Adult Using, Soliciting or Intimidating Minor for Violation

MODEL DISCIPLINARY LANGUAGE - PREMISES

The following standardized language shall be used in every decision where the order or condition is imposed.

Revocation

License number ______________, issued to respondent ___________________, is revoked.

Respondent owner shall, by the effective date of this decision, arrange for the destruction of, the transfer to, sale of or storage in a facility licensed by the board of all dangerous drugs or devices or controlled substances and dangerous drugs and devices. Respondent owner shall provide written proof of such disposition, submit a completed Discontinuance of Business form and return the wall and renewal license to the board within five (5) days of disposition.

Option: Respondent owner shall also, by the effective date of this decision, arrange for the continuation of care for ongoing patients of the pharmacy by, at minimum, providing a written notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that identifies one or more area pharmacies capable of taking up the patients' care, and by cooperating as necessary in the transfer of records or prescriptions for ongoing patients. Within five (5) days of its provision to the pharmacy's ongoing patients, Respondent owner shall provide a copy of the written notice to the board. For the purposes of this provision, "ongoing patients" means those patients for whom the pharmacy has on file a prescription with one or more refills outstanding, or for whom the pharmacy has filled a prescription within the preceding sixty (60) days.

Suspension

License number ______________, issued to respondent ___________________ is suspended for a period of ___________ days beginning the effective of this decision.

Respondent shall cease all pharmacy operations as a [insert license type] during the period of suspension. Failure to comply with this any such suspension shall be considered a violation of probation.

Standard Stay/Probation Order

License number ______________, issued to respondent is revoked; however, the revocation is stayed and respondent is placed on probation for ______________ years upon the following terms and conditions:

Issuance of Probationary License (In cases where a Statement of Issues has been filed.)
Upon satisfaction of all statutory and regulatory requirements for issuance of a [insert license type] license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for ______ years upon the following terms and conditions:

**Surrender**

Respondent owner surrenders license number __________ as of the effective date of this decision. Respondent owner shall relinquish the premises wall license and renewal license to the board within ten (10) days of the effective date of this decision.

The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent’s license history with the board.

Respondent owner shall, within ten (10) days of the effective date, arrange for the destruction of, the transfer to, sale of or storage in a facility licensed by the board of all controlled substances and dangerous drugs and devices. Respondent owner shall further provide written proof of such disposition and submit a completed Discontinuance of Business form according to board guidelines.

Respondent owner shall also, by the effective date of this decision, arrange for the continuation of care for ongoing patients of the pharmacy by, at minimum, providing a written notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that identifies one or more area pharmacies capable of taking up the patients' care, and by cooperating as may be necessary in the transfer of records or prescriptions for ongoing patients. Within five days of its provision to the pharmacy’s ongoing patients, Respondent owner shall provide a copy of the written notice to the board. For the purposes of this provision, "ongoing patients" means those patients for whom the pharmacy has on file a prescription with one or more refills outstanding, or for whom the pharmacy has filled a prescription within the preceding sixty (60) days.

Respondent owner understands and agrees that if he or she [he/she] ever files an application for a licensed premises or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.

Respondent owner may not reapply for any license from the board for three (3) years from the effective date of this decision. Respondent owner stipulates that should he or she [he/she] apply for any license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, correct and admitted by respondent when the board determines whether to grant or deny the application. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board. Respondent is required to report this surrender as disciplinary action.

Respondent owner further stipulates that he or she [he/she] shall reimburse the board for its costs of investigation and prosecution in the amount of $__________ within ________ days of the effective date of this decision.
Option: Respondent owner stipulates that should he or she [he/she] apply for any license from the board on or after the effective date of this decision the investigation and prosecution costs in the amount of $_________ shall be paid to the board prior to issuance of the new license.

Public Reprimand

It is hereby ordered that a public reprimand be issued against licensee, ______________. Respondent owner is required to report this reprimand as a disciplinary action.

Adoption of Stipulation

It is understood by respondent owner that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Attorney General's Office. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.
STANDARD CONDITIONS - To be included in all probation decisions/orders.

1. Definition: Respondent
2. Obey All laws
3. Report to the Board
4. Interview with the Board
5. Cooperate with Board Staff
6. Reimbursement of Board Costs
7. Probation Monitoring Costs
8. Status of License
9. License Surrender While on Probation/Suspension
10. Sale or Discontinuance of Business
11. Notice to Employees
12. Owners and Officers: Knowledge of the Law
13. Premises Open for Business
14. Posted Notice of Probation
15. Violation of Probation
16. Completion of Probation

OPTIONAL CONDITIONS
17. Suspension
18. Community Services Program
19. Restitution
20. Separate File of Records
21. Report of Controlled Substances
22. Surrender of DEA Permit
23. Posted Notice of Suspension
STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

1. Definition: Respondent

For the purposes of these terms and conditions, “respondent” shall refer to [insert name] and all terms and conditions stated herein shall bind and be applicable to the licensed premises and to all owners, managers, officers, administrators, members, directors, trustees, associates, or partners thereof. For purposes of compliance with any term or condition, any report, submission, filing, payment, or appearance required to be made by respondent to or before the board or its designee shall be made by an owner or executive officer with authority to act on behalf of and legally bind the licensed entity.

4.2. Obey All Laws

Respondent owner shall obey all state and federal laws and regulations.

Respondent owner shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws;
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment;
- a conviction of any crime; or
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent’s ________ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distributing, billing, or charging for any dangerous drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

2.3. Report to the Board

Respondent owner shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent owner shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

3.4. Interview with the Board

Upon receipt of reasonable prior notice, respondent owner shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.
4 5.  Cooperate with Board Staff

Respondent owner shall timely cooperate with the board's inspection program and with the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her probation, including but not limited to: timely responses to requests for information by board staff; timely compliance with directives from board staff regarding requirements of any term or condition of probation; and timely completion of documentation pertaining to a term or condition of probation. Failure to timely cooperate shall be considered a violation of probation.

5 6.  Reimbursement of Board Costs

As a condition precedent to successful completion of probation, respondent owner shall pay to the board its costs of investigation and prosecution in the amount of $_________. Respondent owner shall make said payments as follows: ______________. There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent owner shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

OPTION: Respondent shall be permitted to pay these costs in a payment plan approved by the board or its designee, so long as full payment is completed no later than one (1) year prior to the end date of probation.

6 7.  Probation Monitoring Costs

Respondent owner shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

7 8.  Status of License

Respondent owner shall, at all times while on probation, maintain current licensure with the board. If respondent owner submits an application to the board, and the application is approved, for a change of location, change of permit or change of ownership, the board shall retain continuing jurisdiction over the license, and the respondent shall remain on probation as determined by the board. Failure to maintain current licensure shall be considered a violation of probation.

If respondent's license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof or otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

8 9.  License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent owner discontinue business, respondent owner may tender the premises license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other
action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation.

**OPTION** (To be included if the respondent is a pharmacy): Upon acceptance of the surrender, respondent owner shall relinquish the premises wall and renewal license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent owner shall further submit a completed Discontinuance of Business form according to board guidelines and shall notify the board of the records inventory transfer within five (5) days.

Respondent owner shall also, by the effective date of this decision, arrange for the continuation of care for ongoing patients of the pharmacy by, at minimum, providing a written notice to ongoing patients that specifies the anticipated closing date of the pharmacy and that identifies one or more area pharmacies capable of taking up the patients' care, and by cooperating as may be necessary in the transfer of records or prescriptions for ongoing patients. Within five days of its provision to the pharmacy's ongoing patients, Respondent owner shall provide a copy of the written notice to the board. For the purposes of this provision, "ongoing patients" means those patients for whom the pharmacy has on file a prescription with one or more refills outstanding, or for whom the pharmacy has filled a prescription within the preceding sixty (60) days.

Respondent owner may not apply for any new licensure license from the board for three (3) years from the effective date of the surrender. Respondent owner shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

Respondent owner further stipulates that he or she shall reimburse the board for its costs of investigation and prosecution prior to the acceptance of the surrender.

**10. Sale or Discontinuance of Business**

During the period of probation, should respondent sell, trade or transfer all or part of the ownership of the licensed entity, discontinue doing business under the license issued to respondent and the assumption of practice at that location by another full or partial owner, person, firm, business, or entity, under the same or a different premises license number, the board or its designee shall have the sole discretion to determine whether to exercise continuing jurisdiction over the licensed location, under the current or new premises license number, and/or carry the remaining period of probation forward to be applicable to the current or new premises license number.

**9 11. Notice to Employees**

Respondent owner shall, upon or before the effective date of this decision, ensure that all employees involved in permit operations are made aware of all the terms and conditions of probation, either by posting a notice of the terms and conditions, circulating such notice, or both. If the notice required by this provision is posted, it shall be posted in a prominent place and shall remain posted throughout the probation period. Respondent owner shall ensure that any employees hired or used after the effective date of this decision are made aware of the terms and conditions of probation by posting a notice, circulating a notice, or both. Additionally, respondent owner shall submit written notification to the board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to submit such notification to the board shall be considered a violation of probation.
"Employees" as used in this provision includes all full-time, part-time, volunteer, temporary and relief employees and independent contractors employed or hired at any time during probation.

10 12. Owners and Officers: Knowledge of the Law

Respondent shall provide, within thirty (30) days after the effective date of this decision, signed and dated statements from its owners, including any owner or holder of ten percent (10%) or more of the interest in respondent or respondent's stock, and any officer, stating under penalty of perjury that said individuals have read and are familiar with state and federal laws and regulations governing the practice of pharmacy. The failure to timely provide said statements under penalty of perjury shall be considered a violation of probation.

13. Premises Open for Business

Respondent shall remain open and engaged in its ordinary business as a [insert license type] in California for a minimum of ________ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during with this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation, unless respondent is informed otherwise in writing by the board or its designee. If respondent is not open and engaged in its ordinary business as a [insert license type] for a minimum of ________ hours in any calendar month, for any reason (including vacation), respondent shall notify the board in writing within ten (10) days of the conclusion of that calendar month. This notification shall include at minimum all of the following: the date(s) and hours respondent was open; the reason(s) for the interruption or why business was not conducted; and the anticipated date(s) on which respondent will resume business as required. Respondent shall further notify the board in writing with ten (10) days following the next calendar month during which respondent is open and engaged in its ordinary business as a [insert license type] in California for a minimum of ________ hours. Any failure to timely provide such notification(s) shall be considered a violation of probation.

14. Posted Notice of Probation

Respondent owner shall prominently post a probation notice provided by the board or its designee in a place conspicuous to and readable by the public within two (2) days of receipt thereof from the board or its designee. Failure to timely post such notice, or to maintain the posting during the entire period of probation, shall be considered a violation of probation. The probation notice shall remain posted during the entire period of probation.

Respondent owner shall not, directly or indirectly, engage in any conduct or make any statement which is intended to mislead or is likely to have the effect of misleading any patient, customer, member of the public, or other person(s) as to the nature of and reason for the probation of the licensed entity.

Failure to post such notice shall be considered a violation of probation.

15. Violation of Probation
If a respondent owner has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent license, and probation shall be automatically extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent owner violates probation in any respect, the board, after giving respondent owner notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction and the period of probation shall be automatically extended until the petition to revoke probation or accusation is heard and decided.

43 16. Completion of Probation

Upon written notice by the board or its designee indicating successful completion of probation, respondent license will be fully restored.

OPTIONAL CONDITIONS OF PROBATION

44 17. Suspension

As part of probation, respondent’s license to operate a [insert license type] is suspended for [number] [day(s)/month(s)/year(s)] beginning the effective date of this decision. Respondent shall cease all operations as a [insert license type] during the period of suspension. Failure to comply with any such suspension shall be considered a violation of probation.

44. 18. Community Services Program

Within sixty (60) days of the effective date of this decision, respondent owner shall submit to the board or its designee, for prior approval, a community service program in which respondent shall provide free health-care related services to a community or charitable facility or agency for at least [number] hours per [interval] for the first [number] of probation.

Within thirty (30) days of board approval thereof, respondent owner shall submit documentation to the board demonstrating commencement of the community service program. Respondent owner shall report on progress with the community service program in the quarterly reports.

Failure to timely submit, commence, or comply with the program shall be considered a violation of probation.

45. 19. Restitution (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)

Within [number] days of the effective date of this decision, respondent owner shall pay restitution to [name] in the amount of $ [amount]. Failure to make restitution by this deadline shall be considered a violation of probation.
**16. 20. Separate File of Controlled Substances Records**

Respondent owner shall maintain and make available for inspection a separate file of all records pertaining to the acquisition or disposition of all controlled substances. Failure to maintain such file or make it available for inspection shall be considered a violation of probation.

**17. 21. Report of Controlled Substances**

Respondent owner shall submit quarterly reports to the board detailing the total acquisition and disposition of such controlled substances as the board or its designee may direct. Respondent owner shall specify the manner of disposition (e.g., by prescription, due to burglary, etc.) or acquisition (e.g., from a manufacturer, from another retailer, etc.) of such controlled substances. Respondent owner shall report on a quarterly basis or as directed by the board or its designee. The report shall be delivered or mailed to the board no later than ten (10) days following the end of the reporting period as determined by the board or its designee. Failure to timely prepare or submit such reports shall be considered a violation of probation.

**18. 22. Surrender of DEA Permit**

Within thirty (30) days of the effective date of this decision, respondent pharmacy shall surrender its federal Drug Enforcement Administration (DEA) permit to the DEA, for cancellation. Respondent pharmacy shall provide documentary proof of such cancellation to the board or its designee. Thereafter, respondent pharmacy shall not apply/reapply for a DEA registration number without the prior written consent of the board or its designee.

Option: Respondent pharmacy may obtain a DEA permit restricted to Schedule(s) _________ controlled substance(s).

Option: Respondent pharmacy shall not order, receive, or retain any federal order forms, including DEA Form 222 forms, for controlled substances.

**19. 23. Posted Notice of Suspension**

Respondent owner shall prominently post a suspension notice provided by the board in a place conspicuous and readable to the public within two (2) days of receipt thereof from the board or its designee. The suspension notice shall remain posted during the entire period of suspension ordered by this decision. Failure to timely post such notice, or to maintain the posting during the entire period of suspension, shall be considered a violation of probation.

Respondent owner shall not, directly or indirectly, engage in any conduct or make any statement, orally, electronically or in writing, which is intended to mislead or is likely to have the effect of misleading any patient, customer, member of the public, or other person(s) as to the nature of and reason for the closure of the licensed entity.

6/2007 9/2012
Proposal to Amend Section 1760 in Article 8 of Division 10 of Title 16 of the California Code of Regulations to read:

§1760. Disciplinary Guidelines.

In reaching a decision on a disciplinary action under the Administrative Procedure Act (Government Code section 11400 et seq.) the board shall consider the disciplinary guidelines entitled “Disciplinary Guidelines” (Rev. 10/2007 07/2012), which are hereby incorporated by reference. Deviation from these guidelines and orders, including the standard terms of probation, is appropriate where the board, in its sole discretion, determines that the facts of the particular case warrant such a deviation--the presence of mitigating factors; the age of the case; evidentiary problems.

(b) Notwithstanding subsection (a), the Board shall use the uniform standards for substance abuse as provided in Section 1760.1, without deviation, for each individual determined to be a substance-abusing licensee.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code; and Section 11400.20, Government Code. Reference: Sections 315, 315.2, 315.4, 4300 and 4301, Business and Professions Code; and Sections 11400.20 and 11425.50(e), Government Code.
Proposal to Add Section 1760.1 to Article 8 of Division 10 of Title 16 of the California Code of Regulations to read:

§ 1760.1. Uniform Standards for Substance Abuse.

(a) If the conduct found to be a violation involves self-use of drugs and/or alcohol, the licensee shall be presumed to be a substance-abusing licensee for purposes of section 315 of the Code. If the licensee does not rebut that presumption, then the terms and conditions contained in the document entitled "Uniform Standards for Substance-Abusing Licensees with Standard Language for Probationary Orders," new July 17, 2012, which are hereby incorporated by reference, shall be used in any probationary order of the Board affecting that licensee.

(b) Nothing in this Section shall prohibit the Board from imposing additional terms or conditions of probation in any order that the Board determines would provide greater public protection.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code. Reference: Sections 315, 315.2, and 315.4 of the Business and Professions Code; and, Sections 11400.20 and 11425.50(e), Government Code.
Option No. 2 “Trigger” for When SB 1441 Uniform Standards Apply

Title 16. Board of Pharmacy
Proposed Language

Proposal to Amend Section 1760 in Article 8 of Division 10 of Title 16, California Code of Regulations to read:

§ 1760. Uniform Standards Related to Substance Abuse and Disciplinary Guidelines.

In reaching a decision on a disciplinary action under the Administrative Procedure Act (Government Code section 11400 et seq.) the board shall consider the disciplinary guidelines entitled “Disciplinary Guidelines” (Rev. 10/2007 07/2012), which are hereby incorporated by reference. Deviation from these guidelines and orders, including the standard terms of probation, is appropriate where the board, in its sole discretion, determines that the facts of the particular case warrant such a deviation—the presence of mitigating factors; the age of the case; evidentiary problems.

However, neither the Board nor an administrative law judge may impose any conditions or terms of probation that are less restrictive than the uniform standards related to substance abuse listed in Section 1760.1. If a licensee has not yet been identified as a substance-abusing licensee (for example, through stipulation) in a case involving drugs or alcohol, a clinical diagnostic evaluation shall be ordered and the remaining provisions of the Uniform Standards may be made contingent upon a clinical diagnostic evaluator’s report that the individual is a substance-abusing licensee. The clinical diagnostic evaluator’s report shall be submitted in its entirety to the board.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code; and Section 11400.20, Government Code. Reference: Sections 315, 315.2, 315.4, 4300 and 4301, Business and Professions Code; and Sections 11400.20 and 11425.50(e), Government Code.
Proposal to Add Section 1760.1 to Article 8 of Division 10 of Title 16 of the California Code of Regulations to read:

§ 1760.1. Uniform Standards for Substance Abuse.

(a) If a licensee has been identified as a substance-abusing licensee as provided in Section 1760, then the terms and conditions contained in the document entitled "Uniform Standards for Substance-Abusing Licensees with Standard Language for Probationary Orders", new July 17, 2012, which are hereby incorporated by reference, shall be used in any probationary order of the Board affecting that licensee.

(b) Nothing in this Section shall prohibit the Board from imposing additional terms or conditions of probation in any order that the Board determines would provide greater public protection.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code. Reference: Sections 315, 315.2, and 315.4 of the Business and Professions Code; and, Sections 11400.20 and 11425.50(e), Government Code.
Proposal to Amend Section 1760 in Article 8 of Division 10 of Title 16, California Code of Regulations to read:

§ 1760. Uniform Standards Related to Substance Abuse and Disciplinary Guidelines.

In reaching a decision on a disciplinary action under the Administrative Procedure Act (Government Code section 11400 et seq.) the board shall consider the disciplinary guidelines entitled “Disciplinary Guidelines” (Rev. 10/2007 07/2012), which are hereby incorporated by reference. Deviation from these guidelines and orders, including the standard terms of probation, is appropriate where the board, in its sole discretion, determines that the facts of the particular case warrant such a deviation—the presence of mitigating factors; the age of the case; evidentiary problems.

(b) Notwithstanding subsection (a), the Board shall use the uniform standards for substance abuse as provided in Section 1760.1, without deviation, for each individual determined to be a substance-abusing licensee.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code; and Section 11400.20, Government Code. Reference: Sections 315, 315.2, 315.4, 4300 and 4301, Business and Professions Code; and Sections 11400.20 and 11425.50(e), Government Code.
Proposal to Add Section 1760.1 to Article 8 of Division 10 of Title 16 of the California Code of Regulations to read:

§ 1760.1. Uniform Standards for Substance Abuse.

(a) If after notice and hearing conducted in accordance with Chapter 5, Part 1, Division 3, Title 2 of the Government Code (commencing with sections 11500 et seq.), the Board finds that the evidence establishes that an individual is a substance-abusing licensee, then the terms and conditions contained in the document entitled "Uniform Standards for Substance-Abusing Licensees with Standard Language for Probationary Orders", new July 17, 2012, which are hereby incorporated by reference, shall be used in any probationary order of the Board affecting that licensee.

(b) Nothing in this Section shall prohibit the Board from imposing additional terms or conditions of probation in any order that the Board determines would provide greater public protection.

Note: Authority cited: Sections 315, 315.2, 315.4, and 4005, Business and Professions Code. Reference: Sections 315, 315.2, and 315.4 of the Business and Professions Code; and, Sections 11400.20 and 11425.50(e), Government Code.
UNIFORM STANDARDS RELATED TO SUBSTANCE-ABUSING LICENSEES WITH STANDARD LANGUAGE FOR PROBATIONARY ORDERS

New:
July 17, 2012

BE AWARE & TAKE CARE:
Talk to your pharmacist!

California State Board of Pharmacy
Department of Consumer Affairs
Pursuant to Section 315 of the Business and Professions Code, the California State Board of Pharmacy is directed to use the standards developed by the Substance Abuse Coordination Committee (SACC) for substance abusing licensees. On April 11, 2011, the SACC developed standards to be used by all healing arts boards. Administrative Law Judges, parties and staff are therefore required to use the language below, which is developed in accordance with those SACC standards.

To that end, the following probationary terms and conditions shall be used in every case where it has been determined that the individual (Pharmacist, Intern Pharmacist, Pharmacy Technician, Designated Representative) is a substance-abusing licensee as provided in Section 1760.1 of Title 16 of the California Code of Regulations. For purposes of implementation of these conditions of probation, any reference to the Board also means staff working for the Board of Pharmacy or its designee. These conditions shall be used in lieu of any similar standard or optional term or condition proposed in the Board’s Disciplinary Guidelines, incorporated by reference at Title 16, California Code of Regulations Section 1760. However, the Board’s Disciplinary Guidelines should still be used in formulating the penalty and in considering additional terms or conditions of probation appropriate for greater public protection (e.g., other standard or optional terms of probation).

ADDITIONAL PROBATIONARY TERMS AND CONDITIONS

(1) Reporting of Employment and Notice to Employers- During the period of probation, respondent shall provide the board with written consent authorizing communication with all employers and shall notify all present and prospective employers of the decision in case number __________ and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of undertaking any new employment, respondent shall report to the board in writing the name, physical address, and mailing address of all of [his/her] employer(s), and the name(s) and telephone number(s) of all of [his/her] direct supervisor(s), as well as any pharmacist(s)-in-charge, designated representative(s)-in-charge, or other compliance supervisor(s). Respondent shall
sign and return to the board a written consent authorizing the board or its
designee to communicate with all of respondent’s employer(s) and supervisor(s),
and authorizing those employer(s) or supervisor(s) to communicate with the
board or its designee, concerning respondent’s work status, performance, and
monitoring. Failure to comply with the requirements or deadlines of this condition
shall be considered a violation of probation.

Within thirty (30) days of the effective date of this decision, and within fifteen (15)
days of respondent undertaking any new employment, respondent shall cause
(a) [his/her] direct supervisor, (b) his or her pharmacist-in-charge, designated
representative-in-charge, or other compliance supervisor, and (c) the owner or
owner’s representative of his or her employer, to report to the board in writing
acknowledging that the listed individual(s) has/have read the decision in case
number ________, and terms and conditions imposed thereby. If one person
serves in more than one role described in (a), (b), or (c), the acknowledgment
shall so state. It shall be the respondent’s responsibility to ensure that these
acknowledgement(s) are timely submitted to the board. In the event of a change
in the person(s) serving the role(s) described in (a), (b), or (c) during the term of
probation, respondent shall cause the person(s) taking over the role(s) to report
to the board in writing within fifteen (15) days of the change acknowledging that
he or she has read the decision in case number _______, and the terms and
conditions imposed thereby.

If respondent works for or is employed by or through an employment service,
respondent must notify the person(s) described in (a), (b), and (c) above at every
entity licensed by the board, of the decision in case number ________, and the
terms and conditions imposed thereby in advance of respondent commencing
work at such licensed entity. A record of this notification must be provided to the
board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and
within fifteen (15) days of respondent undertaking any new employment by or
through an employment service, respondent shall cause the person(s) described
in (a), (b), and (c) above at the employment service to report to the board in
writing acknowledging that he or she has read the decision in case number
_______, and the terms and conditions imposed thereby. It shall be respondent’s
responsibility to ensure that these acknowledgment(s) are timely submitted to the
board.
Failure to timely notify present or prospective employer(s) or failure to cause the identified person(s) with that/those employer(s) to submit timely written acknowledgments to the board shall be considered a violation of probation.

"Employment" within the meaning of this provision includes any full-time, part-time, temporary, relief, or employment/management service position as a [insert license type], or any position for which a [insert license type] license is a requirement or criterion for employment, whether the respondent is an employee, independent contractor or volunteer.

**Source:** (Uniform Standard #3 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011.)

(2) **Notification of Change(s) in Employment, Name, Address(es), or Phone Number(s)**

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule, if known. Respondent shall further notify the board in writing within ten (10) days of any change in name, residence address, mailing address, or phone number.

Failure to timely notify the board of any change in employer, name, address, or phone number shall be considered a violation of probation.

**Source:** (Uniform Standard #3 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011.)

(3) **Work Site Monitor**

Within ten (10) days of the effective date of this decision, respondent shall identify a work site monitor, for prior approval by the board or its designee, who shall be responsible for supervising respondent during working hours. Upon request, respondent shall provide copies to the board of a signed affirmation from the work site monitor showing that he or she has reviewed the terms and conditions of the licensee’s disciplinary order and agrees to monitor the licensee as set forth by the board. The work site monitor must adhere to all of the following methods of monitoring respondent: (1) the work site monitor shall have face-to-face contact with the licensee in the work environment on a frequent basis as determined by the Board, but at least once per week; (2) the work site monitor shall interview other staff in the office regarding the licensee’s behavior, if applicable; and, (3) the work site monitor shall review the licensee’s work attendance and behavior.
Respondent shall be responsible for ensuring that the work site monitor reports in writing to the board monthly or on another schedule as directed by the board or its designee. Should the designated work site monitor suspect at any time during the probationary period that respondent has abused alcohol or drugs, he or she shall notify the board immediately.

The initial notification shall be made orally within one (1) business day of the occurrence. If occurrence is not during the Board’s normal business hours the oral report must be within one (1) hour of the next business day. The work site monitor shall submit a written report to the Board within 48 hours of occurrence. If, for any reason, including change of employment, respondent is no longer able to be monitored by the approved work site monitor within ten (10) days respondent shall designate a new work site monitor for approval by the board or its designee. Failure to timely identify an acceptable initial or replacement work site monitor, or to ensure monthly reports are submitted to the board by the monitor, shall be considered a violation of probation.

The written reports submitted to the board or its designee by the work site monitor shall include at least the following information: respondent’s name and license number; the work site monitor’s name, work site monitor’s license number (if applicable) and work site location(s); the date(s) the work site monitor had face-to-face contact with respondent; the staff interviewed, if applicable; an attendance report; notes on any changes in respondent’s behavior or personal habits; notes on any indicators that may lead to suspected substance abuse; and the work site monitor’s signature.

Respondent shall complete any required consent forms and sign any required agreement with the work site monitor and/or the board to allow the board or its designee to communicate freely on the subject of respondent’s work performance and sobriety with the work site monitor.

The work site monitor shall not have a financial, personal, familial or other relationship with the respondent that could reasonably be expected to compromise the ability of the monitor to render impartial and unbiased reports to the board. If it is impractical for anyone but respondent’s employer to serve as work site monitor, this requirement may be waived by the board or its designee; however, under no circumstances shall respondent’s work site monitor be respondent’s employee.

The work site monitor shall hold a license with a scope of practice including the scope of practice of the respondent’s license, shall be another health care professional if no monitor with like practice is available, or, as approved by the board or its designee, shall be a person in a position of authority who is capable of monitoring respondent while at work. Each work site monitor who is a licensed pharmacist or other healthcare professional shall have an active, unrestricted
license in California and shall not have been subject to any disciplinary action by the board (or any other licensing agency?) within the last five (5) years.

Respondent shall complete any required consent forms and sign any required agreement with the work site monitor and/or the board or its designee to allow the board to communicate freely on the subject of respondent’s work performance and sobriety with the work site monitor.

**Source:** (Uniform Standard #7 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011.)

**4) Drug and Alcohol Testing** - Respondent, at [his/her] own expense, shall participate in testing, including but not limited to biological fluid testing as directed by the board or its designee for the detection of alcohol, controlled substances, and dangerous drugs. Testing protocols may include biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other testing protocols as directed by the board or its designee. All testing must be pursuant to an observed testing protocol, unless respondent is informed otherwise in writing by the board or its designee. Respondent may be required to participate in testing for the entire probation period and frequency of testing will be determined by the board or its designee.

By no later than thirty (30) days after the effective date of this decision, respondent shall have completed all of the following tasks: enrolled and registered with an approved drug and alcohol testing vendor; provided that vendor with any necessary information and documentation, and any information necessary for payment by respondent; commenced testing protocols, including all required contacts with the testing vendor to determine testing date(s); and begun testing. At all times, respondent shall fully cooperate with the testing vendor, and with the board or its designee, with regard to enrollment, registration, and payment for, and compliance with, testing. Any failure to cooperate timely shall be considered a violation of probation.

Respondent may be required to test on any day, including weekends and holidays. Respondent is required to make daily contact with the testing vendor to determine if a test is required, and if a test is required must submit to testing on the same day.

Though the frequency of testing will be determined by the board or its designee, and shall be designed so as to prevent respondent from anticipating testing dates
(randomized testing), the frequency of testing shall be tested in accordance with the following schedule of minimum ranges: 52-104 test dates during the first year of probation (Level I); 36-104 test dates during the second, third, fourth, and fifth years of probation (Level II); and at least one (1) test per month in each year of probation after the fifth so long as there have been no positive test results during the previous five (5) consecutive years. However, nothing precludes the board from increasing the number of random tests for any reason. The board or its designee may require less frequent testing if any of the following applies:

- Where respondent has previously participated in a treatment or monitoring program requiring testing, the board or its designee may consider that prior testing record in applying the three-tier testing frequency schedule described above;
- Where the basis for probation or discipline is a single incident or conviction involving alcohol or drugs, or two incidents or convictions involving alcohol or drugs that were at least seven (7) years apart, that did not occur at work or on the way to or from work, the board or its designee may skip the first-year testing frequency requirement(s);
- Where respondent is not employed in any health care field, frequency of testing may be reduced to a minimum of twelve (12) tests per year. If respondent wishes to thereafter return to employment in a health care field, respondent shall be required to test at least once a week for a period of sixty (60) days before commencing such employment, and shall thereafter be required to test at least once a week for a full year, before [he/she] may be reduced to a testing frequency of at least thirty-six (36) tests per year;
- Respondent’s testing requirement may be suspended during any period of tolling of the period of probation. If respondent wishes to thereafter return to employment in a health care field and has not been tested for at least 52 times during the first year of probation, respondent shall be required to test at least 52 times for a full year, before [he/she] may be reduced to a testing frequency of at least thirty-six (36) tests per year;
- Where respondent has a demonstrated period of sobriety and/or non-use, the board or its designee may reduce the testing frequency to no less than twenty-four (24) tests per year.

Any detection through testing of alcohol, or of a controlled substance or dangerous drug may cause the board or its designee to increase the frequency of testing or reestablish the testing cycle, in addition to any other action including but not limited to further disciplinary action.
Prior to any vacation or other period of absence from the geographic area of the approved testing vendor, respondent shall seek and receive approval from the board or its designee of an alternate testing vendor in the geographic area to be visited or resided in by respondent. Upon approval, respondent shall enroll and register with the approved alternate drug testing vendor, provide that alternate vendor with any necessary information and documentation, including any necessary payment by respondent. During the period of visitation or residence in the alternate geographic area, respondent shall commence testing protocols with the alternate vendor, including required daily contacts with the testing vendor to determine if testing is required, and required testing. Any failure to timely seek or receive approval from the board or its designee, or to timely enroll and register with, timely commence testing protocols with, or timely undergo testing with, the alternate testing vendor, shall be considered a violation of probation.

Upon detection through testing of a controlled substance or dangerous drug, the board or its designee may require respondent to timely provide documentation from a licensed practitioner authorized to prescribe the detected substance demonstrating that the substance was administered or ingested pursuant to a legitimate prescription issued as a necessary part of treatment. All such documentation shall be provided by respondent within ten (10) days of being requested.

Any of the following shall be considered a violation of probation and shall result in respondent being immediately ordered to cease practice as a [insert license type] until notified by the board in writing that [he/she] may resume practice: failure to timely complete all of the steps required for enrollment/registration with the drug testing vendor, including making arrangements for payment; failure to timely commence drug testing protocols; failure to contact the drug testing vendor as required to determine testing date(s); failure to test as required; failure to timely supply documentation demonstrating that a detected substance was taken pursuant to a legitimate prescription issued as a necessary part of treatment; and/or detection through testing of alcohol, or of a controlled substance or dangerous drug absent documentation that the detected substance was taken pursuant to a legitimate prescription and a necessary treatment. In the event of an order to cease practice after detection through testing of alcohol, or of a controlled substance or a dangerous drug, the board or its designee shall contact respondent and order respondent to: (a) cease practice; and, (b) immediately leave work. The board shall also notify respondent’s employer(s) and work site monitor(s) of the cease practice order.
While the cease practice order is in effect, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs or devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and controlled substances.

While the cease practice order is in effect, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices. Respondent shall not resume practice until notified by the board that the cease practice order has been lifted. Failure to comply with the cease practice order shall be considered a violation of probation.

Specimen collectors must either be certified by the Drug and Alcohol Testing Industry Association or have completed the training required to serve as a collector for the U.S. Department of Transportation. Specimen collectors shall adhere to the current U.S. Department of Transportation Specimen Collection Guidelines. Testing locations shall comply with the Urine Specimen Collection Guidelines published by the U.S. Department of Transportation, regardless of the type of test administered. Laboratories shall be certified and accredited by the U.S. Department of Health and Human Services.

A collection site must submit a specimen to the laboratory within one (1) business day of receipt. A chain of custody shall be used on all specimens. The laboratory shall process results and provide legally defensible test results within seven (7) days of receipt of the specimen. The appropriate board will be notified of non-negative test results within one (1) business day and will be notified of negative test results within seven (7) business days.

Source: (Uniform Standards #4, #8-10 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011 and Section 315.2 of the Business and Professions Code.)
(5) Abstain from Drugs and Alcohol- Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs, or their associated paraphernalia, except when possessed or used pursuant to a legitimate prescription issued as a necessary part of treatment. Respondent shall ensure that [he/she] is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, dangerous drugs or controlled substances, or their associated paraphernalia for which a legitimate prescription has not been issued as a necessary part of treatment, or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

Source: (Uniform Standard #4, of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011, and Section 315.2 of the Business and Professions Code..)

(6) Facilitated Group Recovery and/or Support Meetings

Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a group recovery and/or support meeting that is run by a trained facilitator approved in advance by the board or its designee. The required frequency of group meeting attendance shall be determined by the board or its designee, after taking into consideration respondent’s history, the documented length of the respondent’s sobriety or time that has elapsed since substance abuse, any recommendation(s) from any clinical diagnostic evaluator(s), the scope and pattern of respondent’s use, respondent’s treatment history, and the nature, duration, and severity of respondent's substance abuse. Respondent shall continue regular attendance as directed at an approved facilitated group meeting until the board or its designee advises the respondent in writing that [he/she] may cease regular attendance.

The facilitator shall, upon request by the board or its designee, provide the board with a dated document signed by the facilitator that includes respondent’s name, the group’s name, if any, the date and location of its regular meeting(s), respondent’s attendance record, and respondent’s participation level and progress. Respondent shall provide signed and dated documentation of attendance as required with each quarterly report. Failure to attend as required or to submit documentation of attendance shall be considered a violation of probation.
The approved facilitator shall report any unexcused absence by respondent from a facilitated group meeting to the board within twenty-four (24) hours of its occurrence.

The board or its designee shall select or approve facilitators with at least three (3) years of experience in the treatment and rehabilitation of substance abuse, with a license or certificate from the state or other nationally certified organization. The facilitator(s) shall not have had a financial, personal, or business relationship with respondent within the last year.

Source: (Uniform Standard #5 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011, (7) Clinical Diagnostic Evaluation

Within thirty (30) days of the effective date of this decision, and on a periodic basis thereafter if required by the board or its designee, respondent shall undergo, at [his/her] own expense, clinical diagnostic evaluation(s) by a licensed practitioner selected or approved prior to the evaluation by the board or its designee. The approved evaluator shall be provided with a copy of the board’s [accusation, petition to revoke probation, or other pleading] and decision. Respondent shall sign a release authorizing the evaluator to furnish the board with a current diagnosis and a written report regarding the respondent's judgment and ability to function independently as a [insert license type] with safety to the public. If the evaluator recommends restrictions or conditions on respondent’s practice, including but not limited to, other terms and conditions related to the licensee's rehabilitation and safe practice (e.g., required psychotherapy, prescription coordination and monitoring, restricted practice, inpatient or outpatient treatment), the board or its designee may by written notice to respondent adopt these restrictions or conditions as additional probation terms and conditions, violation of which shall be considered a violation of probation.

The evaluation(s) shall be conducted in accordance with acceptable professional standards for conducting substance abuse clinical diagnostic evaluations. The written report(s) shall set forth, at least, the opinions of the evaluator as to: whether respondent has an alcohol or substance abuse problem; whether respondent is a threat to him/herself or others; and recommendations for alcohol or substance abuse treatment, practice restrictions, or other steps related to respondent’s rehabilitation and safe practice. If the evaluator determines during
the evaluation process that respondent is a threat to him/herself or others, the evaluator shall notify the board within twenty-four (24) hours.

Commencing on the effective date of this decision, respondent is ordered to cease practice and shall not practice as a [insert license type] until:

- Respondent has undergone and completed clinical diagnostic evaluation(s);
- The report(s) of the evaluation(s) has/have been received by the board or its designee; One or more report(s) has concluded that respondent is safe to return to practice as a [insert license type];
- Respondent has submitted to observed bodily fluid testing for the presence of alcohol, dangerous drugs, or controlled substances [pursuant to the Drug and Alcohol Testing Term] at least twice per week for at least thirty (30) days;
- During the testing period, respondent has not had a confirmed positive test result for alcohol, or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment, for at least thirty (30) days;
- The board or its designee has determined that respondent is safe to return to either full-time or part-time practice as a [insert license type], after considering the evaluation report(s), the results of the fluid testing, and criteria including the license type, respondent’s history, respondent’s documented period of sobriety or documented time since last use, respondent’s scope and pattern of use, respondent’s treatment history, respondent’s medical history and current medical condition, the nature, duration, and severity of respondent’s alcohol or substance abuse, and whether respondent is a threat to him/herself or others; and,
- Respondent receives written notice from the board or its designee that practice may resume.

The board or its designee shall select or approve evaluator(s) holding a valid, unrestricted license to practice, with a scope of practice that includes the conduct of clinical diagnostic evaluations and at least three (3) years’ experience conducting such evaluations of health professionals with substance abuse disorders. The evaluator(s) shall not have a financial relationship, personal relationship, or business relationship with respondent within the last five (5) years. The evaluator(s) shall provide an objective/unbiased, and independent evaluation of respondent.
For all such evaluations, a final written report shall be provided to the board no later than ten (10) days from the date the evaluator is assigned the matter unless the evaluator requests additional information to complete the evaluation, not to exceed thirty (30) days. **While the cease practice order is in effect**, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or any area where dangerous drugs or devices or controlled substances are maintained. **While the cease practice order is in effect**, Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and controlled substances.

**While the cease practice order is in effect**, respondent shall not engage in any activity that requires the professional judgment of and/or licensure as a [insert license type]. Respondent shall not direct or control any aspect of the practice of pharmacy, or of the manufacturing, distributing, wholesaling, or retailing of dangerous drugs or devices or controlled substances.

**Source:** (Uniform Standards #1, 2 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011, and Business and Professions Code section 315.4.)

**(8) Drug or Alcohol Abuse Treatment Program** – Upon order of the Board, Respondent shall successfully complete an inpatient, outpatient or any other type of recovery and relapse prevention treatment program as directed by the Board.

When determining if Respondent should be required to participate in inpatient, outpatient or any other type of treatment, the Board shall take into consideration the following criteria: the recommendation of the clinical diagnostic evaluation(s), respondent’s license type, respondent’s licensing history, documented length of sobriety/time that has elapsed since substance abuse, scope and pattern of substance abuse, respondent’s treatment history, respondent’s medical history, respondent’s current medical condition, nature, duration and severity of substance abuse; and, whether respondent is a threat to himself or herself or others.

**Source:** (Uniform Standard #6 of “Uniform Standards Regarding Substance-Abusing Healing Arts Licensees,” revised dated April 2011.)

**********